










The handle http://hdl.handle.net/1887/54686 holds various files of this Leiden University 
dissertation 
 
Author: Rein, Nienke van 
Title: Risk and prevention of bleeding during anticoagulant treatment 









Omslag 17 x 24 x 1,5 cm N_van Rein.pdf   1   29/03/17   20:48

Risk and prevention of bleeding  
during anticoagulant treatment
Nienke van Rein
Risk and prevention of bleeding during anticoagulant treatment
Cover design: Petra Stegeman
Layout and printed by: Off Page
ISBN: 978-94-6182-789-0
© 2017, Nienke van Rein
Risk and prevention of bleeding  
during anticoagulant treatment
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties




geboren te Veendam in 1987
Promotor   Prof. dr. P.H. Reitsma
Copromotor   Dr. W.M. Lijfering
Leden promotiecommissie Prof. dr. F.R. Rosendaal
    Prof. dr. H.J. Guchelaar
    Prof. dr. L.T.W. de Jong-van der Berg
    Prof. dr. F.W.G. Leebeek
The work described in this thesis was performed at the department of Thrombosis and 
Haemostasis, the Einthoven Laboratory for Experimental Vascular Medicine and the 
department of Clinical Epidemiology at the Leiden University Medical Center, Leiden, 
the Netherlands and the Department of Clinical Epidemiology, Aarhus University 
Hospital, Aarhus, Denmark. 
The research described in this thesis was performed within the framework of the 
Center for Translational Molecular Medicine, project INCOAG (grant 01C-201) and was 
supported by a grant of the Dutch Heart Foundation (DHF2008-T093)
Financial support by the Federatie Nederlandse Trombosediensten, Dutch Heart 
Foundation and Koninklijke Nederlandse Maatschappij ter bevordering van de 
Pharmacie for publication of this thesis is greatly acknowledged. Additional financial 
support was kindly provided by Stago, Pfizer, Bayer, Chipsoft, Micronic Holding B.V.  
Table of coNTeNTs
Chapter 1 Introduction and outline 7
Part I Pharmacoepidemiology 21
Chapter 2 Suspected survivor bias in case-control studies: stratify on  
survival time and use a negative control 23
Chapter 3 Statins and risk of bleeding: an analysis to evaluate possible  
bias due to prevalent users and healthy user aspects 31
Chapter 4 Vitamin supplementation on the risk of venous thrombosis:  
results from the MEGA case-control study 47
Chapter 5 Discrepancies between risk estimates when using different  
control groups in a case-control study  65
Part II Bleeding during anticoagulant treatment 77
Chapter 6 Major bleeding rates are high in atrial fibrillation patients  
on triple antithrombotic therapy: results from a nationwide  
Danish cohort study  79
Chapter 7 Major bleeding risks of different Low-Molecular-Weight-Heparin  
agents: a cohort study in 12 934 patients treated for acute  
venous thrombosis 105
Chapter 8 Low-molecular-weight-heparin therapy after acute venous  
thrombosis: systematic review and network meta-analysis 117
Chapter 9 Multi-dose drug dispensing as a tool to improve medication 
adherence: a study in patients using vitamin k antagonists 145
Chapter 10 Vitamin K1 in oral solution or tablets: a crossover trial and 
two randomized controlled trials to compare effects 157
Chapter 11 Increased risk of major bleeding after a minor bleed during  
treatment with vitamin K antagonists is determined by fixed  
common risk factors 173
Chapter 12 Objectives and design of BLEEDS: a cohort study to identify  
new risk factors and predictors for major bleeding during  
treatment with vitamin K antagonists 185
Chapter 13 Persistent endothelial damage is associated with an increased  
risk of major bleeding in patients treated with vitamin K  
antagonists: a population based case-cohort study 205
Chapter 14 General discussion and future perspectives 217
Chapter 15 Nederlandse samenvatting 233
Curriculum vitae 239








The term ‘epidemiology’ is a source of confusion about the nature of this discipline. 
For the public, ‘epidemiology’ evokes a medical discipline that deals with large scale 
outbreaks of infectious diseases. This was the context in which the term was initially 
used: in the 16th century the Spanish physician Angelerio published a study on the 
plague entitled ‘Epidemiologica’.1 In 1850, the London Epidemiologic Society was 
created, which assembled scientists, public health practitioners, and physicians to 
unite their efforts to fight against ‘epidemics’.1 Today, epidemiology remains associated 
with fight against infectious diseases, but it has expanded and is not restricted to 
specific diseases anymore.1 It is currently defined as the study of patterns, causes, and 
effects of health and disease conditions in defined populations.2 Epidemiology consists 
of multiple sub-specialties of which clinical epidemiology, genetic epidemiology, 
molecular epidemiology and pharmacoepidemiology are examples. 
Pharmacoepidemiology is the study of utilization and effects of drugs in large 
numbers of people. It provides estimates of the probability of beneficial effects and 
the probability of adverse events.3 When studying effects of drugs, it is important 
to combine the knowledge on the epidemiology and pharmacology, but also on 
prescription behavior of physicians. 
The first part of this thesis will look deeper into the methods of observational studies 
as the methods form the ‘foundation’ of the ‘pharmacoepidemiological framework’. 
methodological rigidity and pharmacoepidemiology
Chapters 2 and 3 describe methodological aspects of case-control- and cohort 
studies that examine the effects of statins on bleeding. Statins are known to halt or 
reduce atherosclerosis but are also claimed to have a wide range of unintended and 
unexplained beneficial effects.4 In both chapters, methodological aspects of these 
studies are considered that could explain why the wide and varied claims of unintended 
effects of statins are the result of bias and do not represent true benefit. In Chapter 4, 
we examine whether previous claims that vitamin preparations decrease the risk for 
venous thrombosis could be explained by lack of proper adjustment for the lifestyle-
related factors. We look further into explanations for discrepancies between study 
outcomes in Chapter 5. In this chapter we describe how and why outcomes may differ 
when using either of two control groups in a case-control study. The second part of 
this thesis comprises of pharmacoepidemiological studies which focus on preventing 





hIstoRy and PhaRmaCoePIdemIoLogy of 
vItamIn K antagonIsts
history 
The sweet clovers Melilotus alba and Melilotus officinalis became recognized as valuable 
farm crops during the first quarter of the twentieth century.5 In the winter months 
of 1921-22, veterinarians in Canada found numerous large and small hemorrhages 
during the postmortems of cattle dying from a mysterious disease.  The pathologist 
Frank W. Schofield found that in every case sweet clover had been consumed by the 
deceased animals.6 A few years later, Schofield discovered that moldy sweet clover 
caused the symptoms while a clean stack did not.5 It did not take long before it was 
known that sweet clover disease came with a deficiency of prothrombin.7 In 1935, 
Henrik Dam discovered that the fat soluble vitamin K was an anti-hemorrhagic factor.8 
Not much later, Campbell saw the first crystals of dicoumarol under a microscope, 
who was supervised by Karl Link in 1939.9,10 Link kept on working on a more potent 
rodent poison, resulting in warfarin in 1948. In 1951, a US army inductee unsuccessfully 
attempted suicide with warfarin and fully recovered after administration of vitamin K in 
the hospital. The incident was a catalyst for the use of warfarin as a therapeutic agent. 
It was found to be superior to dicoumarol and warfarin was approved for medical use 
in 1954,10 after which phenprocoumon and acenocoumarol followed soon.11,12 
Pharmacology
When warfarin was approved for medical use, it was unknown what the biochemical basis 
of the anticoagulant effect was. During the beginning of the 1970s, it was discovered that 
vitamin K undergoes a cyclic conversion. The cyclic conversion was named the vitamin 
K cycle, and it is this cycle that is inhibited by warfarin.13,14 Vitamin K has three forms, 
and in the cycle the quinone-form becomes converted to the hydroquinone then to the 
epoxide, and back to quinone (see Figure 1).14 Vitamin K-epoxide reductase complex 1 
(VKORC1) converts the epoxide- to the quinone- to the hydroquinone form.11 Vitamin K 
hydroquinone supports carboxylation of γ-glutamic acid residues to γ-carboxyglutamic 
acid (Gla) residues in vitamin K dependent coagulation factors. This latter reaction is 
catalyzed by Gamma-Glutamyl carboxylase (GGCX).11 The Gla residues can bind Ca2+ 
with high affinity which is necessary for biological function - in particular binding to 
negatively charged phospholipid membranes - of vitamin K dependent coagulation 
factors.11 As warfarin inhibits the actions of VKORC1, and thereby the vitamin K cycle, 
lower levels of carboxylated vitamin K dependent coagulation factors (i.e. II, VII, IX, X, 
protein C, S and Z) will circulate and this impairs coagulation reactions.15  
The most commonly prescribed vitamin K antagonists are warfarin, phenprocoumon 
and acenocoumarol, which are all racemic mixtures with one enantiomer being more 




their half-live. Acenocoumarol has the shortest half-life (7 h), warfarin a longer (40 h), 
and phenprocoumon the longest half-life (120 h).15,17 Another difference lies in the 
pharmacokinetics of the drugs: the more potent enantiomers of phenprocoumon 
and warfarin are metabolized by CYP2C9, while the more potent enantiomer of 
acenocoumarol is metabolized by CYP2C19 and CYP2C9.15,16
therapy
Warfarin is the most commonly prescribed vitamin K antagonist in the world, but in 
the Netherlands only phenprocoumon and acencoumaol are available.18 Vitamin K 
antagonists are used to treat and prevent thrombosis and are prescribed for several 
indications. The most common indication is prevention of thromboembolic stroke in 
atrial fibrillation patients.19 Examples of other indications are treatment of acute venous 
thrombosis and prevention of thrombosis after a prosthetic heart valve implantation 
or after vascular surgery.18 The duration of therapy depends on the indication: patients 
who have atrial fibrillation are usually treated for life, whereas patients with a first 
venous thrombosis are often treated for three to six months only. 
Appropriate dosing is a challenge in therapy with vitamin K antagonists: the required 
dose of vitamin K antagonists varies between persons, but can also vary over time within 
a person. The variations within persons are due to changes in for example diet, co-
medication or vitamin K intake, which can vary on a day-to-day basis.15 As the drugs also 
have a narrow therapeutic window, monitoring of the effect of treatment is required.15 
figure 1. vitamin K cycle and pharmacology vitamin K antagonists
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In the Netherlands, anticoagulation clinics were set up to maximize the effectiveness 
and to minimize the bleeding risk of the therapy with vitamin K antagonists.18,20 In these 
clinics the international normalized ratio (INR) is measured on a regular basis, on which 
the dose of the vitamin K antagonist for the next period is based.18 The target range 
of the INR depends on the indication of treatment and can be 2.5 to 3.5 or 3.0 to 4.0 
in the Netherlands.18 After determining the INR, patients receive a calendar with their 
individualized dosing schedule until the next visit, which is generally within six weeks. 
The frequency of the visits depends on the stability of the INR and the value of the INR.18 
Despite this monitoring system, the most common side effects of treatment with 
vitamin K antagonists remain bleeding complications.15 Whether therapy should be 
initiated and continued, always depends on the balance between benefit (preventing 
or treating thrombosis) and harm (bleeding events).15 Major bleeding events occur 
in 1-3% of the patients treated every year.21 The second part of this thesis describes 
strategies that may result in fewer of these major bleeding events in the future, and 
thus better safety of anticoagulant treatment. 
therapeutic interventions
Atrial fibrillation patients can have co-morbidities that can result in treatment with a 
combination of anticoagulants.22,23 Some high risk patients receive combination therapy 
with a vitamin K antagonist, aspirin and clopidogrel (i.e. triple therapy). Literature 
shows that patients who receive triple therapy are at an almost four-fold increased risk 
for major bleeding as compared to those on warfarin monotherapy.24 Overall absolute 
risks for safety and effectiveness outcomes were previously reported,24 but data on 
safety and effectiveness outcomes in groups of patients with different baseline risks 
of bleeding complications or ischemic stroke (e.g elderly or those with a history of a 
bleeding complication) are currently not known. Chapter 6 shows rates of safety- (major 
bleeding) and effectiveness- (myocardial infarction and ischemic stroke) outcomes for 
various forms of anticoagulant treatment in atrial fibrillation patients. 
Chapter 7 and 8 examine anticoagulant treatment of patients with acute venous 
thrombosis. This treatment can routinely consists of administration of rapid-onset 
low-molecular-weight-heparins (LMWHs) overlapped and followed by vitamin K 
antagonists.25 The combination is indicated during the initial period of treatment 
because the onset of the anticoagulant effect of vitamin K antagonists will take several 
days. Therefore LMWHs are prescribed until two consecutive INRs are within the target 
range.15 It is assumed that all LMWHs are equally effective and have similar rates of 
side effects.26 However, pharmacodynamics and pharmacokinetics of these individual 
LMWHs do differ and therefore this assumption may be erroneous.26 Chapter 7 and 8 
present the safety (bleeding risk) and efficacy (recurrent thrombosis risk) outcomes of 




Practical safety interventions for treatment
Interventions to prevent bleeding complications also include ways to increase 
therapeutic compliance. Multidose drug dispensing (MDD) is a dosing aid that provides 
patients with disposable bags containing all drugs intended for one dosing moment.27 
This is especially useful when non-compliant polypharmacy patients have complex 
dosing patterns. Better adherence to treatment with vitamin K antagonists may result 
in fewer thrombotic- and bleeding events, but whether compliance increases after 
initiating MDD in anticoagulated patients has not been studied yet. In Chapter 9, we 
describe whether MDD improves adherence in patients using vitamin K antagonists.
Another practical intervention to reduce the risk of bleeding is to make the route 
of administration of antidotes to anticoagulant drugs easier. Vitamin K is used to 
antagonize the anticoagulant effect of vitamin K antagonists.20 A liquid formulation 
for oral administration of vitamin K has been used for a long time,28 but recently tablets 
have become available. Tablets are easier to ingest and taste better. However, it is 
not known whether the tablets are as effective as the liquid formulation in reversing 
anticoagulant effects of vitamin K antagonists. As the absorption of vitamin K is 
stimulated by fat,29,30 it is possible that an oily solution results in higher bioavailability 
and is therefore a more effective reversal formulation (i.e. decreasing the INR) than 
tablets. Chapter 10 of this thesis describes three trials that relate to this issue. The first 
crossover trial shows the absorption profiles of the liquid formulation as compared with 
the tablets. The other two trials show the effects of the solution and tablets on the INR. 
Prediction of bleeding complications
Preventing major bleeding complications can also be achieved by ceasing or not initiating 
anticoagulant treatment with vitamin K antagonists. This could be considered if the 
harm of the treatment (bleeding) outweighs its benefit (prevention of thrombosis). To 
establish which patients do not benefit from treatment with vitamin K antagonists, 
it is necessary to predict who is at high risk for major bleeding complications. Much 
research has been performed on risk factors for major bleeding complications, which 
can be divided into risk factors related to patient characteristics, comorbidities, co-
medication and the anticoagulant treatment (Table 1). 
These risk factors can be combined in risk prediction models, but these all perform 
relatively poorly.55 Available data also shows that patients who are at high risk of 
recurrent ischemic stroke have the highest risk for intracerebral bleeding,56 which 
complicates the decision whether to treat or continue anticoagulant treatment or to 
discontinue. New predictors for major bleeding complications are therefore necessary. 
Chapter 11 gives leads to what type of predictors we should be looking for. In addition, 
Chapter 12 describes a large prospective cohort study where plasma and DNA is 




between 2012 and 2014. This study is set-up in order to discover new leads to improve 
prediction of major bleeding complications in the future, and its methods are discussed. 
Chapter 13 provides the first results whether markers of endothelial damage could be 
considered as predictors for major bleeding.
table 1. Predictors for major bleeding complications during treatment with vitamin K 
antagonists
Patient characteristics Comorbidity Co-medication anticoagulant treatment
Advanced age31-33 Uncontrolled hypertension34-36 Antiplatelet drugs24 High INR37-41
Genetic profile42,43 Diabetes44,45 Antibiotics46 Low time in therapeutic 
range47-49
Bleeding history34,36,50,51 Cancer52 NSAIDs53,54 Labile INRs36
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objectives: Selection bias in case-control studies occurs when control selection 
is inappropriate. However, selection bias due to improper case sampling is less 
well recognized. We describe how to recognize survivor bias (i.e., selection on 
exposed cases) and illustrate this with an example study.
study design and setting: A case-control study was used to analyze the effect 
of statins on major bleedings during treatment with vitamin K antagonists. A 
total of 110 patients who experienced such bleedings were included 18-1,018 
days after the bleeding complication and matched to 220 controls.
Results: A protective association of major bleeding for exposure to statins (odds 
ratio [OR]: 0.56; 95% confidence interval: 0.29-1.08) was found, which did not 
become stronger after adjustment for confounding factors. These observations 
lead us to suspect survivor bias. To identify this bias, results were stratified on 
time between bleeding event and inclusion, and repeated for a negative control 
(an exposure not related to survival): blood group non-O. The ORs for exposure 
to statins increased gradually to 1.37 with shorter time between outcome and 
inclusion, whereas ORs for the negative control remained constant, confirming 
our hypothesis.
Conclusion: We recommend the presented method to check for overoptimistic 
results, that is, survivor bias in case-control studies.
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2
Survivor bias in case-control studies
IntRoduCtIon
Case-control studies are commonly used because it is an efficient way to study rare 
outcomes. They can be as credible as randomized studies, when correctly designed 
and performed.1 Cases are those who experience the event of interest, and controls 
are a random sample from the source population from which the cases arose.2 
Selection bias in case-control studies is well known to occur when control selection 
is inappropriate.2 However, selection of cases can result in bias as well, which is 
less well recognized. This selection bias can occur when cases are selected a long 
period after the event, and exposed cases have an increased risk of severe illness 
or death compared with nonexposed cases.3 In this article, we provide procedures 
to check for possible selection bias of cases and illustrate this with an example of a 
case-control study on the association of statin use and bleeding risk during treatment 
with vitamin K antagonists.
methods
The study used to illustrate this bias is the “factors in oral anticoagulation safety 
(FACTORS)” case-control study, which has been described before.4 Briefly, cases 
reported a nontraumatic (nonfatal) major bleeding complication, during treatment 
with vitamin K antagonists (oral anticoagulants). Major bleeding was defined as a 
bleeding leading to hospitalization, a sudden hemoglobin decrease of higher than 
1.25 mmol/L, or an intracranial, intra-abdominal, muscle, joint, or intraocular bleeding. 
These bleedings occurred between 1999 and 2001, and because vitamin K antagonists 
are characterized by a narrow therapeutic index, careful monitoring is necessary. In 
the Netherlands, this is performed by anticoagulation clinics.5
For every case, one to four controls without major bleeding event were matched 
on anticoagulation clinic, age, indication of anticoagulation, sex, vitamin K antagonist 
type (acenocoumarol or phenprocoumon), and whether treatment with vitamin K 
antagonists stopped before blood collection. Cases and controls were interviewed, 
and blood was drawn for testing on genetic variants.4 Inclusion of cases took place 
18-1,018 days after the major bleeding event (on average 425 days).
Cases and controls were considered statin users when they reported using this 
medication at time of the bleeding event (for cases) and during the interview (for 
controls). Odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated by 
means of conditional logistic regression, and were adjusted for comorbidity (diabetes 
and hypertension) and use of antiplatelet drugs. Written informed consent was obtained 
from all subjects, and the study was approved by the institutional reviewboards of the 
Leiden University Medical Center and the Academic Medical Center in Amsterdam. All 





Complete data of the 110 cases and 220 controls were available, except for data on 
blood group (unavailable in 10 subjects). Clinical characteristics are shown in Table 1. 
Among both cases and controls, statin users suffered more frequently from comorbid 
conditions and used antiplatelet drugs more frequently.
The OR of developing a major bleeding event in statin vs. nonstatin users was 0.56 
(95% CI: 0.29-1.08; Table 2). We expected that adjustment for comorbidity and use of 
antiplatelet drugs would lead to an even stronger protective risk estimate, as these 
confounding factors increase the risk for bleeding complications6 and are related to 
statin treatment. However, after adjustment for comorbidity and use of antiplatelet 
drugs, no stronger protective risk estimate was observed (OR: 0.53, 95% CI: 0.27-1.03).
These findings were somewhat counterintuitive: first of all, statins gave a nearly 
50% risk reduction of major bleeding, even if the indications for which statins are 
prescribed give an increased risk of major bleeding events. Second, adjustment for 
these confounders did not lead to a stronger protective risk estimate. We could have 
concluded that statins are powerful drugs, but instead hypothesized that this result 
might be biased.
Survivor bias occurs when exposed cases are less likely to take part in a study 
(e.g., because they died or became severely ill) than unexposed cases. This could mean 
that exposed cases in this study (i.e., patients who experienced a bleeding event and 
used statins) were less likely to participate (because of death or severe illness) when 
time between the event and inclusion in the study increased. Therefore, time between 
bleeding event and inclusion was taken into account because with more time between 
table 1. Clincal characteristics by cases or controls and statin use
cases (n = 110) Controls (n = 220)








% mean (sd) % mean (sd) % mean (sd) % mean (sd)
Age, years 69 (10) 67 (12) 67 (10) 70 (11)
Men 94 53 71 55
Body mass index, kg/m2 26.6 (3.4) 25.2 (4.0) 27.2 (4.2) 25.8 (3.8)
Positive smoking history 83 78 88 66
Hypertension 28 30 34 35
Diabetes 33 9 21 14
Antiplatelet drugs 6 4 4 1
Cancer 28 14 13 10
Years of treatment 6.6 (5.9) 5.1 (6.2) 2.9 (4.3) 2.9 (4.4)
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a bleeding event and inclusion the higher the possibility that a potential (exposed) 
case was not able to participate in our study. Therefore, selected cases (with their 
matched controls) were stratified on time between the bleeding event and inclusion 
(less than 2.00, 1.75, 1.50, 1.25, and less than 1.00 year). We saw that ORs increased 
gradually from 0.56 (95% CI: 0.29-1.08) to 1.34 (95% CI: 0.52-3.42) when cases were 
included within 3 and 1 year(s) after the bleeding event, respectively. After adjustment 
for comorbidity, this pattern remained the same (Table 2).
Although this stratified analysis suggests that our results were due to survivor 
bias, numbers were small, which may have led to this finding by chance. We therefore 
decided to explore this potential bias further, and repeated the analysis, only this time 
using exposure to blood group non-O as a “negative control”, meaning an exposure 
that, although related to the outcome, is not related to increased risk of death or severe 
illness.7 Risk estimates should remain stable with increasing time between the event 
and inclusion in the study to confirm our hypothesis of survivor bias. Indeed, the OR 
for major bleeding complications in patients with blood group non-O as compared with 
blood group O was 0.70 (95% CI: 0.43-1.14), and remained stable after stratifying on 
time between the major bleeding event and inclusion (Table 2).
dIsCussIon
We showed that an association found in a straightforward analysis of a case-control 
study can be biased due to selective survival of the cases. In our example, cases with 
major bleeding who were statin users were less likely to participate in our study in 
the period after the event than cases who did not use statins, resulting in finding a 
43% risk reduction of major bleeding during treatment with vitamin K antagonists. 
table 2. Association of major bleeding complications by statin use or blood group non-O, 















Any time 18/92, 56/164 0.56 (0.29-1.08) 0.53 (0.27-1.03) 59/50, 133/78 0.70 (0.43-1.14)
< 2.00 years 18/89, 56/158 0.56 (0.29-1.08) 0.55 (0.28-1.08) 56/50, 129/76 0.68 (0.42-1.11)
< 1.75 years 18/79, 53/140 0.60 (0.31-1.17) 0.59 (0.30-1.20) 51/45, 115/69 0.71 (0.43-1.17)
< 1.50 years 17/69, 45/130 0.74 (0.37-1.51) 0.71 (0.34-1.48) 44/41, 106/63 0.68 (0.40-1.17)
< 1.25 years 13/46, 30/89 1.01 (0.46-2.23) 1.00 (0.42-2.36) 29/29, 73/41 0.58 (0.30-1.12)
< 1.00 year 10/25, 18/54 1.34 (0.52-3.42) 1.37 (0.50-3.81) 17/18, 44/25 0.48 (0.19-1.24)
* Based on conditional logistic regression. † Based on conditional logistic regression and adjusted for 




This could be an important phenomenon that could occur more frequently in case-
control studies. We confirmed this phenomenon by performing our analysis for two 
exposures, but a caveat remains that our study is small numbered. We therefore tried 
to compare this finding with other studies; but to our knowledge, this is the first time 
of reporting on the association of statin use and major bleeding during treatment 
with vitamin K antagonists. However, there are many claims that statins have 
protective effects for several (non)vascular diseases, including multiples sclerosis, 
depression, Alzheimer’s dementia, atherosclerosis, osteoporosis, AIDS, cancer, and 
venous thrombosis.8 For venous thrombosis, a recent meta-analysis of observational 
studies compares statin users with nonstatin users, and shows a relative risk for 
venous thrombosis of 0.62 (95% CI: 0.45-0.86).9 The lowest relative risks (0.20-0.60) 
were found in studies that had enrolled patients who had survived their event until 
inclusion. All other studies reported relative risk estimates that were closer to unity 
(0.74-1.02).9 The studies with the lowest relative risks may therefore have suffered 
from the same problem, supporting the hypothesis that survivor bias may be more 
common and not always recognized as such. This is a problem, as causality is often 
inferred from these studies, which may lead to advice to prevent venous thrombosis 
with statins.10
Although we showed how to detect survivor bias, a possible limitation of our 
method (stratification on time between outcome and inclusion in the study, preferably 
repeated for a negative control) remains that it cannot distinguish survivor bias from a 
possible temporal biological effect of the exposure. To distinguish bias and a temporal 
effect, one should first look into the biology of the exposure toward the outcome. For 
this study, it seems that stratification on time is a good method to study survivor bias, 
as it is biologically implausible that statins do increase the risk for bleedings in the first 
year of use and then become protective.
A limitation of our example study is that numbers became small, especially after 
stratification on time between bleeding event and inclusion of cases. Therefore, the 
risk estimate (that was not more protective after adjustment for confounding factors in 
the stratified analyses) should be interpreted with caution. A way to overcome issues 
of survivor bias includes restriction of the analysis to cases who were included within 
a certain period in the study (dependent on the exposure and outcome). This analysis 
would be preferable when survivor bias is deemed as present. A negative control (when 
available) could be used to verify the presence of the bias if these are likely to occur 
due to chance, as was the case in our study. Another solution could be a study design 
where the exposure (statin use) and the outcome (major bleeding) are not related to 
inclusion in a study, for example, a cohort study.
In summary, when both the exposure and outcome are related to death or severe 
illness, overoptimistic associations could be found in case-control studies. Therefore, 
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we recommend using the method presented in this study (i.e., stratification on time 
between the event and inclusion in the study, preferably for both the exposure of 
interest and, in case of low numbers, also repeated in a negative control) to check for 
selective survival in cases.
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Statins are said to protect against a wide range of diseases. We studied to what 
extent potential bias influences the results of studies on beneficial side effects 
of statins. We selected 8,188 atrial fibrillation patients who started treatment 
with anticoagulants at the Leiden Anticoagulation Clinic in the Netherlands 
between 2003 and 2009 and experienced 1,683 minor and 451 major bleeds 
during 18,105 person-years of follow-up. Statins were associated with a risk 
reduction of 9% for bleeds (hazard ratio 0.91, 95%confidence interval: 0.82, 
1.00). Additionally, analyses were stratified by age, incident users (patients 
who started statins during follow-up, i.e., an inception cohort), and prevalent 
statin users (statin users at baseline), as restriction to incident users avoids 
overoptimistic risk estimates. After stratification, the protective associations 
disappeared or reversed (range of hazard ratios 0.99–3.22), except for patients 
aged 75 years or older. This remaining association could be due to another 
bias as, according to guidelines, in the elderly, statins should be prescribed 
only to those with a reasonable life expectancy. This could have resulted in a 
comparison of fit statin users with less fit non-statin users (healthy user effect). 
The apparent protective association of statins on bleeds may be due to bias. We 
recommend stratification by age and incident and prevalent statin use when 




Statins and bias in cohort studies
IntRoduCtIon
Statins reduce atherosclerosis1 and, consequently, arterial cardiovascular disease2, but 
they are also known for their wide range of unintended beneficial effects. Examples 
in which statin use is associated with lower risk for disease include, among others, 
Alzheimer disease3, Parkinson disease4, depression5, chronic obstructive pulmonary 
disease6, venous thrombosis7, 8, pneumonia9, and fractures10. It has been argued that, 
if many cures are attributed to a single drug, the drug may in fact be ineffective, and 
noncausal explanations such as bias should be sought.11 
A possible bias that may lead to lower risk estimates in observational studies is 
so-called “prevalent user bias.” This type of bias was described by Danaei et al.12 when 
studying associations of statins with mortality. In a meta-analysis, they showed that 
the pooled, multivariate-adjusted mortality hazard ratio for statin use was 0.54 (95% 
confidence interval (CI): 0.45, 0.66) when comparing prevalent statin users (statin 
users at baseline) with nonusers. However, in order to get the most valid results, 
observational studies should attempt to mimic clinical trials. When selecting the 
observational studies that, like the randomized trial, compared patients who started 
using statins during follow-up (an inception cohort design or incident statin users) with 
nonusers, researchers have found that risk estimates of studies with incident statin 
users (hazard ratio 0.77, 95% CI: 0.65, 0.91) were similar to those found in randomized 
controlled trials (hazard ratio 0.84, 95% CI: 0.77, 0.91).12, 13 
Another type of bias may occur as the result of the prescription guidelines of statins: 
The Dutch guideline of 1999 states that statins should be prescribed only to individuals 
with a life expectancy of at least 5 years.14 The renewed guideline from 2006 states 
that statins should be prescribed to individuals with a reasonable life expectancy who 
are not severely ill.15 A comparison of those who start using statins during follow-up 
(incident statin user) with nonusers among the elderly may therefore result in a 
comparison of elderly persons with a reasonable life expectancy with those with a 
short life expectancy, resulting in a so-called “healthy user effect”. 
The present study was performed to examine to what extent these potential biases 
influence its results and conclusions. For this purpose, we performed a cohort study on the 
association of statin use and bleeding risk during treatment with vitamin K antagonists.
methods
study population
A cohort was selected consisting of all patients who were 50 years or older and treated 
for atrial fibrillation at the Leiden Anticoagulation Clinic starting between January 2003 
and December 2009 (8,188 patients). As patients could interrupt their treatment with 




altogether. Data collection Patients’ characteristics and outcomes were collected 
from the computerized patient records from the Leiden Anticoagulation Clinic.16 At 
the anticoagulation clinic, a blood sample is collected every 1–6 weeks to measure 
the international normalized ratio (INR). A standard short history is obtained with 
every venipuncture regarding comedications, intercurrent illness, planned surgery, and 
bleeding complications.16 Baseline data of the cohort include age at start of vitamin 
K antagonist therapy, sex, main indication for vitamin K antagonist therapy, type of 
vitamin K antagonist (acenocoumarol or phenprocoumon), INR target range (2.5–3.5 
or 3.0–4.0), and concomitant medication use. The starting date of medication use 
(for this study: statins, antiplatelet drugs, antidiabetic agents, and antihypertensive 
medications) was reported by the patient or the drug-dispensing pharmacy. Diabetes 
mellitus and hypertension were defined from the first date of use of any antidiabetic 
agent (oral and/or parenteral) or antihypertensive drug, respectively. Patients were 
considered exposed to statins and antiplatelet drugs from the first date of use of the 
drugs until the end date of the study period. Neither informed consent nor approval 
by a medical ethics committee is, according to Dutch law, required for studies in which 
data are collected from the records by a member of the treatment team.
outcomes
Nontraumatic major bleeding events were classified by physicians of the Leiden 
Anticoagulation Clinic. Bleeding events that required hospitalization or blood 
transfusion, that were symptomatic in a critical area or organ, or led to death were 
classified as major.17 Nontraumatic minor bleeding events included all  haemorrhages 
that were not classified as major and were categorized as such by the Anticoagulant 
Clinic’s physicians and/or nurses. We excluded traumatic bleeding events because 
statins could protect against nontraumatic bleeds, while their pharmacological actions 
are not likely to protect against bleeding events caused by trauma.
statistical analyses
For every treatment with vitamin K antagonists, person-time was calculated from 
the start of treatment with vitamin K antagonists until the bleeding event, death, 
moving to a city that was not covered by the Leiden Anticoagulation Clinic, end of 
treatment, or end of the study period (December 31, 2009), whichever occurred first. 
When calculating the person-time for major bleeds, we ignored the occurrence of 
minor bleeds and vice versa. We used a Cox regression model, with time-dependent 
covariates to estimate hazard ratios and 95% confidence intervals. The proportionality 
of the hazards assumption was tested by analysis of Schoenfeld residuals, and for this 
analysis statistical significance was set at the 5% level.
Patients were classified in 3 age groups (50–64 years, 65– 74 years, and 75 years 
or older) to study age-specific associations. Age-specific associations were expected 
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as a potential healthy user effect in elderly patients may be present as a result of the 
prescription guidelines.14, 15
We adjusted for the confounding factors sex, INR target range (3.0–4.0 vs. 2.5–3.5), 
diabetes mellitus (time dependently), hypertension (time dependently), and use of 
antiplatelet drugs (time dependently) in the simple adjusted model. The fully adjusted 
model also included age (by the abovementioned age categories for the overall risk 
estimates and continuously for analyses within age groups, because confounding due 
to age can still be present within an age group). We performed 3 different analyses. 
First, we compared all statin users (as a time-dependent variable) with nonstatin users. 
Then, incident users were compared with nonusers by using only the patients who did 
not use statins at baseline. In the last analysis, prevalent users were compared with 
nonusers; if a patient started to use statins after baseline, his follow-up was censored.
All analyses were performed with the R, version 2.15.2, language and environment 
for statistical computing (R Foundation for Statistical Computing, Vienna, Austria).
ResuLts
Of 8,188 patients, 7,592 had 1, 536 had 2, 53 had 3, 5 patients had 4, and 2 patients had 
5 treatment periods during the study period. Patients with multiple treatment periods 
were treated for a period with vitamin K antagonists, which was discontinued for 
some time and then restarted. A common reason to discontinue vitamin K antagonist 
treatment was a successful cardioversion (either chemical or mechanical).18
The mean age at baseline was 74 (range, 50–103) years, and 4,847 patients (55%) 
were men. The INR target range was 2.5–3.5 in 8,659 (98%) treatment periods as 
recommended for atrial fibrillation in the Netherlands19, and phenprocoumon was used 
during 8,009 (91%) treatment periods. Statin users were more frequently male than 
were nonstatin users. The prevalence of hypertension, diabetes, and use of antiplatelet 
drugs was higher in statin users than nonstatin users (Table 1). Stratification of incident 
statin users by age showed that patients aged 50–64 years were more frequently male 
and had a lower prevalence of diabetes mellitus than patients aged 75 years or older.
During a total follow-up of 15,008 person-years for all bleeds, 15,231 person-years 
for minor bleeding events, and 18,105 person-years for major bleeding events, 1,991 
patients experienced any bleed, 1,683 experienced a minor bleed, and 451 patients 
experienced a major bleeding event. The incidence rate was 133 (95%CI: 127, 139) per 
1,000 person-years for all, 110 (95% CI: 105, 116) per 1,000 person-years for minor, 
and 25 (95% CI: 23, 27) per 1,000 person-years for major bleeding complications. The 
incidence rates of all, major, and minor bleeding complications increased with age 
(Figure 1), and the most common sites of major bleeds were the gastrointestinal tract 




table 1. Baseline Characteristics of the Cohort by Type of Statin User Who Started Treatment 











years ≥75 years total
no. % no. % no. % no. % no. % no. %
General characteristics
 Patients 5,919 2,367 250 308 282 840
 Treatment periods 6,365 100 2,488 100 250 100 309 100 283 100 842 100
 Men 3,306 52 1,541 62 188 75 212 69 134 47 534 63
 Age, yearsa 74 (11) 73 (9) 61 (4) 72 (3) 82 (4) 72 (9)
INR target range, 2.5–3.5 6,242 98 2,417 97 243 97 302 98 271 96 816 97
Vitamin K antagonists
 Phenprocoumon 5,774 91 2,243 90 236 94 289 94 261 92 786 93
 Acenocoumarol 591 9 245 10 14 6 20 6 22 8 56 7
Comedication and comorbidity
 Hypertension 3,528 55 1,739 70 206 82 254 82 237 84 697 83
 Diabetes 535 8 518 21 44 18 72 23 80 28 196 23
 Use of antiplatelet drugs 173 3 305 12 14 6 33 11 27 10 74 9
Abbreviation: INR, international normalized ratio. aMean (standard deviation).
figure 1. Incidence rates per 1,000 person-years of bleeding complications stratified by age of 
patients who started treatment with vitamin K antagonists in Leiden, netherlands, between 
2003 and 2009. Circles, major bleeding events; squares, minor bleeding events; triangles, all 
bleeding events; bars, 95% confidence intervals.
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Statins were used during 3,330 treatment periods and initiated during 842 treatment 
periods (the latter were considered incident statin users). Overall, the crude hazard 
ratio of statin use (prevalent and incident statin use combined) versus non-statin use 
was 0.90 (95% CI: 0.81, 0.99) for all bleeds, 0.91 (95% CI: 0.82, 1.01) for minor bleeds, 
and 0.90 (95% CI: 0.75, 1.11) for major bleeds (Table 2). Adjustment for sex, INR target 
range, diabetes, hypertension, and use of antiplatelet drugs resulted in hazard ratios 
of 0.88 (95% CI: 0.80, 0.97) for all, 0.83 (95% CI: 0.67, 1.02) for major, and 0.90 (95% CI: 
0.81, 1.01) for minor bleeds (Table 2). After further adjustment for age, these hazard 
ratios increased toward unity (Table 2).After stratification by age, no protective risk 
estimates were found in patients aged 50–64 years and 65–74 years, but protective risk 
estimates were still found in the oldest patients for all outcomes (Table 3). Restriction 
to incident statin users (Figure 2) and nonusers yielded higher risk estimates than did 
restriction to prevalent statin users and nonusers for all outcomes (incident users vs. 
nonusers for all bleeding complications: fully adjusted hazard ratio = 1.08, 95% CI: 0.90, 
1.32; minor bleeding complications fully adjusted hazard ratio = 1.18, 95% CI: 0.96, 1.45; 
major bleeding complications fully adjusted hazard ratio = 0.93, 95% CI: 0.63, 1.36). 
Similar results were found in all age groups, except for major bleeds in patients 75 years 
or older (prevalent users fully adjusted hazard ratio = 0.89, 95% CI: 0.68, 1.18; incident 
users fully adjusted hazard ratio = 0.73, 95% CI: 0.45, 1.20).
table 2. Association of Statin Use (Prevalent and Incident Statin Use Combined) With Major 
and Minor Bleeding Complications in a Cohort of Patients Who Started Treatment With 









years HRa 95% CI HRb 95% CI HRc 95% CI
All bleeding complications
 Nonstatin users 9,584 1,357 14.16 1.00 Referent 1.00 Referent 1.00 Referent
 Statin users 5,424 634 11.69 0.90 0.81, 0.99 0.88 0.80, 0.97 0.91 0.82, 1.00
Minor bleeding complications
 Nonstatin users 9,732 1,146 11.78 1.00 Referent 1.00 Referent 1.00 Referent
 Statin users 5,499 537 9.77 0.91 0.82, 1.01 0.90 0.81, 1.01 0.92 0.83, 1.03
Major bleeding complications
 Nonstatin users 11,516 302 2.62 1.00 Referent 1.00 Referent 1.00 Referent
 Statin users 6,589 149 2.26 0.91 0.75, 1.11 0.83 0.67, 1.02 0.90 0.73, 1.11
Abbreviations: CI, confidence interval; HR, hazard ratio; INR, international normalized ratio. 
a Time-dependent analysis. b Time-dependent analysis adjusted for sex, INR target range, diabetes, 
hypertension, and antiplatelet drugs. c Time-dependent analysis adjusted for sex, INR target range, 
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dIsCussIon
This study shows that statin use initially seemed to reduce the risk of minor and major 
bleeding events by 9% in the overall straightforward analysis (i.e., before we stratified 
the analysis by age and incident and prevalent statin users). However, after restriction 
to incident statin users, protective risk estimates largely disappeared or even reversed. 
After stratification by age, the risk estimates showed a protective association in patients 
of 75 years or older. Associations in (pharmaco)epidemiologic studies can be due 
to causal mechanisms but also to confounding or bias.20 As potential explanations 
for the associations found in this study, causal mechanisms, confounding, and bias 
were considered.
The association of statin use with bleeding events during treatment with vitamin K 
antagonists in the initial analysis of this study (fully adjusted hazard ratio = 0.91, 95% 
CI: 0.82, 1.00) was similar to the association that was previously found by Douketis 
et al.21 (adjusted odds ratio 0.91, 95% CI: 0.77, 1.07). Douketis et al. suspected that this 
protective association was due to bias. As shown in this study, bias could partially be due 
to a comparison of prevalent statin users with nonusers, which is in line with what was 
described in the meta-analysis by Danaei et al.12 This bias is not restricted only to statin 
therapy. Hernán et al.22 showed that it is also present in studies on the effects of hormone 
replacement therapy on coronary heart disease when current (prevalent) drug users 
instead of initiators (incident drug users) are compared with nonusers.23 The results of 
these studies12, 22 along with those of the present study suggest that comparisons of drug 
initiators with nonusers yield more reliable risk estimates than comparisons of prevalent 
drug users with nonusers when studying associations of drugs on disease outcomes.














Age, years and Bleeding Events
10.0
figure 2. fully adjusted hazard ratios for association of statins with bleeding complications, 
stratified by age and incident or prevalent statin use, in patients who started treatment with 
vitamin K antagonists in Leiden, netherlands, between 2003 and 2009. Circles, prevalent statin 




Another explanation for an association may be a causal effect, which is usually 
based on potential mechanisms from literature. Statins are known for their inhibitory 
effects on platelet function and their raising levels of procoagulant factors.24, 25 These 
effects may explain the risk estimates indicative of an increased risk for bleeds of 
incident statin users as compared with nonusers in patients aged 50–64 years (hazard 
ratio 1.18–3.22) and 65–74 years (hazard ratio 1.11–1.31). However, this potential 
explanation of the found associations is not in line with the results in patients aged 
75 years or older.
Another bias we will consider is healthy user bias due to prescription guidelines. 
The guidelines state that starting statins in elderly patients should be restricted to 
relatively healthy individuals.14, 15 Especially in the elderly who started using a statin, 
these guidelines may result in a comparison of healthy elderly who started using a statin 
with less healthy ones who did not start using a statin, resulting in healthy user bias. 
The guidelines may explain why risk estimates of statin use for major bleeds remained 
protective in the oldest patients (aged 75 years or older) when considering only incident 
statin use (fully adjusted hazard ratio 0.73).
The last source of spurious associations we will discuss is confounding.20 In this 
study, we were not able to fully adjust for confounding by indication and life style–
dependent confounding factors (because, e.g., body mass index and cholesterol levels 
were unknown). The increased risk estimates found in patients aged 50–64 years may 
be attributable to residual confounding, as these patients may have received statins 
as the result of an unhealthy life style. In addition, diabetes and hypertension were 
classified by first date of use of antidiabetic or antihypertensive drugs. Because diabetic 
or hypertensive treatment could have started a long time after patients developed 
these conditions, misclassification could have occurred. Therefore, adjustments for 
hypertension and diabetes may not have been perfect. Furthermore, comparing the 
results of our study with findings in randomized clinical trials (i.e., a “gold standard”) in 
similar populations could give some indication of the amount of residual confounding, 
but unfortunately these trials have not been conducted.
In summary, a comparison of incident statin users with nonusers may yield most 
reliable risk estimates. Additionally we found that a healthy user bias may be present 
in older patients, suggesting that restriction to incident statin users alone will not 
prevent all biases. These biases may (partially) explain the wide range of unintended 
protective effects attributed to statins. Examples are protections against depression5, 
chronic obstructive pulmonary disease6, and pneumonia9 that were found in case-
control studies where often only prevalent users are considered in the analysis. 
Examples from cohort studies include Parkinson disease4, venous thrombosis7, 8, and 
fractures10, where statin users (prevalent and incident combined) were compared with 
nonusers or never users. We therefore recommend stratification for types of statin 
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users and age in cohort studies. This could prevent overoptimistic risk estimates and 
false positive findings.
This study consisted of a large homogenous and consecutive cohort of atrial 
fibrillation patients with registration of more than 450 major and 1,650 minor 
bleeding events. Still, as a limitation of our sample study, numbers became small after 
stratification by age and incident and prevalent statin users. Additionally, without 
results from a randomized controlled trial in the population under study, we cannot 
rule out that our final adjusted findings are attributable to a causal effect, residual 
confounding, or sampling error. Another potential limitation of this study is that no 
data were present on the end date of statin use, which may have resulted in a dilution 
of the risk estimates.
Our findings support the hypothesis that comparing prevalent statin users with 
nonusers in observational studies leads to biased risk estimates.12 In addition, we 
observed that restriction to incident statin users does not necessarily prevent all bias 
in observational studies on the associations of statins with disease outcomes, because 
a healthy user bias may be present when comparing older incident statin users with 
nonusers. Both biases give overoptimistic views on the pleiotropic effects of statins that 
are similar to what was found in earlier studies on hormone replacement therapy.22, 23 To 
conclude, when studying the associations of statins with disease outcomes in cohorts, 
we recommend stratification by age and by incident and prevalent statin use to avoid 
overoptimistic risk estimates.
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table 1. Distribution and Type of Bleeding Events, Stratified by age Among Patients who 
Started Treatment With Vitamin K Antagonists in Leiden Between 2003 and 2009
all age 50-64 years age 65-74 years age > 75 years
Major non-fatal bleeding complications, n (%)
Total 311 (100) 27 (100) 70 (100) 214 (100)
Cerebral 46 (15) 6 (22) 16 (23) 24 (11)
Gastrointestinal 136 (44) 8 (30) 24 (34) 104 (49)
Muscle and joint 36 (12) 4 (15) 6 (18) 26 (12)
Skin 24 (8) 2 (7) 4 (6) 18 (8)
Respiratory 11 (4) 1 (4) 3 (4) 7 (3)
Epistaxis 7 (2) 2 (7) 3 (4) 2 (1)
Eye 20 (6) 0 5 (7) 15 (7)
Urogenital 28 (9) 4 (15) 9 (13) 15 (7)
Other 3 (1) 0 0 3 (1)
Major fatal bleeding complications, n (%)
Total 140 (100) 2 (100) 15 (100) 123 (100)
Cerebral 99 (71) 2 (100) 13 (87) 84 (68)
Gastrointestinal 20 (14) 0 0 20 (16)
Aneurism 9 (6) 0 0 9 (7)
Respiratory 8 (6) 0 2 (13) 6 (5)
Other 4 (3) 0 0 4 (3)
Minor bleeding complications, n (%)
Total 1705 (100) 219 (100) 471 (100) 1015 (100)
Gastrointestinal 155 (9) 18 (8) 33 (7) 104 (10)
Conjunctiva 458 (27) 65 (30) 153 (32) 240 (24)
Large bruising 404 (24) 51 (23) 87 (18) 266 (26)
Epistaxis 277 (16) 30 (14) 72 (15) 175 (17)
Urogenital 23 (1) 3 (1) 2 (0) 18 (2)
Respiratory 25 (1) 3 (1) 3 (1) 19 (2)








Background: Whether vitamin supplements decrease venous thrombosis risk is 
controversial. Previous reports did not all take confounding fully into account, 
either by randomization or by extensive adjustment.
objective: The aim of our study was to determine whether vitamin 
supplementation decreases the risk of venous thrombosis.
design: A large case-control study included 2506 patients with venous 
thrombosis, 2506 partner controls, and 2684 random-digit dialing (RDD) 
controls. When patients were compared with RDD controls, unconditional 
logistic regression was used to calculate ORs with 95% CIs. When patients 
were compared with partner controls, conditional logistic regression was used, 
providing further adjustment for unmeasured confounding.
Results: Vitamin use yielded a 37% lower risk of venous thrombosis than 
no vitamin use (OR: 0.63; 95% CI: 0.57, 0.70) when comparing patients with 
RDD controls. Adjustment for several putative confounders did not change 
the estimate (OR: 0.68; 95% CI: 0.61, 0.77). The fully adjusted ORs for vitamin 
A, vitamin B-6, vitamin B-12, folic acid, vitamin C, vitamin D, vitamin E, and 
multivitamin use were in the same range. However, when patients were 
compared with partner controls, ORs attenuated to unity. Results were similar 
for provoked and unprovoked events, as well as for deep vein thrombosis and 
pulmonary embolism.
Conclusions: After extensive adjustments, vitamin supplementation was no 
longer associated with a decreased risk of venous thrombosis in this study. 




Vitamin supplementation on the risk of VT: results from the MEGA case-control study
IntRoduCtIon
Venous thrombosis is one of the leading causes of morbidity and mortality worldwide, 
occurring each year in about one in 1000 people in industrialized countries.1 The 
condition can be prevented and treated with anticoagulants, but as a side effect, 
bleeding often occurs.2 Therefore, strategies for the prevention of venous thrombosis 
that are not based on oral anticoagulant treatment are needed. Both basic research 
and observational epidemiologic studies have supported the hypothesis that vitamins 
may inhibit venous thrombosis. For example, based on early findings that elevated 
homocysteine concentrations are associated with thrombotic disease3, 4, as well as 
the knowledge that homocysteine concentrations depend on a series of intracellular 
metabolic reactions in which folate acts as a substrate and vitamin B-12 as a coenzyme, 
it was believed that adequate supplementation of B vitamins could lower homocysteine 
and thus decrease the risk of thrombotic events.5 However, initial therapeutic trials 
with vitamin B supplements that induce a decrease in homocysteine concentration 
have not resulted in an improvement of the thrombotic risk6–8, probably because of the 
existence of a more complicated metabolic network than what was assumed at first 
or the absence of a causal relation between hyperhomocysteinemia and thrombotic 
risk.9 As a consequence, multivitamin supplementation became of interest irrespective 
of the homocysteine concentration, and several studies dealing with the possible 
connection of different vitamins and thrombotic risk have been designed. Most of 
these studies investigated the risk of arterial thrombosis and yielded inconsistent 
results.10-12 For venous thrombosis, studies are scarce. Some showed that vitamin D 
or E supplementation decreases the risk of venous thrombosis13, 14; others showed 
no effect.15 As far as we know, no other observational studies or trials have analyzed 
whether other vitamins such as vitamin A and vitamin C are associated with a decreased 
risk of venous thrombosis.
One issue to keep in mind when studying the effect of vitamin use on venous 
thrombosis is that studies on vitamin therapy are generally not randomized and 
lack proper adjustment for the many lifestyle-related factors that could confound 
the relation. 
In this study, we used data from the Multiple Environmental and Genetic Assessment 
(MEGA) case-control study to analyse whether use of vitamin A, vitamin B-6, vitamin 
B-12, vitamin C, vitamin D, vitamin E, folic acid, or multivitamins decreased the risk of 
venous thrombosis. This study provided an excellent opportunity to study this because 
both measured and unmeasured confounding factors could be taken into account by 
comparing patients with population-derived random-digit dialing (RDD) controls and 






The design of the MEGA case-control study is described elsewhere.16 In short, 4956 
consecutive patients aged 18–70 y, with a first diagnosis of deep vein thrombosis or 
pulmonary embolism, were included from 6 anticoagulation clinics in The Netherlands 
(Amersfoort, Amsterdam, The Hague, Leiden, Rotterdam, and Utrecht) between 
March 1999 and September 2004. Diagnostic information was obtained from hospital 
discharge reports and general practitioners. The diagnosis of deep vein thrombosis 
was confirmed with Doppler ultrasonography, whereas the diagnosis of pulmonary 
embolism was confirmed with a ventilation perfusion lung scan, spiral computed 
tomography, or angiogram. Patients’ partners were invited to participate as controls 
if they were aged 18–70 y and had no history of venous thrombosis. In total, 3297 
partners participated, forming a first control group. Also, from January 2002 through 
September 2004, a total of 3000 additional controls, who were recruited by using 
an RDD method, formed a second control group. These participants were also aged 
18–70 y with no previous history of venous thrombosis.
All participants gave written informed consent. The study was approved by the 
Medical Ethics Committee of the Leiden University Medical Center, Leiden, The 
Netherlands.
data collection and definitions
The index date for patients and partner controls was defined as the date of diagnosis 
of the thrombotic event. For RDD controls, the index date was the date of informed 
consent signing. Participants completed a standardized questionnaire, including items 
on demographic and lifestyle factors, as well as on potential risk factors for venous 
thrombosis.17 Also, self-reported information was obtained on weight, height, and 
smoking habits, according to which participants were classified as current smokers, 
previous smokers, or nonsmokers.18 BMI was calculated according to the following 
formula: weight (kg)/height squared (m2), and participants were classified into 
3 categories (in kg/m2): normal weight (<25), overweight (25–30), and obese (>30). 
A structured questionnaire was taken from all participants regarding, among others, 
medication use. Participants were classified as vitamin users if they reported regular 
use of one or more of the following: folic acid, multivitamins, or vitamins A, B-6, B-12, 
C, D, or E in the 12 mo before the onset of venous thrombosis (for patients) or before 
enrollment in the MEGA study (controls). No information was obtained on the dosage 
of vitamin intake. 
Provoked venous thrombosis was defined as venous thrombosis preceded by 
surgery, plaster cast immobilization, bed rest, leg injury, or hospitalization in the 3 mo 
before the index date or long-distance travel in the 2 mo before the index date.
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Inclusion/exclusion criteria
Of the 4956 patients, we excluded 182 women who were pregnant at the index date 
or within the previous 3 mo. These women were excluded as guidelines recommend 
that women should take folic acid during pregnancy, and pregnancy itself affects 
risk.19 Next we excluded 517 patients from this study for whom information on vitamin 
consumption was missing, which left 4257 patients. Of these patients, 2506 had a 
partner who fulfilled the inclusion criteria and was willing to participate, so 2506 
complete couples remained. After application of the same exclusion criteria on the 
RDD control group, 2684 RDD control participants could be included in our analysis.
statistical analysis
Participants were analyzed as current vitamin users or nonusers but also as users and 
nonusers of different types of vitamins (folic acid, multivitamins, and vitamins A, B-6, 
B-12, C, D, and E). Because the control population consisted of either RDD controls or 
partners of patients, we could perform 2 analyses. In the first analysis, we compared 
patients with RDD controls and adjusted for all measured confounding factors. In the 
second analysis, we used the partners of the patients as control individuals. 
When patients were compared with RDD controls, unconditional logistic regression was 
used to calculate ORs with 95% CIs as a measure of the relative risks for venous thrombosis 
in vitamin users compared with nonusers. This analysis is unconditional, because controls 
were not individually matched to the patients, apart for frequency matching for age and 
sex, for which we adjusted. In the unconditional logistic regression analysis, all patients 
(n = 4257) were compared with all RDD controls (n = 2684). In a separate analysis, we 
also compared patients who had a partner (n = 2506) with RDD controls to see whether 
this would affect our risk estimates. Analyses were adjusted for age, sex, BMI, smoking 
habits, and prevalent arterial cardiovascular diseases, which included prior myocardial 
infarction or ischemic stroke. To avoid that effects of vitamin use on the risk of venous 
thrombosis were attributable to residual lifestyle-related confounders that are associated 
with vitamin use20–22, we also included statin use, hormonal drug use (defined as oral 
contraception or postmenopausal hormone therapy), and physical activity as potential 
sources of confounding. Hormonal drugs were added to the model as a dichotomous 
variable in which all men were classified as unexposed.23, 24 Hyperhomocysteinemia was 
not added as a confounding variable in the models because vitamin supplementation 
in hyperhomocysteinemia is not common in The Netherlands. Patients with provoked 
and unprovoked venous thrombosis, as well as patients with deep vein thrombosis and 
pulmonary embolism, were combined in most analyses but also analyzed separately.
Vitamin use may be related to a general health-conscious behavior, which may 
affect the risk of thrombosis and therefore act as a confounder. Such behavior is 




patients in health consciousness more than RDD controls, and therefore we performed 
a 1:1 matched analysis by conditional logistic regression, which adjusts for associations 
within matched pairs. This method provides adjustment for all unmeasured factors for 
which couples tend to be similar.25 The analysis is conditional because many clinical 
characteristics of controls, who are individually matched to the patients, are likely 
to be similar to patient characteristics. One needs to take this into account in the 
analysis because otherwise, the frequency (of vitamin intake, for example) would 
become similar in cases and controls, leading to biased null findings. In this analysis, 
we also adjusted for all aforementioned potential confounding factors. Although using 
partners as controls results in most controls having the opposite sex as their matched 
case, one can adjust for sex in a partner-matched case-control study by allowing for 
sex with an indicator variable.24
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figure 1. selection of patients and controls in the multiple environmental and genetic 
assessment study. part., partner; RDD, random-digit dialing.
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All statistical analyses were performed with SPSS for Windows, version 20.0 
(SPSS Inc.). Conditional logistic regression was performed by using the COXREG 
procedure, as explained on the SPSS tutorial page at http://www-01.ibm.com/support/
docview.wss?uid=swg21477360.
table 1. Clinical characteristics of the MEGA case-control study1
Patients Partner controls Rdd controls
(n = 4257) (n=2506) (n=2684)
vitamin use2 no3 yes3 no3 yes3 no3 yes3
General characteristics
   Total 2844 (67) 1413 (33) 1688 (67) 818 (33) 1503 (56) 1181 (44)
   Men 1479 (52) 544 (38) 905 (54) 294 (36) 772 (51) 404 (34)
   Age at enrollment, y 49 (18-70) 49 (18-70) 49 (18-70) 49 (18-70) 46 (18-71) 45(18-70)
   Body mass index, kg/m2 27 (14-63) 26 (15-55) 26 (17-48) 25 (17-45) 25 (16-53) 25 (16-50)
   Malignancy 232 (8) 153 (11) 28 (2) 13 (2) 25 (2) 29 (3)
Classical venous thrombosis risk factors
   Present4 1465 (52) 844 (61) 255 (16) 169 (23) 347 (23) 302 (26)
   Without hormonal risk factors 655 (33) 346 (39) 70 (5) 45 (7) 75 (6) 54 (6)
    With hormonal risk factors 
(in women)
798 (60) 483 (58) 179 (26) 119 (26) 271 (38) 243 (32)
   Absent4 1359 (48) 549 (39) 1343 (84) 581 (77) 1142 (77) 858 (74)
Arterial cardiovascular risk factors
   Overweight 1240 (45) 516 (38) 707 (43) 282 (36) 514 (36) 357 (31)
   Obesity 585 (21) 260 (19) 259 (16) 111 (14) 192 (13) 97 (9)
   Previous smoking 854 (30) 421 (30) 502 (30) 260 (32) 410 (27) 317 (27)
   Current smoking 1036 (37) 482 (34) 552 (33) 247 (31) 466 (31) 359 (31)
   Self-reported prior CVD5 112 (4) 49 (4) 44 (3) 11 (1) 38 (2) 26 (2)
   Statin use 120 (4) 30 (2) 97 (6) 37 (4) 98 (7) 61 (5)
   Regular sports activity 845 (33) 470 (37) 539 (36) 319 (44) 595 (45) 550 (53)
1Values are n (%) unless otherwise indicated. CVD, cardiovascular disease; MEGA, Multiple 
Environmental and Genetic Assessment; RDD, random-digit dialing. 2Use of either vitamin A, B-6, B-12, 
folic acid, vitamin C, D, E or multivitamins 3Continuous variables denoted as mean (range), categorical 
variables as number (%) 4Classical risk factors include surgery, malignancy, immobilization, trauma, 
plaster cast, oral contraceptive, hormonal replacement therapy and recent travel 5CVD denotes self-




















    No Vitamin 
therapy
2844 (67) 1503 (56) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
    Vitamin 
therapy
1413 (33) 1181 (44) 0.63 (0.57,0.70) 0.60 (0.53,0.68) 0.68 (0.61,0.76) 0.68 (0.61,0.77)
   Vitamin A 40 (1) 43 (2) 0.57 (0.37,0.89) 0.61 (0.38,0.97) 0.63 (0.38,1.03) 0.65 (0.38,1.12)
   Vitamin B-6 112 (3) 109 (4) 0.63 (0.48,0.83) 0.63 (0.48,0.84) 0.64 (0.48,0.85) 0.61 (0.44,0.84)
   Vitamin B-12 141 (3) 128 (5) 0.67 (0.52,0.86) 0.69 (0.53,0.89) 0.68 (0.52,0.89) 0.65 (0.48,0.87)
   Folic acid 143 (5) 147 (3) 0.67 (0.53,0.85) 0.65 (0.50,0.83) 0.80 (0.62,1.05) 0.85 (0.64,1.13)
   Vitamin C 364 (9) 396 (15) 0.55 (0.47,0.64) 0.57 (0.49,0.68) 0.57 (0.48,0.67) 0.57 (0.48,0.69)
   Vitamin D 86 (2) 57 (2) 0.90 (0.64,1.27) 0.98 (0.69,1.40) 1.06 (0.72,1.54) 1.16 (0.77,1.75)
   Vitamin E 96 (2) 79 (3) 0.71 (0.53,0.97) 0.73 (0.53,1.00) 0.81 (0.58,1.13) 0.87 (0.60,1.25)
   Multivitamins 792 (19) 782 (29) 0.57 (0.51,0.64) 0.60 (0.53,0.68) 0.60 (0.53,0.68) 0.63 (0.55,0.72)
1ORs (95% CIs) were estimated by means of unconditional logistic regression. RDD, random-digit 
dialing. 2Adjusted for age, sex, and partnership where applicable 3Adjusted for age, sex, BMI, smoking, 
and partnership where applicable 4Adjusted for age, sex, BMI, smoking, statin use, hormones use, 
and partnership where applicable 5Adjusted for age, sex, BMI, smoking, statin use, hormones use, 
cardiovascular disease, sports activity, and partnership where applicable
ResuLts
A total of 7696 participants (2506 patients, 2506 partner controls, and 2684 RDD 
controls) were included in this study (Figure 1). The main characteristics of participants 
are presented in Table 1 and Appendix 1 Table 1. The mean age was 49 y (range, 18–70 y) 
in patients and partner controls and 46 y (range, 18–70 y) in RDD controls. Vitamin 
supplements were used  by 796 (32%) patients, 818 (33%) partner controls, and 1181 
(44%) RDD controls. Because patients were matched to their partners, only exposure-
discordant couples (i.e., couples in whom vitamin consumption differs between patient 
and partner) were relevant to the univariable risk analyses.26 In total, there were 744 
discordant couples (i.e., in whom only one of the two used vitamins). Participants who 
used vitamins and those who did not were of similar age. Female participants used 
vitamins more frequently than did men. Patients and RDD controls with malignancy 
used vitamins more frequently (40% compared with 54%) than did participants without 
malignancy (32% compared with 44%), respectively, while in partner controls, there was 
no difference regarding vitamin use between those with and without malignancy. Also, 
participants with classic venous thrombosis risk factors used vitamins more frequently 
54
4
Vitamin supplementation on the risk of VT: results from the MEGA case-control study
than did those without these risk factors, but this was mainly associated with hormone 
use. In vitamin users, the prevalence of hormone use and sporting was higher, whereas 
the prevalence of statin use was lower than in nonusers. Also, participants who used 
vitamins were less likely to be overweight or obese than participants who did not use 
vitamins. No other characteristics were associated with vitamin use.
Overall, vitamin use was associated with a decreased risk of venous thrombosis 
when comparing all patients with RDD controls (OR: 0.63; 95% CI: 0.57, 0.70) (Table 2). 
Adjustment for age, sex, BMI, smoking, statin use, and hormone use yielded an OR of 
0.68 (95% CI: 0.61, 0.77). The fully adjusted ORs for vitamin A, vitamin B-6, vitamin 
B-12, folic acid, vitamin C, vitamin D, vitamin E, and multivitamin use were in the same 
range. The results were the same when we compared patients with a partner with RDD 
controls (Appendix 1 Table 2).
When we compared patients with their partner controls, 361 couples were present 
in whom the patient had been taking vitamins but the partner had not, as well as 383 
couples in whom it was the other way around, resulting in ORs close to unity; the fully 
adjusted ORs also were in the same range. An exception was vitamin A therapy, in 
which the OR was 0.47 (95%CI: 0.24, 0.91), and the fully adjusted OR was 0.46 (95% 
CI: 0.18, 1.20) (Table 3). In a further analysis, we restricted the outcome to deep vein 
thrombosis or pulmonary embolism and analyzed patients with and without classic 
provocative risk factors for venous thrombosis. These analyses showed similar results 
(Tables 4 and 5 and Appendix 1 Table 3).
dIsCussIon
We analyzed data from a large case-control study with the aim to investigate whether 
vitamin supplements decrease venous thrombosis risk by using both population and 
partner controls and found that vitamin B, C, D, and E supplementation is not associated 
with a decreased risk.
In the initial analyses, in which patients were compared with RDD controls, we 
observed a 37% decrease in risk for venous thrombosis in vitamin users compared 
with no vitamin users. After adjustment for many lifestyle-related factors such as BMI, 
smoking, statin use, hormone use, and sports activity, this decrease was still 32%. For 
the individual vitamins, a protective effect was found for vitamin B-6, vitamin B-12, folic 
acid, and vitamin C, with a 39%, 35%, 35%, and 43% decrease in risk after adjustment, 
respectively. On the basis of these results, we could have concluded that one should 
prescribe vitamins to prevent venous thrombosis, especially considering the popular 
opinion that vitamins are otherwise harmless. 27 However, comparison of patients with 
venous thrombosis and their partners showed that the above-mentioned risk estimates 
(with the possible exception of vitamin A) were likely to be confounded, because in this 




















    No Vitamin 
therapy
1710 (68) 1688 (67) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
    Vitamin 
therapy
796 (32) 818 (33) 0.98 (0.84,1.14) 1.03 (0.88,1.20) 1.13 (0.95,1.35) 1.11 (0.91,1.35)
   Vitamin A 38 (1) 23 (1) 0.47 (0.24,0.91) 0.47 (0.23,0.95) 0.58 (0.26,1.25) 0.46 (0.18,1.20)
   Vitamin B-6 56 (2) 59 (2) 0.97 (0.65,1.44) 0.96 (0.63,1.46) 0.97 (0.61,1.54) 0.86 (0.49,1.49)
   Vitamin B-12 75 (3) 65 (3) 1.22 (0.85,1.77) 1.24 (0.84,1.84) 1.04 (0.67,1.61) 0.94 (0.55,1.61)
   Folic acid 73 (3) 69 (3) 1.10 (0.78,1.56) 1.08 (0.74,1.56) 1.19 (0.79,1.79) 1.04 (0.65,1.67)
   Vitamin C 193 (8) 218 (9) 0.82 (0.64,1.06) 0.88 (0.68,1.15) 0.95 (0.71,1.28) 0.96 (0.68,1.36)
   Vitamin D 39 (2) 45 (2) 0.85 (0.53,1.38) 1.01 (0.61,1.70) 0.87 (0.48,1.55) 1.23 (0.61,2.45)
   Vitamin E 53 (2) 46 (2) 1.21 (0.77,1.91) 1.38 (0.85,2.25) 1.36 (0.79,2.33) 1.34 (0.73,2.47)
   Multivitamins 454 (18) 488 (19) 0.89 (0.74,1.07) 0.94 (0.77,1.14) 0.98 (0.79,1.12) 0.99 (0.77,1.26)
1ORs (95% CIs) were estimated by means of unconditional logistic regression. RDD, random-digit 
dialing. 2Adjusted for age, sex, and partnership where applicable 3Adjusted for age, sex, BMI, smoking, 
and partnership where applicable 4Adjusted for age, sex, BMI, smoking, statin use, hormones use, 
and partnership where applicable 5Adjusted for age, sex, BMI, smoking, statin use, hormones use, 
cardiovascular disease, sports activity, and partnership where applicable
compared with nonusers of vitamins (fully adjusted OR: 1.11; 95% CI: 0.91, 1.35). Similar 
results were obtained for all individual vitamins. This could be due to the influence of 
lifestyle-related confounders, which the comparison with partners adjusts for.
Most studies investigating the influence of vitamin intake on the risk of venous 
thrombosis focused on vitamin B-6, vitamin B-12, and folic acid. Because folic acid 
decreases homocysteine concentration, appears to interact with the metabolism 
of nitric oxide, and  reduces superoxide anion generation5, 28, it was assumed that 
supplementation of this vitamin would lead to a decreased risk of venous thrombosis. 
Our results showed no decrease in risk for venous thrombotic events in vitamin B 
users, which is consistent with the results of large clinical trials on first and recurrent 
venous thrombosis, such as the Heart Outcomes Prevention Evaluation and the 
Vitamins and Thrombosis trial7, 29, which showed no benefit of homocysteine-
lowering therapy. Regarding the other vitamins, some studies showed that combined 
antioxidant treatment with vitamins C and E for 4 wk improves endothelial function and 
decreases the plasminogen activator inhibitor 1/tissue plasminogen activator ratio.30 
The Women’s Health Study reported a 21% risk reduction of venous thrombosis in 
women taking vitamin E over a 10-y follow-up period (14). However, results of this 
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   No vitamin therapy 1465 (63) 1503 (57) 1.0 (Reference)
   Vitamin therapy 844 (37) 1181 (44) 0.77 (0.66,0.89)
Unprovoked venous thrombosis
   No vitamin therapy 1359 (71) 1503 (56) 1.0 (Reference)
   Vitamin therapy 549 (29) 1181 (44) 0.61 (0.52,0.72)
Deep vein thrombosis only
   No vitamin therapy 1664 (68) 1503 (57) 1.0 (Reference)
   Vitamin therapy 795 (32) 1181 (44) 0.67 (0.59,0.77)
Pulmonary embolism +/- deep vein thrombosis
   No vitamin therapy 1180 (66) 1503 (56) 1.0 (Reference)
   Vitamin therapy 618 (34) 1181 (44) 0.71 (0.61,0.82)
1Estimated by means of unconditional logistic regression and adjusted for age, sex, BMI, smoking, statin 
use, hormone use, cardiovascular disease, and sports activity. RDD, random-digit dialing.









   No vitamin therapy 865 (64) 1688 (67) 1.0 (Reference)
   Vitamin therapy 486 (36) 818 (33) 1.05 (0.93,1.19)
Unprovoked venous thrombosis
   No vitamin therapy 837 (74) 1688 (67) 1.0 (Reference)
   Vitamin therapy 302 (26) 818 (33) 0.94 (0.81,1.09)
Deep vein thrombosis only
   No vitamin therapy 991 (69) 1688 (67) 1.0 (Reference)
   Vitamin therapy 447 (31) 818 (33) 0.98 (0.86,1.11)
Pulmonary embolism +/- deep vein thrombosis
   No vitamin therapy 719 (67) 1688 (67) 1.0 (Reference)
   Vitamin therapy 349 (33) 818 (33) 1.02 (0.88,1.18)
1Estimated by means of conditional logistic regression and adjusted for partnership, age, sex, BMI, 




study are difficult to interpret. The Women’s Health Study used a 2 X 2 factorial 
randomized design (vitamin E, aspirin, placebo) but failed to show an effect of vitamin 
E alone compared with placebo on venous thrombosis risk. It is therefore possible 
that it was not vitamin E but aspirin, or a combination of both, that decreased the 
risk of venous thrombosis and not vitamin E itself. No other evidence is present that 
supplementation with these antioxidant vitamins leads to a decreased risk for venous 
thrombosis. Our results showed no protective effect of vitamins C, E, or D on venous 
thrombotic risk, but vitamin A consumption showed a beneficial effect. This latter 
result should be interpreted with caution because numbers were small in this analysis. 
Also, in the argument to take vitamins or not, it should be considered that vitamin 
supplements may not be that harmless. For example, use of folic acid might promote 
progression of atherosclerosis31 and increase the risk for carcinogenesis.32 Moreover, 
antioxidant vitamins interfere with essential defensive mechanisms such as apoptosis, 
phagocytosis, and detoxification and might lead to increased mortality33, which makes 
prescription of these supplements less attractive.
Limitations of our study are that data on vitamin use were self-reported without 
information on duration of vitamin use or exact dose for every single vitamin. Also, 
because we could only investigate associations between vitamin supplements and 
venous thrombosis, our findings should not be applied directly to natural vitamins (as 
in food). Given that we did not have data about vitamin status before or after vitamin 
consumption, we were unable to evaluate whether some vitamins would be beneficial 
against venous thrombosis in people with vitamin deficiency at baseline. Furthermore, 
it would have been interesting to consider vitamin K status in MEGA because vitamin K–
dependent coagulation factors can determine venous thrombosis risk. Unfortunately, 
this information was not available. A strength of our research lies in the large study 
size and in the study design, which included both RDD and partner controls, making it 
possible to show that for this research question, protective risk estimates can easily be 
found if not all lifestyle-dependent confounding is accounted for and measured. We 
consider it unlikely that the accuracy or completeness of the recollections retrieved by 
study participants regarding vitamin use in the past is different among RDD controls, 
partner controls, and the patients with venous thrombosis. In addition, if somehow 
the patients did erroneously recall their vitamin use after venous thrombosis diagnosis, 
this would not explain the difference in risk estimates when patients were compared 
with RDD controls or partner controls. It should be noted, however, that using partner 
controls in case-control studies has drawbacks, too. First, patients without a partner are 
not included, which may lead to selection of a certain “type” of patient. This, however, 
should not compromise internal validity but could at most hamper generalization to 
other patients. Second, it is possible that partner controls are more similar to the cases 
with respect to the frequency of exposure than a random sample from the population. 
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This would lead to selection bias and to an underestimation of the effect. However, 
carrying out a matched analysis (such as we did) takes this into account and adjusts for 
such bias should it have occurred. Although the number of comparisons in this study 
was extensive, no adjustment for multiple testing was performed. We decided not to 
adjust for multiple testing because nearly all our analyses pointed toward a lower risk of 
venous thrombosis in vitamin users when patients were compared with RDD controls, 
whereas relative risks were all close to unity when patients were compared with 
partners. This consistent pattern agrees with our null hypothesis (i.e., no decreased 
risk of venous thrombosis in vitamin supplement users after extensive adjustments 
for confounding), and therefore there is no risk of falsely rejecting it (i.e., no risk of 
a type I error) and no need for adjustment for multiple testing. Of note, some of 
the estimates in this analysis had confidence intervals that were wide and sometimes 
included 1.0. However, our most robust estimates (in which we pooled all vitamin 
users together in one group) showed that the risk of venous thrombosis was lower (OR: 
0.68; 95% CI: 0.61, 0.77) and still confounded when patients were compared with RDD 
controls as opposed to a more rigorous adjustment for confounding when patients 
were compared with partners (OR for venous thrombosis: 1.11; 95% CI: 0.91, 1.35). 
Results for the individual vitamin supplements pointed toward the same direction 
(i.e., lower risk of venous thrombosis compared with RDD controls as opposed to 
partners), indicating that relative risk estimates on any vitamin use were likely to be 
confounded by unmeasured confounding factors when patients were compared with 
population-derived RDD controls.
In conclusion, our findings confirm that vitamin B supplementation is not associated 
with a decreased risk of venous thrombosis and adds as a novelty that vitamins C, D, and 
E are not associated with this disease. Furthermore, our study demonstrated that initial 
protective risk estimates were found due to control selection, reinforcing that when 
studying health-conscious related exposures, the control group must be selected with 
care, and lifestyle-dependent confounding should be measured as much as possible.
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table 1. Clinical characteristics of MEGA patients who had a partner
Patients with partners
(n=2506)
vitamin use1 no yes
General characteristics
   Total 1710 (68) 796 (32)
   Men 965 (56) 348 (44)
   Age at enrollment,y 50 (18-70) 49 (18-70)
   Body mass index, kg/m2 27 (16-57) 26 (16-45)
   Malignancy 143 (8) 92 (12)
Classical venous thrombosis risk factors
   Present2 865 (51) 486 (62)
   Without hormonal risk factors 401 (32) 205 (40)
   With hormonal risk factors
    (in women)
460 (63) 276 (63)
   Absent2 837 (49) 302 (38)
Arterial cardiovascular risk factors
   Overweight 798 (48) 307 (40)
   Obesity 336 (20) 141 (18)
   Previous smoking 611 (36) 272 (35)
   Current smoking 555 (33) 241 (31)
   Self-reported prior CVD‡ 64 (4) 32 (4)
   Statin use 84 (5) 15 (2)
   Regular sports activity 533 (34) 274 (38)
1Use of either vitamin A, B-6, B-12, folic acid, vitamin C, D, E or multivitamins. 2Classical risk factors 
include surgery, malignancy, immobilization, trauma, plaster cast, oral contraceptive, hormonal  
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table 2. Risk of venous thrombosis by categories of vitamin supplementation in patients with 

















    No Vitamin 
therapy
1710 (68) 1503 (56) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
    Vitamin 
therapy
796 (32) 1181 (44) 0.61 (0.55,0.69) 0.64 (0.56,0.72) 0.65 (0.58,0.74) 0.64 (0.56,0.74)
   Vitamin A 23 (1) 43 (2) 0.56 (0.34,0.95) 0.58 (0.34,0.99) 0.66 (0.37,1.17) 0.66 (0.35,1.25)
   Vitamin B-6 56 (2) 109 (4) 0.56 (0.40,0.78) 0.56 (0.40,0.79) 0.58 (0.41,0.83) 0.53 (0.36,0.79)
   Vitamin B-12 75 (3) 128 (5) 0.63 (0.47,0.85) 0.65 (0.48,0.89) 0.67 (0.49,0.93) 0.57 (0.40,0.82)
   Folic acid 73 (3) 143 (5) 0.60 (0.45,0.80) 0.57 (0.42,0.77) 0.73 (0.53,1.01) 0.76 (0.54,1.07)
   Vitamin C 193 (8) 396 (15) 0.50 (0.42,0.60) 0.53 (0.44,0.64) 0.53 (0.43,0.65) 0.52 (0.42,0.64)
   Vitamin D 39 (2) 57 (2) 0.72 (0.47,1.09) 0.79 (0.51,1.23) 0.83 (0.52,1.32) 0.88 (0.54,1.46)
   Vitamin E 53 (2) 79 (3) 0.67 (0.47,0.96) 0.68 (0.47,0.98) 0.74 (0.50,1.09) 0.83 (0.54,1.26)
   Multivitamins 454 (18) 782 (29) 0.57 (0.50,0.65) 0.60 (0.52,0.68) 0.60 (0.52,0.69) 0.61 (0.52,0.71)
1Estimated by means of unconditional logistic regression. 2Adjusted for age and sex. 3Adjusted for age, 
sex, BMI and smoking. 4Adjusted for age, sex, BMI, smoking, statin use and hormones use. 5Adjusted for 
age, sex, BMI, smoking, statin use, hormones use, cardiovascular disease and sports activity.








   No vitamin therapy 865 (64) 1503 (56) 1.0 (Reference)
   Vitamin therapy 486 (36) 1181 (44) 0.73 (0.62,0.87)
Unprovoked venous thrombosis
  No vitamin therapy 837 (74) 1503 (56) 1.0 (Reference)
   Vitamin therapy 302 (26) 1181 (44) 0.57 (0.48,0.69)
Deep vein thrombosis only
   No vitamin therapy 991 (69) 1503 (56) 1.0 (Reference)
   Vitamin therapy 447 (31) 1181 (43) 0.63 (0.54,0.75)
Pulmonary embolism +/- deep vein thrombosis
   No vitamin therapy 719 (67) 1503 (56) 1.0 (Reference)
   Vitamin therapy 349 (33) 1181 (44) 0.68 (0.57,0.81)
1Estimated by means of unconditional logistic regression. 2Adjusted for age, sex, BMI, smoking, statin 







Background: Control selection in case-control studies is challenging and can 
result in bias when done inappropriately. Literature that compares odds ratios 
(ORs) between different control groups is scarce. 
objective: To investigate whether ORs differ when using partner and random 
digit dialling (RDD) controls. We hypothesized that the difference in ORs would 
increase when comorbidity related quality of life of the control decreased.
methods: We used data from the Multiple Environmental and Genetic 
Assessment of risk factors for venous thrombosis study, with patients with first 
venous thrombosis and partner- and RDD controls who were included between 
1999 and 2004. Exposures to comorbidity were any self-reported chronic 
diseases, acute arterial thromboembolic events and malignancies. Quality of 
life associated with comorbidity (i.e. exposure of interest) was based on prior 
validated EQ-5D scores, where 0 indicates that a person is dead and 1 that 
a person is completely healthy. ORs and 95% confidence intervals (CIs) were 
estimated by means of logistic regression and adjusted for sex and age. The 
ratio of ORs (ORRDD/ORPartner) was calculated to quantify the difference between 
ORs when using both control groups.
Results: 4956 Patients, 2917 partner controls and 3000 RDD controls were 
enrolled. Eighteen exposures were included in the analyses with ORRDD/ORPartner 
between 0.35 and 2.03. A low quality of life (i.e. EQ-5D score of the exposure) 
was associated with a decreased ORRDD/ORPartner. This differences in risk 
estimates, and therefore the ratio between the risk estimates, may be due 
to lower participation rates among severely diseased (i.e. exposed) partners 
compared with RDD controls.
Conclusions: Discrepancies between risk estimates obtained with a partner 
control group as compared with a RDD control group increase with exposures 
that affect quality of life. 
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IntRoduCtIon
A case-control study design is commonly used as an efficient way to study disease 
outcomes.1 The principle of the design is that frequencies of exposure among diseased 
(cases) and referent subjects (controls) are compared to determine whether an 
association exists between the exposure and disease. Ideally, selection of cases and 
controls occurs from the same study base, where controls represent the exposure rate 
of the study base that the cases arose from.2,3 When performed correctly, case-control 
studies can be as credible as randomised studies4, but as all study designs, they are 
susceptible to bias.2
Defining the study base, and thereby a representative control group, can be 
challenging, especially when the study base is not clear, for example when hospital-
based cases are used.3 Even when an appropriate control group is selected, bias can 
still occur in case of different participation rates among cases and controls which are 
related to the exposure of interest and if the tendency to participate is stronger (or 
weaker) in cases than controls.5,6 
Literature where risk estimates in case-control studies are compared between 
different control groups is scarce, since the majority of case-control studies only include 
one control group. However, some studies contain two or more control groups, such as 
the ‘Multiple Environmental Genetic Assessment (MEGA) case-control study to assess 
risk factors for venous thrombosis’.7 The two control groups included in the MEGA study 
were a partner- and random digit dialling (RDD) control group. Partner controls were 
included as control subjects as the main focus was on genetic risk factors for venous 
thrombosis and their interaction with environmental and life-style factors. However, 
as there was only a small group of young male patients which yielded an even smaller 
control group of young female partners, it was difficult to analyse women-specific risk 
factors. To remedy the case-control imbalance in sex and age and to boost statistical 
power, the MEGA study also included an RDD control group at a later stage.8
During participant selection of a recently published trial from us9, we came to the 
impression that patients were less willing to participate in the trial if they and a relative 
(e.g. partner, child), were also ill. However, if this tendency for non-participation in a 
study really exists has as far as we know not been empirically studied. We therefore 
hypothesized that partner controls are less willing to participate in a study if they, 
next to their partner (i.e. the case), are (seriously) ill. In addition, we hypothesized that 
RDD controls with chronic diseases that impair quality of life may be overrepresented 
as these control individuals will be more at home and therefore more accessible to 
contact by telephone as compared to healthy RDD controls. If true, differences in 
participation rates can lead to discrepancies between risk estimates (odds ratios [ORs]) 







The design of the MEGA case-control study is described elsewhere.7 In short, 4956 
consecutive patients aged 18–70 years, with a first objectively diagnosed deep vein 
thrombosis or pulmonary embolism, were included from 6 anticoagulation clinics in 
The Netherlands (Amersfoort, Amsterdam, The Hague, Leiden, Rotterdam, and Utrecht) 
between March 1999 and September 2004. 
Two control groups were selected using the same exclusion criteria as for the 
patients. The first control group consisted of partners of the patients. Partners who 
were aged 18 to 70 years and had no history of venous thrombosis were asked to 
participate from March 1999 to September 2004. In total, 3586 partners were eligible, 
18 suffered from end stage disease and 651 refused to participate, leaving 2917 
participating partner controls. 
From January 2002 to September 2004, a second control group was recruited using 
RDD as described by Waksberg.10 4346 Eligible controls from the same geographical 
area as the patients were asked to participate, and were frequency matched to the 
patients on age and sex. With each telephone call we asked a specific person within 
a household to participate depending on our needs to fulfill age and sex criteria. The 
RDD method is only useful if the vast majority of individuals live in households with a 
fixed (land-line) telephone. In December 2005 fixed (land-line) telephone coverage in 
the Netherlands was very high (96%), and sufficient for RDD selection.8
15 potential RDD controls suffered from end stage disease and 1331 refused to 
take part, leaving 3000 RDD controls. All participants gave written informed consent 
in accordance with the Declaration of Helsinki. The study was approved by the Ethics 
Committee of the Leiden University Medical Center, Leiden, the Netherlands and has 
been described in detail elsewhere.8
data collection
All participants were asked to fill in a standardized questionnaire within a few weeks 
after inclusion in the study. The questionnaire was returned by 4543 (92%) patients, 
2757 (95%) partner controls and 2789 (93%) RDD controls. The index date was defined 
as the date of venous thrombosis for the patients, and the date of completing the 
questionnaire for the control subjects. The questionnaire provided information on 
current comorbidity, weight, height, use of medication, and risk factors for venous 
thrombosis, such as malignancies in the five years prior to the index date. 
At least three months after anticoagulation therapy was discontinued, or during 
anticoagulation therapy in patients who were treated for over one year, patients and 
controls visited the anticoagulation clinic for a blood sample. From December 1999, 
self-administered buccal swabs were obtained by mail when participants were not able 
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or willing to give a blood sample. From June 2002, buccal swabs were the only used 
method to obtain DNA. DNA was obtained from 4290 (87%) cases, 2544 (92%) partner 
controls and 2023 (67%) RDD controls. Common genetic risk factors, such as factor V 
Leiden and ABO blood group, were determined, as has been described previously.7,11
Exposures of interest were all chronic diseases, acute arterial thromboembolic 
events (i.e. ischemic stroke, myocardial infarction) and malignancies. To classify quality 
of life when having a comorbidity (i.e. an exposure of interest), we used EQ-5D scores. 
EQ-5D scores are a standardized validated measure of health status for clinical and 
economical applications. For every disease (expressed as ICD-9 code), a value between 
0 and 1 is determined, where 1 indicates that a person is alive and completely healthy 
and 0 indicates that a person is dead (see Supplementary Appendix 1).12,13 In addition, 
ORs for the association of Factor V Leiden and ABO-blood group on venous thrombosis 
were estimated and compared when taking partner and RDD controls. Both genetic 
variants are not related with changes in quality of life and we therefore expected that 
both control groups should yield similar ORs (i.e. a ‘negative control of the analysis’14,15), 
as neither is associated with changes in quality of life, and therefore should yield similar 
ORs according to the hypothesis. 
statistical analysis
Self-reported information from the questionnaire was used to classify whether 
participants had been exposed to chronic diseases, acute arterial thromboembolic 
events (i.e. ischemic stroke, myocardial infarction) and malignancies. Dates of cancer 
diagnosis were available and participants were considered exposed to cancer if 
they reported having a cancer diagnosis a year before the index date. ORs and 95% 
confidence intervals (CIs) were estimated by means of conditional logistic regression 
for the partner controls and adjusted for age and sex. RDD controls were compared 
to patients using (unconditional) logistic regression and ORs were also adjusted for 
age and sex.
The ratio of ORs (ORRDD/ORPartner) was calculated to quantify the difference between 
ORs when using the partner- or the RDD control group. This ratio was plotted against 
the EQ-5D of that exposure to show a potential trend between discrepancies of ORs 
and the quality of life. All statistical analyses were performed in R 2.15.2.
ResuLts
In total, 4956 patients and 5917 controls were enrolled, of which 2917 were partner 
controls and 3000 were RDD controls. Patients and partner controls were slightly older 
(49 years, range 18 to 70 and 50 years, range 18 to 70 years respectively) than RDD 




table 1. Clinical characteristics
cases Cases with partner Partner controls Rdd controls
General characteristics
Patients 4956 2917 2917 3000
Men 2682 (54) 1449 (50) 1463 (50) 1719 (57)
Age 49 (13) 50 (12) 50 (12) 45 (13)
BMI 27 (5) 27 (5) 26 (4) 25 (4)
Cancer
Prostate 24 (0) 14 (0) 2 (0) 2 (0)
Breast 39 (1) 14 (0) 4 (0) 5 (0)
Colorectal 65 (1) 29 (1) 3 (0) 2 (0)
Chronic diseases
Hyperthyroidism 40 (1) 16 (1) 22 (1) 15 (1)
Hypothyroidism 91 (2) 64 (2) 55 (2) 54 (2)
Bronchitis 253 (5) 134 (5) 72 (2) 82 (3)
Emphysema 66 (1) 35 (1) 16 (1) 16 (1)
Diabetes mellitus 183 (4) 89 (3) 92 (3) 88 (3)
Paralysis 46 (1) 24 (1) 4 (0) 12 (0)
Liver disease 27 (1) 14 (0) 8 (0) 11 (0)
Nephropathy 60 (1) 27 (1) 7 (0) 12 (0)
Rheumatoid arthritis 145 (3) 75 (3) 61 (2) 59 (2)
Multiple sclerosis 30 (1) 20 (1) 5 (0) 12 (0)
Heart failure 76 (2) 42 (1) 23 (1) 32 (1)
Angina pectoris 64 (1) 35 (1) 28 (1) 17 (1)
Previous acute events
Myocardial infarction 137 (3) 79 (3) 46 (2) 54 (2)
Stroke 54 (1) 29 (1) 21 (1) 23 (1)
Intracranial haemorrhage 36 (1) 24 (1) 6 (0) 4 (0)
Kidney function, eGFR
0-15 11 (0) 3 (0) 2 (0) 2 (0)
15-30 11 (0) 8 (5) 2 (0) 2 (0)
30-60 421 (18) 317 (21) 178 (13) 224 (15)
60-90 761 (32) 480 (32) 523 (39) 497 (34)
> 90 1176 (49) 676 (46) 628 (47) 731 (50)
Continuous variables denoted as mean (SD), categorical variables as number (%)
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colorectal and prostate) was higher among patients than controls. Acute events were 
more prevalent among patients than controls, as well as chronic diseases, except for 
hypo- and hyperthyroidism (Table 1). 
Eighteen exposures were included in the analyses which yielded ORs between 0.72 
(95% CI 0.38 to 1.38) and 16.04 (95% CI 3.93 to 65.45). The ratio of ORs (ORRDD/ORPartner) 
was between 0.35 and 0.79 of eight exposures, between 0.80 and 1.19 of five exposures 
and between 1.20 and 2.03 of five exposures (Table 2). 
table 2. Association between exposure and venous thrombosis when using partner and RDD 
controls
exposure
adjusted odds ratios* (95% confidence interval) Ratio oRs
oRRdd*/oRPartner*Rdd controls Partner controls
Bronchitis 1.82 (1.41 to 2.35) 1.98 (1.46 to 2.69) 0.95
Emphysema 2.01 (1.16 to 3.49) 2.32 (1.24 to 4.33) 0.79
Angina 1.77 (1.03 to 3.03) 1.23 (0.74 to 2.04) 1.44
Myocardial infarction 1.23 (0.89 to 1.70) 1.74 (1.19 to 2.54) 0.71
Heart failure 1.19 (0.78 to 1.80) 1.84 (1.10 to 3.09) 0.65
Haemorrhagic stroke 4.91 (1.74 to 13.84) 3.97 (1.62 to 9.72) 1.24
Ischemic stroke 1.22 (0.74 to 2.00) 1.37 (0.77 to 2.43) 0.89
Paralysis 2.19 (1.16 to 4.17) 5.85 (2.02 to 16.88) 0.37
Multiple sclerosis 1.37 (0.70 to 2.68) 3.94 (1.48 to 10.53) 0.35
Rheumatoid arthritis 1.35 (0.99 to 1.84) 1.25 (0.88 to 1.79) 1.08
Diabetes 1.05 (0.81 to 1.37) 0.95 (0.70 to 1.30) 1.11
Hypothyroidism 0.95 (0.67 to 1.34) 0.97 (0.66 to 1.42) 0.98
Hyperthyroidism 1.46 (0.80 to 2.66) 0.72 (0.38 to 1.38) 2.03
Renal failure 3.01 (1.61 to 5.62) 4.34 (1.79 to 10.56) 0.69
Liver disease 1.32 (0.65 to 2.68) 1.73 (0.73 to 4.13) 0.76
Breast cancer 2.66 (1.24 to 5.72) 3.68 (1.49 to 9.11) 1.38
Bowel cancer 16.04 (3.93 to 65.45) 11.22 (3.44 to 36.57) 0.69
Prostate cancer 2.14 (0.81 to 5.64) 3.94 (1.31 to 11.82) 1.45




Figure 1 shows that declining EQ-5D scores (i.e. quality of life) of the exposure was 
associated with a decreased ratio between the ORs of the partner controls and ORs of 
the RDD controls, with a r2 of the regression line of 0.54. The lowest ratio of ORs was 
found for the exposures paralysis and heart failure, which are both associated with a 
low quality of life (EQ-5D scores 0.35 and 0.49 respectively). The highest ratios of the 
ORs were found for hyperthyroidism and prostate cancer, which are both associated 
with a high quality of life (EQ-5D scores 0.74 and 0.90 respectively).  
The ratio of ORs of Factor V Leiden was 1.01 (ORRDD 3.35, 95% CI 2.72 to 4.14; ORPartner 
3.31, 95% CI 2.68 to 4.09). The ratio of ORs of blood group non-O was 0.95 (ORRDD 2.10, 
95% CI 1.88 to 2.35; ORPartner 2.21, 95% CI 1.95 to 2.49) 
figure 1. association between quality of life and ratio between the odds ratios when using 
two different control groups
dIsCussIon
The results of this study showed that decreased quality of life due to exposure to a 
chronic condition was associated with higher ORs when using RDD controls as compared 
with partner controls. These results indicate that, consistent with our hypothesis, 
differences in risk estimates between the two control groups were associated with 
impaired quality of life. This hypothesis was confirmed by our second analysis that 
showed that two exposures not associated with changes in quality of life (genetic 
variants), gave similar risk estimates for both control groups. 
Exposures associated with a low quality of life showed lower risk estimates when 
using RDD controls than partner controls. These differences in risk estimates and 
therefore differences of the ratio between the risk estimates could be due to lower 
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participation rates among partner controls than RDD controls when being severely 
ill. These lower participation rates would result in higher risk estimates when using 
partner controls instead of RDD controls. The reason for the differences between 
the risk estimates could not be determined in this study as data on reasons not to 
participate were not available. 
To our knowledge, there is no literature that describes differences between 
participation rates of partner- and RDD- or other control groups. However, RDD 
control groups have been studied extensively in the past, especially in comparison 
with other population based controls. One study found that RDD controls, as compared 
with controls who were recruited by mail and visited at home, were subject to  more 
screening tests and had a slightly higher prevalence of health outcomes such as a 
high cholesterol.16 These differences could indicate that ill subjects recruited by RDD 
may participate more frequently as compared with other control groups, potentially 
explaining the differences found between the partner- and RDD controls. Another 
explanation for the different risk estimates found between the partner- and RDD 
controls may be that the burden of care for the patient by a very ill partner (control) 
is high and may result in declining to participate in a study. 
This is the first study that looks into differences between partner controls and 
RDD controls. Due to the recruitment of two control groups, it was possible to study 
potential differences in risk estimates when using partner controls as compared 
with RDD controls. Due to the large numbers of participants and the extensive 
questionnaire, it was possible to study a wide range of exposures (rare, common, 
severe and less severe illnesses). A limitation is that exposures were self-reported, 
which may have resulted in non-reliable risk estimates. However, it is not expected 
that patients would answer differently as compared with the controls regarding their 
current illnesses. Additionally, it is unlikely that RDD controls would give less reliable 
answers than partner controls (or the other way around) on their current illnesses, 
meaning that the results are unlikely to be explained by differential misclassification. 
Another limitation is that it is not possible to study the cause of the difference in 
ORs. Therefore, a recommendation cannot be given on the most appropriate control 
group when studying research questions with exposures that impair the quality of 
life considerably. Future research is needed to determine what the source of these 
discrepancies is and show what control group is most appropriate under these 
circumstances.
In summary, results of this study showed that discrepancies between risk estimates 
obtained with a partner control group as compared with a RDD control group increase 
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aPPendIx 1 
table 1. EQ-5D scores used in the study
disease eQ-5d score Reference
Bronchitis 0.624 Sullivan et al. 2011
Emphysema 0.537 Sullivan et al. 2011
Angina 0.574 Sullivan et al. 2011
Myocardial infarction 0.605 Sullivan et al. 2011
Heart failure 0.493 Sullivan et al. 2011
Haemorrhagic stroke 0.657 Sullivan et al. 2011
Ischemic stroke 0.519 Sullivan et al. 2011
Paralysis 0.35 Sullivan et al. 2011
Multiple sclerosis 0.495 Sullivan et al. 2011
Rheumatoid arthritis 0.51 Sullivan et al. 2011
Diabetes 0.664 Sullivan et al. 2011
Hypothyroidism 0.736 Sullivan et al. 2011
Hyperthyroidism 0.736 Sullivan et al. 2011
Renal failure 0.525 Sullivan et al. 2011
Liver disease 0.623 Sullivan et al. 2011
Breast cancer 0.756 Sullivan et al. 2011
Bowel cancer 0.673 Sullivan et al. 2011
Prostate cancer 0.85 Sullivan et al. 2011









Background: Patients with atrial fibrillation generally require treatment with 
vitamin K antagonists (VKAs) and at times with additional platelet aggregation 
inhibitors. Data are scarce on bleeding rates in high-risk groups receiving 
combnation therapy, such as the elderly or patients with a high CHA2DS2-VASc 
score.
methods: We conducted a nationwide cohort study of Danish atrial fibrillation 
patients aged 50 years or older. Treatments were ascertained from a prescription 
database. These included no anticoagulant treatment and treatment with VKAs, 
aspirin, clopidogrel, and combinations of anticoagulant drugs. Incidence rates 
(IRs) of major bleeding and hazard ratios were estimated, overall and stratified 
by treatment modality, age, CHA2DS2-VASc score, and comorbidity.
Results: We identified 216,109 patients with atrial fibrillation. Median age was 
75 years and 48% were women. Over a total follow-up period of 854,914 patient-
years (py), 24,414 major bleeds occurred [incidence rate (IR) 2.9/100 pys, 95% 
confidence interval (CI) 2.8-2.9/100 pys]. Compared with VKA monotherapy, 
adjusted hazard ratios of major bleeding were 1.52 (95% CI 1.37-1.69) for dual 
antiplatelet therapy, 1.78 (95% CI 1.71-1.86) for therapy with a VKA and an 
antiplatelet drug, and 3.73 (95% CI 3.23-4.31) for triple therapy. Subgroup 
analyses showed  similar patterns. The IR for major bleeding was 11.9/100 pys 
among triple-therapy patients. Very high major bleeding rates occurred among 
patients over 90 years (IR 50.0/100 pys, 95% CI 24.4-91.8) and in patients with 
a CHA2DS2-VASc score over 6 (IR 20.0/100 pys, 95% CI 10.2-35.7). 
Conclusions: Patients with atrial fibrillation on triple therapy experienced high 
rates of major bleeding compared with patients on dual therapy or monotherapy. 
The exceptionally high bleeding rates observed in patients on triple therapy 
over the age of 90 years or with a CHA2DS2-VASc score over 6 suggest that such 
therapy should be carefully considered in these patients. 
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IntRoduCtIon
Persistent atrial fibrillation often requires long-term treatment with oral anticoagulants.1 
As patients with atrial fibrillation often have other underlying cardiovascular diseases, 
concurrent treatment with platelet inhibitors also may be indicated.1,2 Previous research 
has shown that concurrent use of vitamin K antagonists (VKAs) with a single platelet 
inhibitor increases the risk of bleeding complications twofold to threefold compared 
with VKA monotherapy.3 Triple therapy with VKA, aspirin, and clopidogrel has been 
associated with an almost fourfold increased risk of major bleeds compared with VKA 
monotherapy.3 Although these relative risks are high, they do not provide sufficient 
information to assess clinical safety implications. For this, knowledge of absolute rates is 
needed, especially in patient groups with risk factors for major bleeding complications.4 
As well, sufficient numbers of patients are required to allow comparison of bleeding 
rates associated with several combinations of anticoagulant drugs. 
We therefore conducted a cohort study in a nationwide setting (i.e., the entire 
population of Denmark) to determine rates of major bleeds in patients with atrial 
fibrillation who used combinations of anticoagulant and antiplatelet drugs. Our 
approach took several high-risk groups into account. 
methods
setting and databases
The Danish National Health Service provides tax-funded medical care to all Danish 
residents.5 The Danish Civil Registration System (CRS) issues a unique Civil Personal 
Register (CPR) number to all Danish residents at birth or upon immigration, which 
permits patient-level linkage of data among all Danish medical databases.5 The data 
sources used in this study were the Danish National Patient Registry (DNPR)5, the Danish 
Registry of Medicinal Product Statistics (DRMPS)6, and the Danish Registry of Causes 
of Death.7 
The DNPR is a nationwide registry containing information on all inpatient 
hospitalizations since 1977 and on all hospital specialist outpatient clinic and emergency 
room visits since 1995. Each record contains the patient’s CPR number, dates of hospital 
inpatient and outpatient encounters, the discharge date (if applicable), and one or more 
discharge diagnoses, including a dedicated field for the primary diagnosis. Diagnoses 
were coded according to the International Classification of Diseases, Eighth Revision 
(ICD-8) from 1977 to 1993 and according to the Tenth Revision (ICD-10) thereafter.8 
The nationwide DRMPS contains information on all prescriptions dispensed at 
community pharmacies in Denmark since 1995. All records contain the patient’s 
CPR number, date of dispensing, quantity of drugs dispensed, and the Anatomical 




The nationwide Danish Registry of Causes of Death contains information on all 
deaths in Denmark since 1875.  Each record from 1994 on contains the deceased 
person’s CPR number, date of death, and cause(s) of death classified by ICD-10 codes, 
including a code for the primary cause of death.7
study population
The study included all patients in Denmark aged 50 years or older with a first-time 
primary or secondary hospital inpatient or outpatient discharge diagnosis of atrial 
fibrillation or flutter registered in the DNPR between 1 January 1995 and 31 December 
2012. Younger patients were not included, as atrial fibrillation is rare in persons under 
age 50.10 Patients with an atrial fibrillation diagnosis in an acute setting (e.g., emergency 
room) were not eligible for inclusion. The diagnosis of atrial fibrillation and flutter has 
a positive predictive value of 99% in the DNPR.11 
exposure
Data on redeemed prescriptions for VKAs (warfarin and phenprocoumon), and platelet 
inhibitors (aspirin and clopidogrel) were obtained from the DRMPS using ATC codes 
(see Appendix 1 for codes). Patients were considered exposed starting on the day they 
filled a prescription for a VKA or platelet inhibitor. Length of exposure to VKAs was 
assumed to be 90 days per prescription, as drugs for chronic conditions are seldomly 
provided for more than three months in Denmark. Length of exposure to antiplatelet 
drugs was assumed to be one day per pill dispensed plus an extra 14 days as a wash-out 
period. The wash-out period was used to account for delay in picking up a prescribed 
drug from a pharmacy as well as the duration of action of individual drugs. Among the 
anticoagulant and antiplatelet drugs examined in this study, the only over-the-counter 
medicine is low-dose aspirin. However, patients treated long-term with low-dose 
aspirin usually receive a prescription to allow financial reimbursement, as reported 
in other studies.3,12 Therefore aspirin use was included and coded as a prescription. 
Based on medication use, seven categories of exposure were identified: no 
anticoagulant treatment; monotherapy with a VKA; monotherapy with aspirin; 
monotherapy with clopidogrel; dual therapy with a VKA and one antiplatelet drug 
(clopidogrel or aspirin); dual antiplatelet therapy with aspirin and clopidogrel; and triple 
therapy (VKA, aspirin, and clopidogrel).
outcomes, comorbidities and comedications
Outcomes of interest were major bleeds (primary outcome), ischemic strokes, 
myocardial infarctions (MIs), and all-cause mortality (secondary outcomes). The 
DNPR and the Danish Registry of Causes of Death were used to ascertain outcomes, 
classified according to ICD-10 codes (see Appendix 1). Outcomes included both primary 
and secondary diagnoses recorded in the DNPR (excluding diagnoses made during 
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emergency room visits). The outcomes of fatal bleed, fatal ischemic stroke, and fatal 
MI were included only if the event was recorded as the primary cause of death in the 
Danish Registry of Causes of Death. 
Diagnostic codes in the DNPR were used to identify comorbidities, defined as 
the presence, at any time, in a patient’s record of ischemic heart disease, valvular 
heart disease, hypertension, MI, ischemic stroke, diabetes, liver disease, renal failure, 
malignancy, and previous major bleeds (see Appendix 1). Based on these diagnostic 
codes and clinical characteristics, we computed CHA2DS2-VASc scores. This score is 
based on age, sex, a history of congestive heart failure, hypertension, stroke/transient 
ischemic attack/thromboembolism, vascular disease, and diabetes mellitus.13 
Use of anticoagulants during the 180 days preceding diagnosis of atrial fibrillation 
was ascertained from the DRMPS  (see ATC codes in Appendix 1). 
statistical analysis 
Patients were followed from the date of their atrial fibrillation diagnosis until occurrence 
of each of the study outcomes (major bleeding event, ischemic stroke, and MI), death 
or end of the study period (31 December 2013). When calculating follow-up time 
until a major bleed or another outcome, we did not consider the occurrence of the 
other outcomes. For example, when major bleeding events were studied, MIs were 
disregarded in the analysis even if a patient had an MI before the bleeding event. 
Rates [incidence rates per 100 person-years (pys)] of the outcomes were estimated 
and further stratified by risk groups defined a-priori  (i.e., age in 10-year categories, 
CHA2DS2-VASc score, sex, previous ischemic heart disease, previous major bleeds, 
previous ischemic stroke, and previous MI). Exposure was considered as a time-
dependent variable in all analyses. 
In a secondary analysis, relative risk estimates of major bleeds were estimated 
for the different exposure groups using VKA monotherapy as the reference category. 
Hazard ratios (HRs) along with 95% confidence intervals (CIs) were estimated using a 
time-dependent Cox model. HRs were adjusted for the following confounding factors: 
sex and, as time-dependent variables, ischemic heart disease, valvular heart disease, 
liver disease, kidney failure, and cancer. HRs were not estimated for secondary outcomes 
(i.e., ischemic stroke, MI, and all-cause mortality), as confounding by indication for 
these outcomes would make such comparative results difficult to interpret. A sensitivity 
analysis was performed in which outcomes from the Danish Registry of Causes of 
Death were excluded. The rationale was that causes of death are more prone to 
misclassification than diagnoses and thus could influence the parameter estimates.
All analyses were performed using R version 2.15.2 (R Core Team (2014). R: A 
language and environment for statistical computing. R Foundation for Statistical 
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ResuLts
Characteristics
We identified 216,109 patients aged 50 years or older who were admitted to a 
hospital or who had an outpatient visit in a hospital clinic with a first-time diagnosis 
of atrial fibrillation between 1995 and 2013 (see Table 1). Median age was 75 years 
[interquartile range (IQR) 67-83 years] and 103,430 patients (48%) were women. The 
most common treatments were monotherapy with a VKA [52,953 patients (25%)] or 
aspirin [57,511 patients (27%)] or dual therapy with a VKA and an antiplatelet drug 
[26,971 patients (12%)]. Triple therapy was prescribed to 1962 patients (0.9%). The 
prevalence of a history of ischemic heart disease or a MI was highest among patients 
treated with aspirin and clopidogrel or with aspirin, clopidogrel, and a VKA (see Table 1). 
major bleeding by type of therapy
Median follow-up was three years (IQR 1-7 years), resulting in total follow-up time of 
854,914 pys. A total of 24,414 major bleeds occurred during follow-up. Of these, 1141 
(4.6%) were fatal. Major bleeding rates were lowest in patients not treated with an 
anticoagulant and increased with the number of anticoagulants or antiplatelet drugs 
used concurrently (incidence rates between 1.4 and 11.9 per 100 pys; see Table 2). 
Incidence rates and adjusted HRs for major bleeding, using VKA monotherapy as 
reference, were slightly lower in aspirin users than in VKA users, but higher in clopidogrel 
users. Compared with VKA monotherapy, adjusted HRs of major bleeding were 1.52 
(95% CI 1.37-1.69) for dual antiplatelet therapy, 1.78 (95% CI 1.71-1.86) for therapy with 
both a VKA and an antiplatelet drug, and 3.73 (95% CI 3.23-4.31) for triple therapy.













No anticoagulant therapy 6147 310,859 2.0 (1.9-2.0) 0.81 (0.79-0.84) 0.82 (0.80-0.86)
VKA monotherapy 6070 249,559 2.4 (2.4-2.5) reference reference
Aspirin monotherapy 7409 271,917 2.7 (2.7-2.8) 1.12 (1.09-1.16) 0.93 (0.89-0.96)
Clopidogrel monotherapy 336 8427 4.0 (3.6-4.4) 1.62 (1.45-1.81) 1.11 (1.00-1.24)
Dual antiplatelet therapy 397 7296 5.4 (4.9-6.0) 2.06 (1.86-2.28) 1.52 (1.37-1.69)
VKA+ antiplatelet drug 3862 77,994 5.0 (4.8-5.1) 1.98 (1.90-2.06) 1.78 (1.71-1.86)
Triple therapy 193 1617 11.9 (10.3-13.7) 4.24 (3.67-4.89) 3.73 (3.23-4.31)
* Adjusted for sex and the following comorbidities: ischemic heart disease, valvular heart disease, liver 




table 3. Incidence rate and hazard ratio of major bleeding associated with single, dual, and 












Age  50-59 yrs
No anticoagulant therapy 271 40,093 0.7 (0.6-0.8) 0.55 (0.46-0.66) 0.62 (0.52-0.75)
VKA monotherapy 211 17,289 1.2 (1.1-1.4) reference reference
Aspirin monotherapy 156 15,614 1.0 (0.9-1.2) 0.85 (0.69-1.04) 0.84 (0.68-1.04)
Clopidogrel monotherapy 6 348 1.7 (0.7-3.6) 1.19 (0.49-2.90) 0.99 (0.41-2.42)
Dual antiplatelet therapy 14 426 3.3 (1.9-5.4) 2.27 (1.30-3.98) 1.83 (1.03-3.24)
VKA+ antiplatelet drug 112 4303 2.6 (2.2-3.1) 2.13 (1.69-2.68) 1.83 (1.45-2.32)
Triple therapy 11 114 9.6 (5.1-16.8) 6.75 (3.67-12.39) 5.35 (2.88-9.95)
Age  60-69 yrs
No anticoagulant therapy 874 83,284 1.0 (1.0-1.1) 0.65 (0.59-0.71) 0.69 (0.63-0.76)
VKA monotherapy 1033 64,284 1.6 (1.5-1.7) reference reference
Aspirin monotherapy 687 53,125 1.3 (1.2-1.4) 0.80 (0.73-0.89) 0.79 (0.71-0.87)
Clopidogrel monotherapy 39 1532 2.5 (1.8-3.4) 1.57 (1.14-2.17) 1.22 (0.88-1.69)
Dual antiplatelet therapy 43 1557 2.8 (2.0-3.7) 1.62 (1.19-2.20) 1.29 (0.95-1.76)
VKA+ antiplatelet drug 637 20,014 3.2 (2.9-3.4) 1.95 (1.77-2.16) 1.72 (1.56-1.91)
Triple therapy 45 484 9.3 (6.9-12.3) 5.10 (3.78-6.88) 4.18 (3.08-5.66)
Age  70-79 yrs
No anticoagulant therapy 1890 90,445 2.1 (2.0-2.2) 0.87 (0.81-0.92) 0.89 (0.83-0.94)
VKA monotherapy 2311 97,775 2.4 (2.3-2.5) reference reference
Aspirin monotherapy 1907 80,940 2.4 (2.3-2.5) 0.98 (0.92-1.04) 0.92 (0.86-0.98)
Risk groups
Rates of major bleeding were lowest in the youngest age group (incidence rates between 
0.7 and 9.6 per 100 pys) (see Table 3) and in the group with a CHA2DS2-VASc score of 
0 (incidence rates between 0.6 and 2.6 per 100 pys) (see Table 4). As in the overall 
analysis, major bleeding rates increased with age and the number of anticoagulants used 
concurrently. For each 10-year increase in age, major bleeding rates in patients on triple 
therapy increased concurrently (9.6 per 100 pys for persons aged 50-59, 9.3 per 100 pys 
for persons aged 60-69, 12.6 per 100 pys for persons aged 70-79, 13.2 per 100 pys for 
persons aged 80-89, and 50.0 per 100 pys for those aged 90 and over). When incidence 
rates were contrasted with monotherapy as the reference group, the adjusted HRs closely 
followed the pattern of increased major bleeding risk with age. Similar results were found 
for the CHA2DS2-VASc scores. Absolute rates of major bleeds were highest in patients who 
used triple therapy and who had a CHA2DS2-VASc score above 6 (IR 20.0, 95% CI 10.2-35.7). 
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table 3. Incidence rate and hazard ratio of major bleeding associated with single, dual, and 












Clopidogrel monotherapy 97 2610 3.7 (3.0-4.5) 1.49 (1.21-1.84) 1.16 (0.94-1.14)
Dual antiplatelet therapy 121 2462 4.9 (4.1-5.9) 1.89 (1.57-2.27) 1.47 (1.22-1.77)
VKA+ antiplatelet drug 1541 32,301 4.8 (4.5-5.0) 1.96 (1.84-2.09) 1.74 (1.63-1.86)
Triple therapy 86 684 12.6 (10.1-15.5) 4.71 (3.80-5.85) 3.87 (3.11-4.81)
Age  80-89 yrs
No anticoagulant therapy 2366 77,094 3.1 (2.9-3.2) 0.83 (0.78-0.88) 0.84 (0.79-0.89)
VKA monotherapy 2252 64,053 3.5 (3.4-3.7) reference reference
Aspirin monotherapy 3378 93,034 3.6 (3.5-3.8) 0.98 (0.93-1.04) 0.95 (0.90-1.00)
Clopidogrel monotherapy 157 3094 5.1 (4.3-5.9) 1.34 (1.13-1.59) 1.15 (0.97-1.37)
Dual antiplatelet therapy 174 2367 7.4 (6.3-8.5) 1.92 (1.64-2.25) 1.61 (1.38-1.89)
VKA+ antiplatelet drug 1453 19,992 7.3 (6.9-7.6) 2.01 (1.88-2.15) 1.87 (1.74-2.00)
Triple therapy 42 317 13.2 (9.7-17.7) 3.32 (2.45-4.51) 2.82 (2.08-3.84)
Age > 90 years
No anticoagulant therapy 746 19,942 3.7 (3.5-4.0) 0.81 (0.70-0.94) 0.84 (0.72-0.98)
VKA monotherapy 263 6158 4.3 (3.8-4.8) reference reference
Aspirin monotherapy 1281 29,204 4.4 (4.2-4.6) 0.99 (0.86-1.14) 1.02 (0.89-1.18)
Clopidogrel monotherapy 37 834 4.4 (3.2-6.1) 0.96 (0.66-1.38) 0.95 (0.66-1.38)
Dual antiplatelet therapy 45 485 9.3 (6.8-12.3) 1.80 (1.28-2.54) 1.72 (1.22-2.44)
VKA+ antiplatelet drug 119 1484 8.0 (6.7-9.6) 1.93 (1.55-2.41) 1.88 (1.41-2.35)
Triple therapy 9 18 50.0 (24.4-91.8) 9.34 (4.61-18.94) 8.43 (4.15-17.13)
* Adjusted for sex and the following comorbidities: ischemic heart disease, valvular heart disease, liver 
disease, kidney failure, and cancer.
ab 3. (Continued)
Compared with male patients, female patients had higher major bleeding rates (see 
Table 5). Patients with ischemic heart disease and patients who experienced a MI had 
similar rates of major bleeding. Rates were higher in patients with a history of ischemic 
stroke or a history of major bleeding. Results of the sensitivity analysis (see Appendix 2, 
Tables 1 to 4) were similar to those of the overall analysis. 
Ischemic events and death
Rates of MI, ischemic stroke, and death increased with age and were highest among 
individuals who received clopidogrel monotherapy or two antiplatelet drugs with or 
without a VKA. Rates of ischemic stroke varied between 0.0 to 7.0 per 100 pys, rates of 
MIs varied between 0.0 to 14.2 per 100 pys, and death rates ranged from 0.0 to 55.0 




table 4. Incidence rate and hazard ratio of major bleeding associated with single, dual and 













No anticoagulant therapy 156 26,955 0.6 (0.5-0.7) 0.57 (0.45-0.73) 0.55 (0.43-0.70)
VKA monotherapy 115 10,973 1.0 (0.9-1.3) reference reference
Aspirin monotherapy 59 7066 0.8 (0.6-1.1) 0.83 (0.61-1.14) 0.81 (0.59-1.11)
Clopidogrel monotherapy 0 30 NA NA NA
Dual antiplatelet therapy 0 6 NA NA NA
VKA+ antiplatelet drug 32 1238 2.6 (1.8-3.6) 2.34 (1.58-3.47) 2.35 (1.58-3.47)
Triple therapy 0 1 NA NA NA
CHA2DS2-VASc 1,2
No anticoagulant therapy 1417 118,405 1.2 (1.1-1.3) 0.67 (0.62-0.72) 0.72 (0.67-0.77)
VKA monotherapy 1559 85,894 1.8 (1.7-1.9) reference reference
Aspirin monotherapy 1085 63,262 1.7 (1.6-1.8) 0.96 (0.89-1.04) 0.93 (0.86-1.00)
Clopidogrel monotherapy 27 1043 2.6 (1.7-3.7) 1.42 (0.97-2.08) 1.38 (0.94-2.02)
Dual antiplatelet therapy 27 984 2.7 (1.8-3.9) 1.33 (1.91-1.94) 1.59 (1.08-2.34)
VKA+ antiplatelet drug 612 17,802 3.4 (3.2-3.7) 1.81 (1.65-1.99) 1.87 (1.70-2.05)
Triple therapy 16 274 5.8 (3.5-9.3) 2.59 (1.58-4.24) 3.29 (2.00-5.42)
CHA2DS2-VASc 3,4
No anticoagulant therapy 3144 126,358 2.5 (2.4-2.6) 0.95 (0.91-1.00) 0.93 (0.88-0.98)
VKA monotherapy 2921 113,539 2.6 (2.5-2.7) reference reference
Aspirin monotherapy 3854 134,483 2.9 (2.8-3.0) 1.10 (1.05-1.16) 1.01 (0.96-1.06)
Clopidogrel monotherapy 148 3511 4.2 (3.6-4.9) 1.59 (1.35-1.88) 1.39 (1.18-1.64)
Dual antiplatelet therapy 156 3064 5.1 (4.3-5.9) 1.76 (1.50-2.07) 1.64 (1.39-1.93)
VKA+ antiplatelet drug 1915 38,304 5.0 (4.8-5.2) 1.87 (1.76-1.98) 1.83 (1.72-1.94)
Triple therapy 84 808 10.4 (8.3-12.8) 3.80 (3.09-4.67) 3.99 (3.24-4.91)
CHA2DS2-VASc 5
No anticoagulant therapy 897 26,593 3.4 (3.2-3.6) 0.94 (0.86-1.03) 0.92 (0.84-1.01)
VKA monotherapy 935 26,680 3.5 (3.3-3.7) reference Reference
Aspirin monotherapy 1484 43,266 3.4 (3.3-3.6) 0.96 (0.88-1.04) 0.90 (0.83-0.98)
Clopidogrel monotherapy 78 2075 3.8 (3.0-4.7) 1.03 (0.82-1.30) 0.90 (0.71-1.13)
Dual antiplatelet therapy 111 1764 6.3 (5.2-7.5) 1.64 (1.34-2.00) 1.48 (1.21-1.80)
VKA+ antiplatelet drug 784 13,389 5.9 (5.5-6.3) 1.62 (1.47-1.78) 1.57 (1.42-1.73)
Triple therapy 45 314 14.3 (10.6-19.0) 3.47 (2.57-4.68) 3.30 (2.44-4.46)
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table 4. Incidence rate and hazard ratio of major bleeding associated with single, dual and 













No anticoagulant therapy 416 9901 4.2 (3.8-4.6) 0.97 (0.85-1.11) 0.94 (0.82-1.08)
VKA monotherapy 419 9837 4.3 (3.9-4.7) reference reference
Aspirin monotherapy 704 18,364 3.8 (3.6-4.1) 0.89 (0.79-1.00) 0.86 (0.76-0.97)
Clopidogrel monotherapy 57 1240 4.6 (3.5-5.9) 1.05 (0.80-1.39) 0.97 (0.73-1.28)
Dual antiplatelet therapy 73 1080 6.8 (5.3-8.5) 1.48 (1.15-1.90) 1.37 (1.07-1.76)
VKA+ antiplatelet drug 383 5717 6.7 (6.1-7.4) 1.53 (1.34-1.76) 1.49 (1.30-1.72)
Triple therapy 28 170 16.5 (11.2-23.5) 3.39 (2.31-4.98) 3.13 (2.13-4.61)
CHA2DS2-VASc 7-9
No anticoagulant therapy 117 2648 4.4 (3.7-5.3) 0.94 (0.73-1.21) 0.90 (0.70-1.17)
VKA monotherapy 121 2637 4.6 (3.8-5.5) reference reference
Aspirin monotherapy 223 5475 4.1 (3.6-4.6) 0.87 (0.70-1.09) 0.84 (0.67-1.05)
Clopidogrel monotherapy 26 528 4.9 (3.3-7.1) 1.03 (0.68-1.58) 0.98 (0.64-1.51)
Dual antiplatelet therapy 30 398 7.5 (5.2-10.6) 1.49 (1.00-2.23) 1.39 (0.92-2.08)
VKA+ antiplatelet drug 136 1545 8.8 (7.4-10.4) 1.84 (1.44-2.35) 1.76 (1.38-2.26)
Triple therapy 10 50 20.0 (10.2-35.7) 3.55 (1.85.6.79) 3.23 (1.68-6.20)
* Adjusted by sex and the following comorbidities: ischemic heart disease, valvular heart disease, liver 
disease, kidney failure, and cancer.
ab 4. (Continued)
dIsCussIon
Our study showed that the incidence rate of major bleeding increased with the number 
of prescribed anticoagulants. Nearly all groups treated with triple therapy experienced 
high rates of bleeding complications, up to 50.0 per 100 pys in the oldest age group. 
Relative risk estimates did not change greatly after adjustment for confounding factors, 
indicating that triple therapy was associated with a 2.8- to 8.4-fold increased risk of 
major bleeding complications compared with VKA monotherapy. 
major bleeding 
We found that triple therapy was associated with a four-fold average increased risk 
of major bleeding, compared with VKA monotherapy. This was consistent across 
subgroups and agrees with the literature.3 The clinical impact of relative risks depends 
on their absolute values. We expected that groups with a low baseline bleeding risk 
(e.g., patients aged 50 to 60 years or with a CHA2DS2-VASc score of 1 to 2) would 




table 5. Incidence rate and hazard ratio of major bleeding associated with single, dual, and 













No anticoagulant therapy 2659 153,008 1.7 (1.7-1.8) 0.78 (0.74-0.82) 0.78 (0.74-0.82)
VKA monotherapy 2322 104,588 2.2 (2.1-2.3) reference reference
Aspirin monotherapy 3355 138,171 2.4 (2.3-2.5) 1.09 (1.04-1.15) 0.89 (0.84-0.94)
Clopidogrel monotherapy 135 4485 3.0 (2.5-3.6) 1.34 (1.13-1.60) 0.92 (0.77-1.09)
Dual antiplatelet therapy 159 3048 5.2 (4.5-6.1) 2.16 (1.84-2.54) 1.57 (1.33-1.85)
VKA+ antiplatelet drug 1328 27,786 4.8 (4.5-5.0) 2.07 (1.93-2.21) 1.91 (1.78-2.04)
Triple therapy 65 415 15.7 (12.2-19.8) 5.91 (4.62-7.57) 5.18 (4.04-6.64)
Male
No anticoagulant therapy 3488 157,851 2.2 (2.1-2.3) 0.86 (0.82-0.90) 0.86 (0.82-0.90)
VKA monotherapy 3748 144,971 2.6 (2.5-2.7) reference reference
Aspirin monotherapy 4054 133,746 3.0 (2.9-3.1) 1.18 (1.13-1.24) 0.96 (0.92-1.00)
Clopidogrel monotherapy 201 3942 5.1 (4.4-5.8) 1.95 (1.69-2.25) 1.30 (1.13-1.50)
Dual antiplatelet therapy 238 4248 5.6 (4.9-6.3) 2.00 (1.75-2.28) 1.49 (1.31-1.71)
VKA+ antiplatelet drug 2534 50,208 5.0 (4.9-5.2) 1.91 (1.82-2.01) 1.74 (1.65-1.83)
Triple therapy 128 1202 10.6 (8.9-12.6) 3.60 (3.02-4.30) 3.33 (2.79-3.98)
Previous MI
No anticoagulant therapy 948 33,594 2.8 (2.6-3.0) 0.86 (0.79-0.95) 0.86 (0.78-0.94)
VKA monotherapy 785 23,922 3.3 (3.1-3.5) reference reference
Aspirin monotherapy 1639 60,705 2.7 (2.6-2.8) 0.83 (0.77-0.91) 0.78 (0.71-0.85)
Clopidogrel monotherapy 122 2804 4.4 (3.6-5.2) 1.30 (1.08-1.58) 1.09 (0.90-1.32)
Dual antiplatelet therapy 254 4923 5.2 (4.6-5.8) 1.45 (1.26-1.67) 1.29 (1.12-1.49)
VKA+ antiplatelet drug 1148 21,649 5.3 (5.0-5.6) 1.59 (1.46-1.75) 1.59 (1.45-1.75)
Triple therapy 134 1052 12.7 (10.7-15.0) 3.35 (2.79-4.04) 3.47 (2.89-4.18)
Previous major bleed
No anticoagulant therapy 1542 32,508 4.7 (4.5-5.0) 0.96 (0.89-1.04) 0.95 (0.88-1.03)
VKA monotherapy 1179 25,004 4.7 (4.5-5.0) reference reference
Aspirin monotherapy 1573 30,444 5.2 (4.9-5.4) 1.06 (0.99-1.15) 0.96 (0.89-1.04)
Clopidogrel monotherapy 114 1633 7.0 (5.8-8.4) 1.39 (1.15-1.69) 1.15 (0.95-1.40)
Dual antiplatelet therapy 87 1069 8.1 (6.6-10.0) 1.49 (1.20-1.85) 1.26 (1.01-1.57)
VKA+ antiplatelet drug 763 9297 8.2 (7.6-8.8) 1.67 (1.53-1.83) 1.61 (1.46-1.76)
Triple therapy 35 199 17.6 (12.4-24.2) 2.98 (2.13-4.18) 2.82 (2.01-3.96)
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No anticoagulant therapy 1236 32,084 3.9 (3.6-4.1) 1.17 (1.08-1.26) 1.08 (1.00-1.17)
VKA monotherapy 1329 40,909 3.2 (3.1-3.4) reference reference
Aspirin monotherapy 2040 52,283 3.9 (3.7-4.1) 1.19 (1.11-1.27) 1.05 (0.97-1.12)
Clopidogrel monotherapy 170 4108 4.1 (3.6-4.8) 1.24 (1.05-1.45) 1.10 (0.93-1.29)
Dual antiplatelet therapy 155 2318 6.7 (5.7-7.8) 1.95 (1.65-2.31) 1.69 (1.43-2.01)
VKA+ antiplatelet drug 1100 17,573 6.3 (5.9-6.6) 1.86 (1.72-2.01) 1.80 (1.66-1.95)
Triple therapy 50 313 16.0 (12.0-20.9) 4.12 (3.10-5.47) 3.86 (2.90-5.13)
Ischemic heart disease
No anticoagulant therapy 2165 81,222 2.7 (2.6-2.8) 0.88 (0.83-0.94) 0.86 (0.81-0.91)
VKA monotherapy 2059 68,794 3.0 (2.9-3.1) reference reference
Aspirin monotherapy 3396 125,011 2.7 (2.6-2.8) 0.90 (0.85-0.95) 0.83 (0.78-0.87)
Clopidogrel monotherapy 214 5188 4.1 (3.6-4.7) 1.34 (1.17-1.55) 1.09 (0.95-1.26)
Dual antiplatelet therapy 337 6429 5.2 (4.7-5.8) 1.58 (1.40-1.77) 1.41 (1.25-1.58)
VKA+ antiplatelet drug 2195 44,540 4.9 (4.7-5.1) 1.60 (1.51-1.70) 1.59 (1.50-1.69)
Triple therapy 185 1539 12.0 (10.4-13.9) 3.42 (2.94-3.98) 3.58 (3.07-4.16)
*Adjusted for age at baseline, sex, and the following comorbidities: ischemic heart disease, valvular 
heart disease, liver disease, kidney failure, and cancer.
 
this was not the case, as major bleeding rates were at least 5.8 per 100 pys. One 
explanation is that triple therapy causes major bleeding. An alternate explanation 
may be that the indication for this therapy, i.e., high risk of atherothrombosis, is also 
associated with a high risk of bleeding.14 All other subgroups experienced very high 
major bleeding rates (at least 9.3 per 100 pys) while receiving triple therapy. Bleeding 
rates gradually increased with age, as is well known. Bleeding rates also increased 
with higher CHA2DS2-VASc scores, which is to be expected since elements of the score, 
such as age, diabetes mellitus, hypertension, and a history of ischemic stroke, are risk 
factors for bleeding.14 
We also observed that female patients experienced higher major bleeding rates 
than male patients, in contrast to the findings of previous studies.14 This makes it likely 
that there is an alternate explanation, such as confounding, for the sex difference in 
bleeding rates. 
High major bleeding rates also were observed among patients on triple therapy with 
ischemic heart disease or a history of a major bleeding or ischemic event. In addition, 





of major bleeding than patients with a history of MI or with ischemic heart disease. 
The reason may be that ischemic strokes and major bleeds are risk factors for future 
major bleeding. This has not been reported for ischemic heart disease or history of MI.14 
Clinical implications
The high rates of major bleeding found among patients receiving triple therapy 
raises the question whether concomitant use of three anticoagulants is advisable. 
However, risk factors for ischemic events and major bleeding overlap15, making it hard 
to distinguish which patients are at high risk for major bleeding, but not at risk for 
ischemic events, and vice versa. In addition, due to confounding by indication, this 
non-randomized study does not permit evaluation of the effectiveness of combinations 
of antithrombotic drugs (i.e., medication could have been indicated due to high risk of 
thromboembolic outcomes). Still, two important findings in our study were that among 
patients receiving triple therapy, half of those aged over 90 years experienced a major 
bleed per year and that patients with a CHA2DS2-VASc scores of 7 to 9 had a bleeding 
rate of 20.0 per 100 pys. These very high bleeding rates suggest that triple therapy 
may be contraindicated in these groups. 
strengths and limitations
This population-based cohort study contained data from over 200,000 patients with 
large numbers of outcome events, making the results robust and generalizable to the 
currently treated population and allowing multiple subgroup analyses. A limitation 
is its reliance on dispensed prescriptions as recorded in a pharmacy registry, as 
filled prescriptions do not imply that  patients actually took the medications. Still, if 
patients did not take their medications, results would have been diluted. The rates 
and risk estimates of bleeding complications would likely have been higher if patients 
had been compliant. Another limitation is the study’s observational design, which 
precludes strong recommendations about optimal treatment choices for patients. 
Another potential limitation is that ICD codes do not distinguish between paroxysmal, 
persistent, and permanent atrial fibrillation16, and these specific diagnoses may have 
influenced choice of treatment. In addition, only bleeding events that resulted in 
hospital admissions or were fatal were considered major. This may have resulted in 
underestimation of rates of major bleeding. 
ConCLusIon
This study showed that patients with atrial fibrillation on triple therapy experienced 
a high rate of major bleeding. Some subgroups, such as patients over 90 years of age 
and patients with a CHA2DS2-VASc of 7 to 9, had very high bleeding rates, suggesting 
that triple therapy should be carefully considered in these patients. 
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aPPendIx 1. 
diagnosis and pharmaceutical codes used in the study
Study population - Danish National Registry of Patients
Atrial fibrillation ICD-10 code 148
Baseline drug use - Danish Registry of Medicinal Product Statistics
Warfarin ATC code B01AA03
Phenprocoumon ATC code B01AA04
Aspirin ATC code B01AC06
Clopidogrel ATC code B01AC04
Baseline comorbidities - Danish National Registry of Patients
Ischemic heart disease ICD-10 code I20-I25; ICD-8 code 409-415
Valvular heart disease ICD-10 code I34-I37; ICD-8 code 393-398, 424
Heart failure ICD-10 code I50; ICD-8 code 427.0, 427.1
Hypertension ICD-10 code I10-I15; ICD-8 code 399-405
Diabetes ICD-10 code E10-E14; ICD-8 code 249, 250
Liver disease ICD-10 code K70-K77, R16 and R17; ICD-8 code 570-573, 782.8, 785.1, 785.2
Renal failure ICD-10 code N17-N19 and R34; ICD-8 code 403, 404, 579-585
Malignancy ICD-10 code C00-C97; ICD-8 code 139-240
Systemic embolism ICD-10 code I26 and I74; ICD-8 code 444, 450
Ischemic stroke ICD-10 code I63-I66, I69.3 and I69.4; ICD-8 code 431, 439
Myocardial infarction ICD-10 code I21; ICD-8 code 410
Major bleed ICD-10 code D62, I60-I62, I69.0, I69.1, I69.2, J94.2, K25.0, K25.2, K25.4, 
K25.6, K26.0, K26.2, K26.4, K26.6, K27.0, K27.2, K28.0, K28.2, K28.4, K28.6, K92.0, K92.1, 
K92.2, N02, R04, R31, S06.4, S06.5 and S06.6; ICD-8 code 430, 431, 531.0, 531.2, 532.0, 
532.2, 533.0, 534.0, 534.2, 783.0, 783.1, 784.5, 785.7, 789.3
Exposure - Danish Registry of Medicinal Product Statistics
Warfarin ATC code B01AA03
Phenprocoumon ATC code B01AA04
Aspirin ATC code B01AC06
Clopidogrel ATC code B01AC04
Outcomes - Danish National Registry of Patients and Danish Registry of Causes of Death
Major bleeds ICD 10 codes D62, I60-I62, I69.0, I69.1, I69.2, J94.2, K25.0, K25.2, K25.4, 
K25.6, K26.0, K26.2, K26.4, K26.6, K27.0, K27.2, K28.0, K28.2, K28.4, K28.6, K92.0, K92.1, 
K92.2, N02, R04, R31, S06.4, S06.5 and S06.6
Ischemic stroke ICD-10 code I63















































Major bleeding rates are high in AF patients on triple antithrombotic therapy
table 1. Sensitivity analysis excluding cause of death: incidence rate and hazard ratio of 












No anticoagulant therapy 5775 310,859 1.9 (1.8-1.9) 0.79 (0.76-0.82) 0.80 (0.77-0.83)
VKA monotherapy 5883 249,559 2.4 (2.3-2.4) reference reference
Aspirin monotherapy 6961 271,917 2.6 (2.5-2.6) 1.09 (1.05-1.13) 0.90 (0.87-0.94)
Clopidogrel monotherapy 311 8427 3.7 (3.3-4.1) 1.55 (1.38-1.74) 1.08 (0.96-1.21)
Dual antiplatelet therapy 380 7296 5.2 (4.7-5.7) 2.04 (1.84-2.26) 1.51 (1.36-1.68)
VKA+ antiplatelet drug 3771 77,994 4.8 (4.7-5.0) 2.00 (1.92-2.08) 1.80 (1.72-1.87)
Triple therapy 192 1617 11.9 (10.2-13.7) 4.36 (3.78-5.04) 3.82 (3.30-4.42)
* Adjusted for sex and the following comorbidities: ischemic heart disease, valvular heart disease, liver 




table 2. Sensitivity analysis excluding cause of death: incidence rate of non-fatal major 












Age  50-59 yrs
No anticoagulant therapy 259 40,093 0.65 (0.57-0.73) 0.55 (0.46-0.66) 0.62 (0.52-0.75)
VKA monotherapy 210 17,289 1.21 (1.06-1.39) reference reference
Aspirin monotherapy 153 15,614 0.98 (0.83-1.15) 0.85 (0.69-1.04) 0.84 (0.68-1.04)
Clopidogrel monotherapy 5 348 1.44 (0.53-3.19) 1.19 (0.49-2.90) 0.99 (0.41-2.42)
Dual antiplatelet therapy 13 426 3.05 (1.70-5.09) 2.27 (1.30-3.98) 1.83 (1.03-3.24)
VKA+ antiplatelet drug 110 4203 2.62 (2.16-3.14) 2.13 (1.69-2.68) 1.83 (1.45-2.32)
Triple therapy 11 114 9.65 (5.07-16.77) 6.75 (3.67-12.39) 5.35 (2.88-9.95)
Age  60-69 yrs
No anticoagulant therapy 832 83,284 1.00 (0.93-10.69) 0.65 (0.59-0.71) 0.69 (0.63-0.76)
VKA monotherapy 1009 64,284 1.57 (1.48-1.67) reference reference
Aspirin monotherapy 657 53,125 1.24 (1.15-1.33) 0.80 (0.73-0.89) 0.79 (0.71-0.87)
Clopidogrel monotherapy 38 1532 2.48 (1.78-3.37) 1.57 (1.14-2.17) 1.22 (0.88-1.69)
Dual antiplatelet therapy 43 1557 2.76 (2.02-3.69) 1.62 (1.19-2.20) 1.29 (0.95-1.76)
VKA+ antiplatelet drug 625 20,014 3.12 (2.89-3.38) 1.95 (1.77-2.16) 1.72 (1.56-1.91)
Triple therapy 45 484 9.30 (6.86-12.33) 5.10 (3.78-6.88) 4.18 (3.08-5.66)
Age  70-79 yrs
No anticoagulant therapy 1811 90,445 2.00 (1.91-2.10) 0.86 (0.81-0.92) 0.89 (0.83-0.94)
VKA monotherapy 2253 97,775 2.30 (2.21-2.40) reference reference
Aspirin monotherapy 1829 80,940 2.26 (2.16-2.37) 0.98 (0.92-1.04) 0.92 (0.86-0.98)
Clopidogrel monotherapy 91 2610 3.49 (2.82-4.26) 1.49 (1.21-1.84) 1.16 (0.94-1.44)
Dual antiplatelet therapy 117 2462 4.75 (3.95-5.67) 1.89 (1.57-2.27) 1.47 (1.22-1.77)
VKA+ antiplatelet drug 1503 32,301 4.65 (4.42-4.89) 1.96 (1.84-2.09) 1.74 (1.63-1.86)
Triple therapy 86 684 12.57 (10.12-15.45) 4.71 (3.80-5.85) 3.87 (3.11-4.81)
Age  80-89 yrs
No anticoagulant therapy 2217 77,094 2.88 (2.76-3.00) 0.83 (0.78-0.88) 0.84 (0.79-0.89)
VKA monotherapy 2171 64,053 3.39 (3.25-3.53) reference reference
Aspirin monotherapy 3154 93,034 3.39 (3.27-3.51) 0.98 (0.93-1.04) 0.95 (0.90-1.00)
Clopidogrel monotherapy 144 3094 4.65 (3.94-5.46) 1.34 (1.13-1.59) 1.15 (0.97-1.37)
Dual antiplatelet therapy 169 2367 7.14 (3.12-8.28) 1.92 (1.64-2.25) 1.61 (1.38-1.89)
VKA+ antiplatelet drug 1416 19,992 7.08 (6.72-7.46) 2.01 (1.88-2.15) 1.87 (1.74-2.00)
Triple therapy 42 317 13.25 (9.67-17.74) 3.32 (2.45-4.51) 2.82 (2.07-3.84)
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Major bleeding rates are high in AF patients on triple antithrombotic therapy
table 2. Sensitivity analysis excluding cause of death: incidence rate of non-fatal major 












Age > 90 yrs
No anticoagulant therapy 656 19,942 3.29 (3.05-3.55) 0.81 (0.70-0.94) 0.84 (0.72-0.98)
VKA monotherapy 240 6158 3.90 (3.43-4.41) reference reference
Aspirin monotherapy 1168 29,204 4.00 (3.78-4.23) 0.99 (0.86-1.14) 1.02 (0.89-1.18)
Clopidogrel monotherapy 33 843 3.91 (2.74-5.43) 0.96 (0.66-1.38) 0.95 (0.66-1.38)
Dual antiplatelet therapy 38 485 7.84 (5.62-10.64) 1.80 (1.28-2.54) 1.72 (1.22-2.44)
VKA+ antiplatelet drug 117 1484 7.88 (6.55-9.41) 1.93 (1.55-2.41) 1.88 (1.51-2.35)
Triple therapy 8 18 44.44 (20.64-84.40) 9.34 (4.61-18.94) 8.43 (4.15-17.13)
* Adjusted by sex  and the following comorbidities: ischemic heart disease, valvular heart disease, liver 





table 3. Sensitivity analysis excluding cause of death: incidence rate of non-fatal major 













No anticoagulant therapy 2456 153,008 1.61 0.75 (0.71-0.79) 0.75 (0.71-0.79)
VKA monotherapy 2237 104,588 2.14 reference reference
Aspirin monotherapy 3122 138,171 2.26 1.05 (1.00-1.11) 0.86 (0.82-0.92)
Clopidogrel monotherapy 122 4485 2.72 1.26 (1.05-1.51) 0.88 (0.73-1.06)
Dual antiplatelet therapy 151 3048 4.95 2.14 (1.81-2.52) 1.57 (1.33-1.86)
VKA+ antiplatelet drug 1292 27,786 4.65 2.09 (1.95-2.24) 1.93 (1.80-2.07)
Triple therapy 64 415 15.42 6.10 (4.75-7.82) 5.34 (4.16-6.87)
Male
No anticoagulant therapy 3319 157,851 2.10 0.84 (0.80-0.88) 0.84 (0.80-0.88)
VKA monotherapy 3646 144,971 2.51 reference reference
Aspirin monotherapy 3839 133,746 2.87 1.15 (1.10-1.20) 0.94 (0.89-0.98)
Clopidogrel monotherapy 189 3942 4.79 1.89 (1.63-2.18) 1.26 (1.09-1.46)
Dual antiplatelet therapy 229 4248 5.39 1.98 (1.73-2.26) 1.48 (1.29-1.69)
VKA+ antiplatelet drug 2479 50,208 4.94 1.93 (1.83-2.03) 1.74 (1.66-1.84)
Triple therapy 128 1202 10.65 3.70 (3.10-4.41) 3.40 (2.85-4.07)
Previous MI
No anticoagulant therapy 902 33,594 2.69 0.84 (0.77-0.93) 0.84 (0.76-0.92)
VKA monotherapy 765 23,922 3.20 reference reference
Aspirin monotherapy 1547 60,705 2.55 0.81 (0.74-0.88) 0.76 (0.69-0.83)
Clopidogrel monotherapy 115 2804 4.10 1.26 (1.04-1.53) 1.07 (0.88-1.30)
Dual antiplatelet therapy 241 4923 4.90 1.41 (1.22-1.63) 1.27 (1.10-1.47)
VKA+ antiplatelet drug 1122 21,649 5.18 1.60 (1.46-1.75) 1.60 (1.46-1.76)
Triple therapy 134 1052 12.74 3.46 (2.87-4.16) 3.60 (2.99-4.33)
Previous bleed
No anticoagulant therapy 1446 32,508 4.45 0.93 (0.86-1.00) 0.92 (0.85-1.00)
VKA monotherapy 1148 25,004 4.59 reference reference
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Table 3. Sensitivity analysis excluding cause of death: incidence rate of non-fatal major 












Aspirin monotherapy 1482 30,444 4.87 1.03 (0.95-1.11) 0.94 (0.87-1.01)
Clopidogrel monotherapy 109 1633 6.67 1.37 (1.12-1.66) 1.15 (0.94-1.40)
Dual antiplatelet therapy 86 1069 8.04 1.51 (1.21-1.88) 1.29 (1.03-1.61)
VKA+ antiplatelet drug 746 9297 8.02 1.68 (1.53-1.84) 1.61 (1.47-1.77)
Triple therapy 35 199 17.59 3.07 (2.19-4.30) 2.89 (2.06-4.06)
Previous ischemic stroke
No anticoagulant therapy 1135 32,084 3.54 1.11 (1.03-1.21) 1.04 (0.96-1.12)
VKA monotherapy 1279 40,909 3.13 reference reference
Aspirin monotherapy 1842 52,283 3.52 1.11 (1.04-1.20) 0.99 (0.92-1.07)
Clopidogrel monotherapy 154 4108 3.75 1.17 (0.99-1.38) 1.04 (0.88-1.23)
Dual antiplatelet therapy 150 2318 6.47 1.97 (1.66-2.33) 1.71 (1.44-2.03)
VKA+ antiplatelet drug 1075 17,573 6.12 1.89 (1.74-2.05) 1.82 (1.68-1.98)
Triple therapy 50 313 15.97 4.30 (3.24-5.71) 4.00 (3.01-5.32)
Ischemic heart disease
No anticoagulant therapy 2043 81,222 2.52 0.85 (0.80-0.91) 0.84 (0.79-0.89)
VKA monotherapy 2001 68,794 2.91 reference reference
Aspirin monotherapy 3213 125,011 2.57 0.88 (0.83-0.93) 0.81 (0.76-0.85)
Clopidogrel monotherapy 197 5188 3.80 1.27 (1.10-1.47) 1.05 (0.90-1.21)
Dual antiplatelet therapy 321 6429 4.99 1.55 (1.37-1.74) 1.39 (1.23-1.56)
VKA+ antiplatelet drug 2142 44,540 4.81 1.61 (1.52-1.71) 1.59 (1.50-1.69)
Triple therapy 184 1539 11.96 3.52 (3.02-4.10) 3.66 (3.14-4.26)
* Adjusted for sex and the following comorbidities: ischemic heart disease, valvular heart disease, liver 
disease, kidney failure, and cancer.




table 4. Sensitivity analysis excluding cause of death: incidence rate of non-fatal major 













No anticoagulant therapy 151 26,955 0.56 0.57 (0.44-0.72) 0.54 (0.42-0.69)
VKA monotherapy 113 10,973 1.03 reference reference
Aspirin monotherapy 56 7066 0.79 0.80 (0.58-1.11) 0.78 (0.57-1.08)
Clopidogrel monotherapy 0 30 NA NA NA
Dual antiplatelet therapy 0 6 NA NA NA
VKA+ antiplatelet drug 32 1238 2.58 2.39 (1.61-3.54) 2.39 (1.61-3.55)
Triple therapy 0 1 NA NA NA
CHA2DS2-VASc 1,2
No anticoagulant therapy 1342 118,405 1.13 0.65 (0.60-0.70) 0.70 (0.65-0.75)
VKA monotherapy 1522 85,894 1.77 reference reference
Aspirin monotherapy 1033 63,262 1.63 0.93 (0.86-1.01) 0.90 (0.83-0.98)
Clopidogrel monotherapy 26 1043 2.49 1.40 (0.95-2.07) 1.36 (0.92-2.01)
Dual antiplatelet therapy 27 984 2.74 1.36 (0.93-1.99) 1.62 (1.10-2.38)
VKA+ antiplatelet drug 602 17,802 3.38 1.83 (1.66-2.01) 1.88 (1.71-2.07)
Triple therapy 16 274 5.84 2.66 (1.63-4.36) 3.34 (2.03-5.51)
CHA2DS2-VASc 3,4
No anticoagulant therapy 2954 126,358 2.34 0.92 (0.87-0.97) 0.90 (0.86-0.95)
VKA monotherapy 2841 113,539 2.50 reference reference
Aspirin monotherapy 3646 134,483 2.71 1.07 (1.02-1.12) 0.99 (0.94-1.04)
Clopidogrel monotherapy 150 3511 4.27 1.55 (1.31-1.83) 1.36 (1.15-1.62)
Dual antiplatelet therapy 151 3064 4.93 1.75 (1.49-2.06) 1.62 (1.38-1.92)
VKA+ antiplatelet drug 1876 38,304 4.90 1.88 (1.78-2.00) 1.83 (1.73-1.94)
Triple therapy 94 808 11.63 3.92 (3.19-4.81) 4.04 (3.28-4.98)
CHA2DS2-VASc 5
No anticoagulant therapy 831 26,593 3.12 0.91 (0.83-1.01) 0.89 (0.81-0.98)
VKA monotherapy 893 26,680 3.35 reference reference
Aspirin monotherapy 1376 43,266 3.18 0.93 (0.86-1.01) 0.88 (0.81-0.96)
Clopidogrel monotherapy 73 3075 2.37 1.01 (0.80-1.28) 0.89 (0.70-1.13)
Dual antiplatelet therapy 106 1764 6.01 1.64 (1.34-2.00) 1.48 (1.20-1.81)
VKA+ antiplatelet drug 758 13,389 5.66 1.64 (1.49-1.80) 1.58 (1.43-1.74)
Triple therapy 45 314 14.33 3.63 (2.69-4.91) 3.41 (2.52-4.62)
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table 4. Sensitivity analysis excluding cause of death: incidence rate of non-fatal major 













No anticoagulant therapy 393 9901 3.97 0.96 (0.84-1.11) 0.94 (0.81-1.08)
VKA monotherapy 399 9837 4.06 reference reference
Aspirin monotherapy 650 18,364 3.54 0.86 (0.76-0.98) 0.84 (0.74-0.95)
Clopidogrel monotherapy 51 1239 4.12 0.99 (0.74-1.33) 0.92 (0.69-1.23)
Dual antiplatelet therapy 66 1080 6.11 1.41 (1.09-1.83) 1.31 (1.00-1.71)
VKA+ antiplatelet drug 370 5717 6.47 1.56 (1.35-1.80) 1.51 (1.31-1.74)
Triple therapy 27 170 15.88 3.46 (2.34-5.13) 3.17 (2.17-4.70)
CHA2DS2-VASc 7-9
No anticoagulant therapy 104 2648 3.93 0.88 (0.67-1.15) 0.85 (0.65-1.12)
VKA monotherapy 115 2637 4.36 reference reference
Aspirin monotherapy 200 5475 3.65 0.82 (0.65-1.04) 0.80 (0.63-1.01)
Clopidogrel monotherapy 21 528 3.98 0.88 (0.55-1.41) 0.85 (0.53-1.36)
Dual antiplatelet therapy 30 398 7.54 1.59 (1.06-2.37) 1.48 (0.99-2.23)
VKA+ antiplatelet drug 133 1545 8.61 1.90 (1.48-2.44) 1.82 (1.41-2.34)
Triple therapy 10 50 20.00 3.83 (2.00-7.34) 3.47 (1.80-6.67)
* Adjusted by sex and the following comorbidities: ischemic heart disease, valvular heart disease, liver 








Background: Low-molecular-weight-heparins (LMWHs) are considered 
members of a class of drugs with similar anticoagulant properties. However, 
pharmacodynamics and pharmacokinetics between LMWHs differ, which may 
result in different bleeding risks. As these agents are used by many patients, 
small differences may lead to a large effect on numbers of major bleeding events.
objectives: To determine major bleeding risks for different LMWH agents and 
dosing schedules.
methods: Cohort with acute venous thrombosis patients from four 
anticoagulation clinics who used a LMWH and a vitamin K antagonist. Patients 
were followed until they ceased LMWH treatment or until major bleeding. 
Exposures were classified according to different types of LMWHs and for b.i.d. 
and o.d. use. Cumulative incidences for major bleeding per 1000 patients and 
risk ratios were calculated and adjusted for study center. 
Results: The study comprised of 12,934 patients with a mean age of 59 years 
and 6218 (48%) men. The cumulative incidence for major bleeding was 2.5 per 
1000 patients (95% confidence interval [CI] 1.7-3.5). Enoxaparin b.i.d. or o.d. was 
associated with a relative bleeding risk of 1.7 (95%CI 0.2-17.5) compared with 
nadroparin o.d. In addition, a nadroparin b.i.d. dosing schedule was associated 
with a 2.0-fold increased major bleeding risk (95%CI 0.8-5.1) as compared with 
a nadroparin o.d. dosing schedule.
Conclusions: Absolute major bleeding rates were low for all LMWH agents 
and dosing schedules in a large, unselected cohort. Twice daily dosing with 
nadroparin appeared to be associated with an increased major bleeding risk 
as compared with once daily dosing as also suggested in a meta-analysis of 
controlled clinical trials. 
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BaCKgRound
Low-molecular-weight-heparins (LMWH) are widely used for prevention and treatment 
of venous thrombosis (the composite of deep vein thrombosis and pulmonary 
embolism).1 The LMWHs currently on the market are considered members of a class 
of drugs with similar anticoagulant properties. However, pharmacodynamics and 
pharmacokinetics between LMWHs differ. For example, the half-life of the anti-Xa 
activity is 4.3 hours for enoxaparin as compared with 2.4 hours for dalteparin.2 Such 
differences in duration of anticoagulant effect could result in different bleeding risks 
between LMWH agents. For the acute treatment of venous thrombosis, a head to 
head trial was conducted that compared two different LMWHs, i.e. dalteparin omni die 
(o.d., i.e. once daily) versus tinzaparin o.d. In this randomized study, with 505 patients, 
dalteparin appeared to have a lower bleeding risk than tinzaparin (relative risk 0.40, 
95% confidence interval [CI] 0.08 to 2.07) yet confidence intervals included unity and 
the authors concluded that the bleeding rate was similar for both LMWHs.3 To prevent 
venous thrombosis after a spinal cord injury with a LMWH, head-to-head trials were 
performed to compare dalteparin with enoxaparin which showed that overall bleeding 
rates were similar4,5, while others showed that enoxaparin may in favour with respect 
to major bleeding.6 It is currently unclear whether one LMWH should be preferred over 
the other in the treatment of venous thrombosis even though small differences in major 
bleeding rates may lead to a large reduction in major bleeding events because these 
agents are used by many patients on an annual basis.
We therefore set out to perform a cohort study in 12 934 patients with acute 
venous thrombosis who were treated with LMWH (and concurrently received VKA) to 
determine major bleeding risk for several LMWHs agents and dosage schedules.
methods
study population and data collection
All patients over 18 years of age, with a new onset of venous thrombosis between 
2006 and 2013 who received initial treatment with a LMWH (nadroparin o.d., 
nadroparin bis in die [b.i.d., i.e. twice daily], tinzaparin o.d., enoxaparin, dalteparin 
o.d.) and a VKA and were treated at one of the four participating anticoagulation 
clinics in the Netherlands (Leiden, Rotterdam, The Hague and Utrecht) were 
included. Enoxaparin treatment was not stratified by o.d. and b.i.d. use because 
numbers were too small. New onset was defined as an acute diagnosis of a first or 
recurrent venous thrombosis. Diagnoses were made at hospitals and were based 
on the international diagnosis criteria, after which patients received therapeutic 
dosages of LMWHs for at least 5 days.7 At the anticoagulation clinics, patients with 




three days when VKA and LMWH treatment are combined. LMWH treatment is 
ceased after at least five days of treatment and when two consecutive INRs are 
in target range.7 At each appointment blood is drawn to measure the INR and a 
standard short questionnaire is taken (and electronically stored) by a nurse to list 
any changes in co-medication or onset of new diseases and to enquire if patients 
experienced bleeding events or have any surgical procedures planned.8 If patients 
missed their appointment, they are contacted by nurses of the anticoagulation clinic 
and a new appointment is made on short notice. 
Patient characteristics and information regarding major bleeding events were 
derived from the computerized medical records of the anticoagulation clinics. Data 
included age, sex, indication for VKA treatment, type of LMWH, duration of LMWH 
exposure, concomitant drug use and date of major bleeding events. Patients were 
considered exposed to a LMWH from the subscription date at the anticoagulant clinic 
until ceasing treatment with the LMWH plus an additional two days wash-out period, 
or until a patient died, changed anticoagulation clinic or experienced a major bleeding, 
whichever occurred first. Of note, in this study it was not planned that the patient 
records were used before the data collection took place. However, the data was 
necessary for patient care and collected during treatment.
outcome
The outcome of our study was non-traumatic major bleeding which was notified 
through the routine procedures of the anticoagulation clinic. If patients mentioned 
any bleeding event or hospitalization related to a bleeding event during the visits or 
calls, information was obtained from the hospital, patient or general practitioner to 
classify the bleeding event as minor or major. Bleeding events were considered major if 
these required blood transfusion, were symptomatic in a critical area or organ, or led to 
death.9 In addition, bleedings for which patients were hospitalized were also considered 
major bleedings. These bleedings were classified according to a standardized protocol 
by trained physicians of the anticoagulation clinics, who were not involved in the 
current study.
statistical analysis
Patients were considered exposed to a LMWH from the subscription date at the 
anticoagulant clinic until date of ceasing treatment with LMWHs plus an additional two 
days wash-out period. Risks (cumulative incidences) and risk ratios were calculated and 
adjusted for study center by Mantel–Haenszel methods.10 Nadroparin o.d. was a-priori 
chosen as the reference category in these analyses, as this was the most frequently used 
type of LMWH treatment. We adjusted only for study center as the choice of a LMWH 
agent is determined hospital wide and therefore not related to patient characteristics. 
Furthermore, the choice of the vitamin K antagonist is strongly associated with the 
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anticoagulation clinic on which basis we assume that no other confounding factors 
than the anticoagulation clinic are present. A sensitivity analysis was performed where 
results were restricted to first venous thrombotic events because patients with a 
recurrent venous thrombotic event have different patient characteristics that also 
relate to bleeding risk.11 As a second sensitivity analysis, we computed incidence rates 
per 100 person-years to confirm that incidence rates would yield a similar pattern of 
risk estimates as cumulative incidences.
All analyses were performed with R version 2.15.2 (R Core Team (2014). R: A language 
and environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria. URL http://www.R-project.org/).
ResuLts
The study cohort comprised 12 934 patients who experienced an acute venous 
thrombotic event (Figure 1 and Table 1). The mean age at baseline was 59 years (standard 
deviation 17 years) and 6218 (48%) patients were male. Most patients were treated at 
the anticoagulation clinic in Rotterdam (3883 patients; 30%). A deep vein thrombosis 
(DVT) was the indication of treatment for 8058 patients (62%) and 4889 patients (38%) 
experienced a pulmonary embolism (PE). In 11 237 (87%) patients the thrombotic 
episode concerned a first event of whom 6735 experienced a DVT. The remaining 
1697 (13%) patients had a recurrent thrombotic episode, of whom 1326 experienced 
a DVT. The most frequently used LMWHs were nadroparin o.d. (5317 patients) and 








VTE patients at one of the four 
anticoagulation clinics (16 013) 
Already ceased LMWH 
treatment (2091) 
Patients with fondaparinux, 
danaparoid (6) 
Eligible patients (12 934)  
Under 18 years of age (36) 
  
Not noted what LMWH 
was used (946) 




table 1. Patient characteristics 
nadroparin nadroparin tinzaparin enoxaparin dalteparin
o.d. b.i.d. o.d. o.d.
General characteristics
Patients 5317 2076 3338 264 1939
Male sex, n (%) 2657 (50) 904 (44) 1638 (49) 125 (47) 894 (46)
Age, years, mean (SD) 58 (17) 61 (18) 59 (16) 57 (17) 57 (17)
Indication VKA treatment
Deep vein thrombosis, n (%) 3402 (64) 1302 (63) 2042 (61) 137 (52) 1175 (61)
First, n (%) 2735 (80) 1093 (84) 1735 (85) 115 (84) 1057 (90)
Recurrent, n (%) 667 (20) 212 (16) 307 (15) 22 (16) 118 (10)
Pulmonary embolism, n (%) 1924 (36) 776 (37) 1298 (39) 127 (48) 764 (39)
First, n (%) 1695 (88) 731 (93) 1220 (94) 122 (96) 761 (100)
Recurrent, n (%) 229 (12) 59 (8) 78 (6) 5 (4) 3 (0)
Vitamin K antagonist
Acenocoumarol, n (%) 1399 (26) 1059 (51) 2204 (66) 223 (84) 1861 (96)
Phenprocoumon, n (%) 3918 (74) 1017 (49) 1134 (34) 41 (16) 78 (4)
Co-medication
Antihypertensive(s), n (%) 1137 (21) 373 (18) 511 (15) 38 (14) 54 (3)
Antidiabetic(s), n (%) 376 (7) 179 (9) 248 (7) 20 (8) 151 (8)
NSAID(s), n (%) 384 (7) 135 (7) 248 (7) 21 (8) 187 (10)
Anti-platelet drug(s), n (%) 152 (3) 100 (5) 138 (4) 13 (5) 112 (6)
Anticoagulation clinic
The Hague, n (%) 2409 (45) 611 (29) 587 (18) 18 (7) 20 (1)
Leiden, n (%) 1873 (35) 544 (26) 729 (22) 62 (23) 30 (2)
Rotterdam, n (%) 347 (7) 561 (27) 1079 (32) 89 (34) 1807 (93)
Utrecht, n (%) 688 (13) 360 (17) 943 (28) 95 (36) 82 (4)
The median duration of treatment with LMWH was 5 days (interquartile range 
2 to 9 days, Table 2). In total, 32 of the 12 934 patients (corresponding cumulative 
incidence 2.47 per 1000 patients, 95% CI 1.74 to 3.49) experienced a major bleeding 
event during combined VKA and LMWH treatment, which is similar to cumulative 
incidences reported in clinical trials.12 The cumulative incidence (per 1000 patients) of 
major bleeding during combined treatment was 2.07 (95% CI 1.11 to 3.75) in nadroparin 
o.d. users, 3.37 (95% CI 1.48 to 7.10) in nadroparin b.i.d. users; 2.70 (95% CI 1.33 to 5.20) 
in tinzaparin o.d. users, 3.79 (95% CI 0.00 to 23.34) in enoxaparin o.d. or b.i.d. users and 
2.06 (95% CI 0.60 to 5.50) in dalteparin o.d. users (Table 2). The sensitivity analysis with 
incidence rates showed similar patterns of risk estimates as analysis with cumulative 
110
7
Major bleeding risks of different LMWHs: a cohort study in 12 934 patients treated for acute VT
incidences (Supplementary Table 1). Risk ratios for the different LMWH agents were 
between 1.00 and 1.83 using nadroparin o.d. as reference LMWH and increased after 
adjustment for study center (Table 2). The relative risk estimate for nadroparin b.i.d. 
was 1.98 (95% CI 0.76 to 5.14) as compared with nadroparin o.d. treatment. When we 
compared the absolute risk difference in b.i.d. dosing nadroparin as compared with 
o.d. dosing, we observed an absolute risk increase of 0.13% (95% CI -0.15% to 0.41%). 
Patients with a first venous thrombotic event had similar cumulative incidences of 
major bleeding as patients with recurrent events.
dIsCussIon
In this study, the absolute risk of major bleeding was low among patients who 
were registered at the anticoagulation clinic with an acute venous thrombotic event 
(between 2.0 to 3.5 per 1000 patients during combined treatment with VKA and 
LMWH), indicating that the combination of a VKA and LMWH for a short period 
is relatively safe for these patients. The relative risk estimates for major bleeding 
events were highest in patients treated with nadroparin b.i.d. and enoxaparin o.d. or 
b.i.d. These results should nevertheless be interpreted with caution since numbers 
were small and confidence intervals showed that a similar risk of bleeding events 














All venous thrombotic events
Nadroparin o.d. 5317 11 6 (3 to 10) 2.07 (1.11-3.75) reference reference
Nadroparin b.i.d. 2076 7 5 (2 to 10) 3.37 (1.48-7.10) 1.63 (0.63-4.20) 1.98 (0.76-5.14)
Tinzaparin o.d. 3338 9 5 (2 to 8) 2.70 (1.33-5.20) 1.30 (0.54-3.14) 1.24 (0.46-3.58)
Enoxaparin 264 1 5 (2 to 8) 3.79 (0.00-23.34) 1.83 (0.24-14.13) 1.74 (0.17-17.46)
Dalteparin o.d. 1939 4 4 (2 to 7) 2.06 (0.60-5.50) 1.00 (0.32-3.13) 4.19 (0.47-37.00)
First venous thrombotic event
Nadroparin o.d. 4425 9 6 (3 to 10) 2.03 (1.01-3.93) reference reference
Nadroparin b.i.d. 1805 7 5 (2 to 9) 3.88 (1.70-8.16) 1.91 (0.71-5.11) 2.32 (0.85-6.31)
Tinzaparin o.d. 2953 8 5 (2 to 8) 2.71 (1.27-5.44) 1.33 (0.51-3.45) 2.30 (0.92-5.78)
Enoxaparin 273 1 5 (2 to 8) 3.66 (0.00-22.58) 1.80 (0.23-14.16) 1.98 (0.19-21.09)
Dalteparin o.d. 1819 3 4 (2 to 7) 1.65 (0.32-5.08) 0.81 (0.22-2.99) 3.97 (0.42-37.59)




for these LMWHs as compared with the other LMWHs cannot be ruled out. Despite 
the small numbers, enoxaparin o.d. or b.i.d. treatment was associated with a higher 
bleeding risk than nadroparin o.d., tinzaparin o.d. and dalteparin o.d. treatment. 
These results are similar to what was found in a meta-analysis12, where all LMWHs 
gave lower bleeding risk as compared with UFH (nadroparin odd ratio [OR] 0.41, 
95% CI 0.14 to 1.17; tinzaparin OR 0.30, 95% CI 0.12 to 0.73 and dalteparin OR 0.15, 
95% CI 0.02 to 1.44), while enoxaparin gave risk estimates around unity (OR 1.14, 
95% CI 0.50-2.16). 
Our results also indicate that nadroparin o.d. users were at lower risk for bleeding 
complications than nadroparin b.i.d. users. While we cannot exclude that these results 
are a chance finding or due to confounding, they are in line with a Cochrane review 
from previous trials in acute venous thrombosis patients. This review suggested that 
b.i.d. treatment with a LMWH results in higher bleeding rates as compared with o.d. 
treatment (relative risk 1.29; 95% CI, 0.79-2.50).13 In addition, one trial showed that 
nadroparin b.i.d. gave higher rates of bleeding complications as compared with o.d. 
(relative risk 1.64; 95% CI 0.74-3.57).14 When combining results from our study and the 
latter study in a post-hoc meta-analysis with a random effects model, the OR indicates 
a 1.77 increased risk (95% CI 0.97-3.23) for patients using b.i.d. nadroparin as compared 
with o.d. nadroparin.
Some methodological aspects of our study need comment. First, this study 
evaluated bleeding risks in a large population of unselected venous thrombosis 
patients from four anticoagulation clinics, which makes our results generalizable to 
the community. However, as a limitation, patients were included after registration 
at the anticoagulation clinic, which is usually a couple of days after the diagnosis of a 
venous thrombotic event at the hospital. During these few days, we could have missed 
the bleeding events. If so, this would have influenced the absolute bleeding rates found 
in our study. Therefore, our results are only applicable to patients discharged from 
hospital. A second limitation is that few bleeding events occurred which prevented us 
from performing several subgroup analyses in patients who are potentially at high risk 
of major bleeding. The small numbers also hamper the robustness of our results and 
may have inflated the risk estimate of bleeding events in the enoxaparin o.d. or b.i.d. 
group. In addition, we were not able to stratify enoxaparin treatment by o.d. and b.i.d. 
use due to small numbers and we had no patients who used a dalteparin b.i.d regimen. 
Another limitation is that we were only able to adjust for study center. However, the 
choice of LMWH is not based on patient characteristics, but based on the preference 
of the hospital for a specific type of LMWH that the patient presents him or herself. 
Therefore, we assume that patient characteristics are not associated with the type 
of LMWH prescribed and therefore consider it unlikely that residual confounding has 
influenced our results. 
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In conclusion, the absolute risk for major bleeding complications during treatment 
with LMWH and VKA in patients with an acute venous thrombosis who were treated 
at an anticoagulation clinic was low, with an approximate risk of 2.5 per 1000 patients. 
These small numbers prevent us from concluding whether one LMWH should be 
preferred over the other. Furthermore, twice daily dosing with nadroparin appeared 
to be associated with an increased major bleeding risk as compared with once daily 
dosing, which is in accordance with the literature. 
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aPPendIx 1







All venous thrombotic events
Nadroparin o.d. 151 11 2.07 (1.11-3.75) 7.3 (3.8-12.7)
Nadroparin b.i.d. 59 7 3.37 (1.48-7.10) 11.9 (5.2-23.5)
Tinzaparin o.d. 82 9 2.70 (1.33-5.20) 11.0 (5.4-20.1)
Enoxaparin 6 1 3.79 (0.00-23.34) 16.7 (8.3-82.2)







Background: Low-molecular-weight heparin (LMWH) are often referred to as 
one class of drugs which are all equally effective. However, pharmacokinetic 
and pharmacodynamics between various LMWHs do differ, which may result in 
different efficacy (preventing thrombosis) and safety (major bleeding) profiles. 
Therefore, it remains unknown whether different LMWHs are indeed equally 
effective and safe. 
objective: To compare the efficacy and safety of different LMWHs among 
patients with acute venous thrombosis.
methods: We performed a systematic review and network meta-analysis 
including randomized controlled trials that assessed the effects of unfractionated 
heparin (UFH) and/or LMWHs in venous thrombosis patients. Outcomes were 
recurrent venous thrombosis and major bleeding. An extension of frequentist 
random effects models for mixed multiple treatment comparisons to estimate 
risk ratios (RRs) and 95% confidence intervals (CIs) was used with UFH as reference 
category. Treatment with LMWHs was stratified by dosing frequency (once daily 
[o.d.] or twice a day [b.i.d.]) and treatment duration (whole study period versus 
initial period as bridging towards treatment with vitamins K antagonists). Risk 
of bias analysis was performed according to the Cochrane tool.
Results: 4120 Publications were retrieved through a search strategy and 49 
randomized controlled trials were included. Three studies compared LMWHs 
directly, while other studies compared an LMWH with UFH. The risk of bias 
assessments indicated for all studies at least one category with a risk of bias, 
but for most studies at least two, which may bias the risk estimates. Treatments 
during the initial period with the most beneficial risk-benefit profile were 
dalteparin b.i.d. (RR recurrent venous thrombosis 0.48, 95% CI 0.10 to 2.31; RR 
major bleeding 0.55, 95% CI 0.07 to 4.68), reviparin o.d. (RR recurrent VT 0.54, 
95% CI 0.28 to 1.05; RR major bleeding 0.50, 95% CI 0.05 to 5.51) and nadroparin 
o.d. (RR recurrent VT 0.57, 95% CI 0.29 to 1.14; RR major bleeding 0.46, 95% CI 
0.12 to 1.81).
Conclusion: Results suggest that dalteparin b.i.d., reviparin o.d. and nadroparin 
o.d. during the initial treatment period may give the fewest recurrent venous 
thrombotic- and major bleeding events in patients with an acute venous 
thrombosis. Results should be interpreted with caution as confidence intervals 
were wide, comparisons were mainly indirect and risk of bias was considerable. 
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IntRoduCtIon
Heparins are widely used for prevention and acute treatment of venous thrombosis.1 
In the past, the most commonly prescribed heparin was unfractionated heparin (UFH), 
which was a time-consuming treatment as it required constant monitoring and dosage 
changing accordingly.2 In the 1980s, the fixed dose low-molecular-weight heparin 
(LMWH) treatment was introduced, which was later shown to be superior to UFH.3 
LMWHs are often referred to as one class of drugs all of which are equally effective.4 
However, pharmacokinetic and pharmacodynamics between various LMWHs do differ, 
which may result in different efficacy (preventing thrombosis) and safety (major bleeding) 
profiles.4 Several trials compared treatment of a single LMWH with UFH in terms of 
efficacy and safety. However, only three trials directly compared LMWHs, but these 
trials were underpowered to determine whether one LMWH is superior to another.5-7 
Therefore, it remains unknown whether all LMWHs are equally effective and safe. 
Because LMWHs are mostly compared with UFHs, standard meta-analytic techniques 
will not be able to assess the optimal LMWH; in contrast, a network meta-analysis allows 
evidence from direct and indirect comparisons to be used for all possible comparisons.8 
We therefore aimed to compare the efficacy and safety of different LMWH agents 
among patients with acute venous thrombosis in a network meta-analysis. 
methods
data sources and searches
A systematic literature search was conducted to identify studies on PubMed (695 hits), 
Medline (483), Embase (1497), Web of Science (617) and the Cochrane Register of 
Controlled Trials (828). The databases were searched for randomized controlled trials 
without any language restrictions from inception until 20 December 2013. The search 
string consisted of MeSH headings and subheadings, text words, and word variations 
for ‘randomized controlled trials’, ‘venous thromboembolism’ and ‘low-molecular-
weight-heparin’. The search strategy was amended for every database. Appendix 1 
shows the full search string. 
study selection
All publications were independently screened on title and abstract by two investigators 
(NvR and TvdH). Potentially relevant publications were independently reviewed in full 
length by two investigators (NvR and KSG) and included in the analysis if they met the 
following criteria: 1) Randomized controlled trial with adult venous thrombosis patients 
(deep vein thrombosis, pulmonary embolism or a combination of both). 2) Patients 
were randomised to one regiment of subcutaneous LMWHs and intravenous or 




still be present on today’s market (2016). 3) At least one of the primary or secondary 
outcomes was reported. In case of multiple publications from the same study, the most 
updated or extensively described study was included. Potential disagreements were 
resolved by consensus. 
data extraction and risk of bias assessment
Extracted data included baseline characteristics, treatment regimens, study duration 
and outcomes. LMWHs were classified according to treatment duration (three months, 
i.e. whole study period [W] or the initial [I] period as bridging therapy to vitamin K 
antagonist therapy) and dosage scheme (twice a day (b.i.d.) or once a day (o.d.)). 
The treatment regimens available were: UFH, I certoparin b.i.d., I dalteparin b.i.d., 
I dalteparin o.d., W dalteparin b.i.d., W dalteparin o.d., I danaparoid b.i.d., I enoxaparin 
b.i.d., I enoxaparin o.d., W enoxaparin o.d., I fondaparinux o.d., I nadroparin b.i.d., 
I nadorparin o.d., W nadroparin o.d., W parnaparin o.d., I reviparin o.d., I reviparin 
b.i.d., I tinzaparin o.d. and W tinzaparin o.d.  
Two reviewers (NvR and KSG) independently assessed the risk of bias of the 
publications and extracted all data. Risk of bias of included publications was determined 
based on the Cochrane risk of bias assessment tool.9 This risk bias assessment 
includes the following items: allocation sequence generation, allocation concealment, 
participant masking, personnel and outcome assessors, completeness of outcome 
data, and selective outcome reporting. We also scored whether diagnoses were made 
according to standard procedures. These were the following for venous thrombosis: 
(1) a new constant intraluminal filling defect not present on the last available venogram; 
(2) if the venogram was not diagnostic, either an abnormal 125I-fibrinogen leg scan or 
abnormal impedance plethysmogramor ultrasound result that had been normal before 
the suspected recurrent episode.10 For diagnosis of pulmonary embolism we considered 
the following as standard: (1) a segmental defect on the perfusion lung scan that was 
unmatched on the ventilation scan or chest roentgenogram; (2) positive pulmonary 
angiography; (3) pulmonary embolism at autopsy.3 Bleeds were classified as major if 
they were intracranial, retroperitoneal, led directly to death, necessitated transfusion 
or they led to the interruption of antithrombotic treatment or (re)operation.3 
outcome measures
Outcomes were symptomatic recurrent venous thrombosis and major bleeding events. 
Recurrent venous thrombosis was considered an event if occurred within the first three 
months of treatment and allocated according to the intention to treat principle. Major 
bleeding events were considered during the treatment with LMWHs or during the first 
fourteen days of treatment. If these data were not available, we considered the number 
of bleeds during the shortest period that was reported. 
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statistical analysis 
A network meta-analysis was conducted to compare different LMWHs (stratified by 
period of LMWH treatment (initial or whole study period) and by dosing schedule (o.d. 
or b.i.d.)). We used an extension of frequentist random effects models for mixed multiple 
treatment comparisons to estimate risk ratios (RRs) and 95% confidence intervals (CIs). 
The network meta-analysis was performed with the mvmeta command for Stata, 
as described by White and colleagues.11 We used crude data from a 2×2 table in the 
analysis, which is reasonable given the randomized design of all studies. For publications 
with zero events in one cell of a 2×2 table, all cells of that 2×2 table were inflated by 
adding 0.5. If more than one study provided data for the same stratum we checked 
consistency of the results. An interaction term was added to the model to estimate the 
difference in results from direct and indirect evidence. All potential interactions were 
tested in an overall test for inconsistency in our network meta-analysis. All statistical 
analyses were performed with Stata, version 12.0 (Statacorp LP).
ResuLts
study selection
The electronic searches yielded 4120 publications, which were 2223 unique publications 
(Figure 1). 2051 Studies were excluded based on the title and abstract, and another 124 















2051 Publications excluded based on  
         selection criteria 
    
4120 Publications retrieved through electronic searches 
1897 Duplicates 
    
2223 Potential relevant publications 
172 Publications selected for data abstraction 
124 Publications excluded 
   75 Based on selection criteria 
   47 Reporting on the same study 
   1 Unattainable 
    
49 Publications included in the network meta-analysis 





All studies were randomized controlled trials carried out between 1986 and 2011. 
12 Trials were single centre, 4 studies did not report the number of study centres 
and 33 were multicentre trials (Table 1). The total number of participants was 
19,487 and ranged from 40 to 2205 per study. There were 9 studies that included 
patients with pulmonary embolism (PE), 30 that included patients with deep 
vein thrombosis (DVT) and 10 studies that included both PE and DVT. 48 Studies 
reported recurrent venous thrombosis as an outcome and 48 studies reported 
major bleeding as an outcome.
Risk of bias
The random sequence generation was adequate in 24 (49%) of the 49 included studies 
(Figure 2). Assigned treatment was adequately concealed prior to allocation in 13 studies 
(27%), while concealment of allocation was not present in three studies (6%) and 
unclear in 33 studies (67%). The treatment was not blinded in most studies (43 studies, 
88%) due to the difference in route of administration between low molecular weight 
heparin (i.e. subcutaneous) and unfractionated heparin (i.e. intravenous). Outcome 
assessment was blinded in 31 studies (63%), 21 studies (43%) reported incomplete 
data and 47 studies (96%) obtained industry sponsored funding, while two studies (4%) 
obtained independent funding. 
network meta-analysis 
The full network is shown in Figure 3. Most comparisons of LMWHs were against UFH, with 
one head-to-head comparison of dalteparin with tinzaparin, one head-to-head comparison 
of nadroparin with parniparin and one head-to-head comparison of enoxaparin with 
fondaparinux. In addition, 8 studies compared LMWH treatment during the initial period 
and the whole study period and 7 studies compared an o.d. dosing schedule directly with 
a b.i.d. schedule. Because none of the potential strata in the network contained two or 
more studies, it was not possible to check inconsistency of the network. 
Network analysis of individual LMWH agents
39 Trials were included to compare different LMWH agents. 10 Studies were not 
considered for this analysis as these did not compare two heparins, but treatment 
during the initial and whole period or an o.d versus b.i.d. dosing schedule of the same 
LMWH. Table 2 and 3 show the results of the network analysis for recurrent venous 
thrombosis and major bleeding respectively. Results regarding recurrent venous 
thrombosis indicate that, with UFH as a reference, dalteparin (RR 1.06, 95% CI 0.53 
to 2.14), danaparoid (RR 0.92, 95% CI 0.06 to 14.66) and nadroparin (RR 0.85, 95% 
CI 0.53 to 1.38) were associated with the highest relative risks for recurrent venous 
thrombosis which was similar to UFH. The other LMWHs gave risk relative risk in the 
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figure 2. Risk of bias summary
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figure 3. networks of included Lmwh and ufh trials. 
Each line represents a direct comparison between two treatments from one or more trials. Certo, 
Certoparin; Dalte, Dalteparin; Enoxa, Enoxaparin; Fonda, Fondaparinux; Nadro, Nadroparin; Par, 
Parniparin; Revi, Reviparin; Tinza, Tinzaparin; UFH, Unfractionated Heparin
range of 0.65 to 0.75, however with broad confidence intervals. Results with respect 
to major bleeding with UFH as a reference category indicated that reviparin (RR 1.11, 
95% CI 0.47 to 2.63), parniparin (RR 1.14, 95% CI 0.04 to 31.33) fondaparinux (RR 1.04, 
95% CI 0.57 to 1.88) and enoxaparin (RR 0.98, 95% CI 0.58 to 1.65) were associated 
with the highest major bleeding risks, while the other LMWHs were associated with 
lower risk estimates (RRs 0.45 to 0.69). 
LMWH agents stratified by period and dosing schedule
46 Trials were included to compare different LMWH agents stratified by treatment period. 
Treatment periods were stratified according to duration: treatment during the whole study 
period (three months) or the initial period as bridging therapy to vitamin K antagonist 
therapy. Results stratified by the period of LMWH treatment indicated that a combination 
of a LMWH and VKA for the whole study period gives lower risks for recurrent venous 
thrombosis, but increased risks for major bleeding complications as compared with the 
LMWH treatment during the initial period only (Figure 4A, Appendix 2 Table 1 and 2). 
Initial treatment with enoxaparin (RR 0.71, 95% CI 0.50 to 1.00) and certoparin (RR 0.66, 
128
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LMWH therapy after acute venous thrombosis: systematic review and network meta-analysis
95% CI 0.39 to 1.11) with UFH as a reference category gave the lowest risks of recurrent 
venous thrombosis, while initial treatment with nadroparin gave slightly higher recurrent 
venous thrombosis risks (RR 0.88, 95% CI 0.55 to 1.42), but lower major bleeding risks than 
enoxaparin (RR 0.59, 95% CI 0.20 to 1.70 as compared with RR 0.96, 95% CI 0.57 to 1.63) 
and similar risks as compared with certoparin (RR 0.62, 95% CI 0.28 to 1.38). 
After further stratification by o.d. and b.i.d. dosing schedules, results still indicated 
that treatment of a LMWH combined with a vitamin K antagonist during the whole study 
period was associated with the lowest risk of recurrent venous thrombosis, but also the 
highest risk for major bleeding (Figure 4B, Appendix 2 Table 3 and 4). Treatments during 
the initial period with the most beneficial risk-benefit profile with UFH as a reference 
were dalteparin b.i.d. (RR recurrent venous thrombosis 0.48, 95% CI 0.10 to 2.31; RR 
major bleeding 0.55, 95% CI 0.07 to 4.68), reviparin o.d. (RR recurrent VT 0.54, 95% 
CI 0.28 to 1.05; RR major bleeding 0.50, 95% CI 0.05 to 5.51) and nadroparin o.d. (RR 
recurrent VT 0.57, 95% CI 0.29 to 1.14; RR major bleeding 0.46, 95% CI 0.12 to 1.81). 
dIsCussIon
Results of this network meta-analysis for the treatment of venous thrombosis 
including over 19,000 patients showed that risks of recurrent venous thrombosis 
and major bleeding may differ between LMWHs. However, it should be underlined 
that confidence intervals were wide, which hampers an ultimate verdict regarding 
the optimal treatment. The network analysis on the comparison of individual LMWHs 
showed that nadroparin and dalteparin are associated with higher risks of recurrent 
venous thrombosis than the other LMWHs, although the imprecision of the estimates 
should clearly be taken into account. Results from a previous (standard) meta-analysis3 
showed that tinzaparin, dalteparin and reviparin were the LMWHs with the highest 
risk of recurrent venous thrombosis. These differences may be explained by the 
higher number of studies included in the present network analysis (49 versus 22). The 
rates of bleeding complications were highest among users of parniparin, reviparin, 
fondaparinux and enoxaparin users, which is in line with the results from the meta-
analyses from van Dongen et al.3 
After stratifying by treatment period and b.i.d. and o.d. treatment regimens, 
results indicated that dalteparin b.i.d., reviparin o.d. and nadroparin o.d. gave the 
lowest recurrent venous thrombotic- and major bleeding risk. The results may suggest 
that treatment with dalteparin b.i.d., reviparin o.d. and nadroparin o.d. may be 
preferable over the other LMWH treatment regimens. Still, we should interpret these 
results with caution as confidence intervals were wide and risk estimates therefore 





figure 4. Risk ratios stratified by (a) initial and whole treatment duration and (B) further by 
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The present network meta-analysis included studies that compared UFHs and/or 
LMWHs with or without a vitamin K antagonist. The current guideline of the American 
college of Chest Physicians recommends direct oral anticoagulants to treat venous 
thrombosis, where LMWHs have to be administered before treating with dabigatran 
or edoxaban, but not when using apixaban or rivaroxaban1. These treatment regimens 
differ from the treatments in included studies in this network meta-analysis. However, 
as we do not expect vitamin K antagonists or direct oral anticoagulants to influence 
the effects of LMWHs and populations treated with LMWHs have not changed, 
results of this study will in all probability be generalizable to the current venous 
thrombosis population. 
This network meta-analysis included 49 randomized controlled trials, which enabled 
us to study differences between LMWHs, but also between LMWH regimens. Still, the 
number of events was small, which hampers the robustness of the results and did not 
enable us to compare dosages of LMWHs. In addition, differences in risk estimates may 
not be clinically relevant as the relative risks between LMWHs were not very high and 
absolute risks of recurrent venous thrombosis and major bleeding were low. Also, UFH 
treatment was similar in the studies, but not identical: different reference values were 
used for the activated partial thromboplastin time (activated partial thromboplastin 
time ranging from 1.5 to 3.5 times the control value). In addition, three head-to-head 
trials were performed to compare LMWHs directly, which were all underpowered and 
made us mainly rely on indirect evidence for the comparisons of individual LMWHs. Due 
to the limited number of head-to-head trials, we were not able to test the consistency 
of the network statistically, which did not enable us to confirm the robustness of 
our results. In addition, risk of bias assessments indicated for all studies at least one 
category with a risk of bias, but for most studies at least two, which may bias the 
risk estimates. 
To conclude, results from this network meta-analysis suggest that dalteparin b.i.d., 
reviparin o.d. and nadroparin o.d. during the initial treatment period may give the 
fewest recurrent venous thrombotic- and major bleeding events in patients with an 
acute venous thrombosis. Results should be interpreted with caution as confidence 





1. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline 
and Expert Panel Report. Chest. Feb 2016;149(2):315-352.
2. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin 
compared with continuous intravenous unfractionated heparin in the treatment of proximal 
deep vein thrombosis. Archives of internal medicine. Jul 12 1993;153(13):1541-1546.
3. van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular 
weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. 
The Cochrane database of systematic reviews. Oct 18 2004(4):CD001100.
4. White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same? British journal 
of haematology. Apr 2003;121(1):12-20.
5. Wells PS, Anderson DR, Rodger MA, et al. A randomized trial comparing 2 low-molecular-
weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary 
embolism. Archives of internal medicine. Apr 11 2005;165(7):733-738.
6. Bellosta R, Ferrari P, Luzzani L, et al. Home therapy with LMWH in deep vein thrombosis: 
randomized study comparing single and double daily administrations. Angiology. Jun-Jul 
2007;58(3):316-322.
7. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment 
of symptomatic deep venous thrombosis: a randomized trial. Annals of internal medicine. 
Jun 01 2004;140(11):867-873.
8. Lumley T. Network meta-analysis for indirect treatment comparisons. Statistics in medicine. 
Aug 30 2002;21(16):2313-2324.
9. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing 
risk of bias in randomised trials. Bmj. Oct 18 2011;343:d5928.
10. Buller HR, Lensing AW, Hirsh J, ten Cate JW. Deep vein thrombosis: new non-invasive 
diagnostic tests. Thrombosis and haemostasis. Jul 12 1991;66(1):133-137.
11. White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-




LMWH therapy after acute venous thrombosis: systematic review and network meta-analysis
aPPendIx 1 
Pubmed
(“Heparin, Low-Molecular-Weight”[Mesh] OR “low molecular weight heparin”[all fields] 
OR ”low molecular weight heparins”[all fields] OR ”LMWHs”[all fields] OR ”LMWH”[all 
fields] OR ”Dalteparin”[all fields] OR ”Enoxaparin”[all fields] OR ”Nadroparin”[all 
fields] OR (”low molecular weight”[all fields] AND heparin*[all fields]) OR ”Lmw 
heparin”[all fields] oR ”Lmw heparins”[all fields]) AND (“Venous Thrombosis”[Mesh] 
OR “Venous Thrombosis”[all fields] OR “Venous Thromboses”[all fields] OR “venous 
thrombotic”[all fields] OR “Phlebothrombosis”[all fields] OR “Phlebothromboses”[all 
fields] OR “Vein Thromboses”[all fields] OR “Vein Thrombosis”[all fields] OR “Deep-
Venous Thrombosis”[all fields] OR “Deep-Venous Thromboses”[all fields] OR “Deep-
Vein Thrombosis”[all fields] OR “Deep-Vein Thromboses”[all fields] OR “DVT”[all 
fields] OR “Thrombophlebitis”[all fields] OR “Thrombophlebitides”[all fields] OR 
“venous thromboembolism”[all fields] OR  “venous thromboembolic”[all fields] OR 
“Venous Thromboembolism”[Mesh] OR “Pulmonary Embolism”[Mesh] OR “Pulmonary 
Embolisms”[all fields] OR “Pulmonary Thromboembolisms”[all fields] OR “Pulmonary 
Thromboembolism”[all fields] OR “pe”[tw])
medLIne
(exp *Heparin, Low-Molecular-Weight/ OR “low molecular weight heparin”.ti OR ”low 
molecular weight heparins”.ti OR ”LMWHs”.ti OR ”LMWH”.ti OR ”Dalteparin”.ti OR 
”Enoxaparin”.ti OR ”Nadroparin”.ti OR ”Clexane”.ti OR ”Fragmin”.ti OR ”Tedelparin”.ti OR 
”Danaparoid”.ti OR ”Orgaran”.ti OR ”Fondaparinux”.ti OR ”Fondaparin”.ti OR ”Arixtra”.
ti OR ”Fraxodi”.ti OR ”Fraxiparin”.ti OR ”Tinzaparin”.ti OR ”Innohep”.ti OR ”Certoparin”.
ti OR ”Sandoparin”.ti OR ”Reviparin”.ti OR (”low molecular weight”.ti AND heparin*.
ti) OR ”LMW Heparin”.ti OR ”LMW Heparins”.ti) AND (exp *Venous Thrombosis/ OR 
“Venous Thrombosis”.ti OR “Venous Thromboses”.ti OR “venous thrombotic”.ti OR 
“Phlebothrombosis”.ti OR “Phlebothromboses”.ti OR “Vein Thromboses”.ti OR “Vein 
Thrombosis”.ti OR “Deep-Venous Thrombosis”.ti OR “Deep-Venous Thromboses”.
ti OR “Deep-Vein Thrombosis”.ti OR “Deep-Vein Thromboses”.ti OR “DVT”.ti OR 
“Thrombophlebitis”.ti OR “Thrombophlebitides”.ti OR “venous thromboembolism”.ti OR 
“venous thromboembolic”.ti OR exp *Venous Thromboembolism/ OR exp *Pulmonary 
Embolism/ OR “Pulmonary Embolisms”.ti OR “Pulmonary Thromboembolisms”.ti OR 





(exp *low molecular weight heparin/ OR “low molecular weight heparin”.ti OR ”low 
molecular weight heparins”.ti OR ”LMWHs”.ti OR ”LMWH”.ti OR ”Dalteparin”.ti OR 
”Enoxaparin”.ti OR ”Nadroparin”.ti OR ”Clexane”.ti OR ”Fragmin”.ti OR ”Tedelparin”.
ti OR ”Danaparoid”.ti OR ”Orgaran”.ti OR ”Fondaparinux”.ti OR ”Fondaparin”.ti OR 
”Arixtra”.ti OR ”Fraxodi”.ti OR ”Fraxiparin”.ti OR ”Tinzaparin”.ti OR ”Innohep”.ti OR 
”Certoparin”.ti OR ”Sandoparin”.ti OR ”Reviparin”.ti OR (”low molecular weight”.ti AND 
heparin*.ti) OR ”LMW Heparin”.ti OR ”LMW Heparins”.ti) AND (exp *Vein Thrombosis/ 
OR “Venous Thrombosis”.ti OR “Venous Thromboses”.ti OR “venous thrombotic”.ti OR 
“Phlebothrombosis”.ti OR “Phlebothromboses”.ti OR “Vein Thromboses”.ti OR “Vein 
Thrombosis”.ti OR “Deep-Venous Thrombosis”.ti OR “Deep-Venous Thromboses”.
ti OR “Deep-Vein Thrombosis”.ti OR “Deep-Vein Thromboses”.ti OR “DVT”.ti OR 
“Thrombophlebitis”.ti OR “Thrombophlebitides”.ti OR “venous thromboembolism”.ti 
OR  “venous thromboembolic”.ti OR exp * venous thromboembolism/ OR exp *Lung 
Embolism/ OR “Pulmonary Embolisms”.ti OR “Pulmonary Thromboembolisms”.ti OR 
“Pulmonary Thromboembolism”.ti OR “pe”.ti) AND (exp Clinical Trial/ OR trial.ti OR 
RCT.ti OR random*.ti)
web of science
TI=(low molecular weight heparin OR “low molecular weight heparin” OR ”low 
molecular weight heparins” OR ”LMWHs” OR ”LMWH” OR ”Dalteparin” OR ”Enoxaparin” 
OR ”Nadroparin” OR ”Clexane” OR ”Fragmin” OR ”Tedelparin” OR ”Danaparoid” 
OR ”Orgaran” OR ”Fondaparinux” OR ”Fondaparin” OR ”Arixtra” OR ”Fraxodi” OR 
”Fraxiparin” OR ”Tinzaparin” OR ”Innohep” OR ”Certoparin” OR ”Sandoparin” OR 
”Reviparin” OR (”low molecular weight” AND heparin*) OR ”LMW Heparin” OR ”LMW 
Heparins”) AND TI=(Vein Thrombosis OR Venous Thrombosis OR “Venous Thrombosis” 
OR “Venous Thromboses” OR “venous thrombotic” OR “Phlebothrombosis” OR 
“Phlebothromboses” OR “Vein Thromboses” OR “Vein Thrombosis” OR “Deep-Venous 
Thrombosis” OR “Deep-Venous Thromboses” OR “Deep-Vein Thrombosis” OR “Deep-
Vein Thromboses” OR “DVT” OR “Thrombophlebitis” OR “Thrombophlebitides” 
OR “venous thromboembolism” OR  “venous thromboembolic” OR  venous 
thromboembolism OR Lung  Embolism OR “Pulmonary Embolisms” OR “Pulmonary 
Thromboembolisms” OR “Pulmonary Thromboembolism” OR “pe”) AND TS=(trial 
OR trials OR trial* OR RCT OR RCTS OR random OR randomised OR randomised OR 
random* OR placebo OR placebo*)
136
8
LMWH therapy after acute venous thrombosis: systematic review and network meta-analysis
Cochrane
(low molecular weight heparin OR low molecular weight heparin OR low molecular 
weight heparins OR LMWHs OR LMWH OR Dalteparin OR Enoxaparin OR Nadroparin 
OR Clexane OR Fragmin OR Tedelparin OR Danaparoid OR Orgaran OR Fondaparinux 
OR Fondaparin OR Arixtra OR Fraxodi OR Fraxiparin OR Tinzaparin OR Innohep OR 
Certoparin OR Sandoparin OR Reviparin OR (low molecular weight AND heparin*) 
OR LMW Heparin OR LMW Heparins) AND (Vein Thrombosis OR Venous Thrombosis 
OR Venous Thrombosis OR Venous Thromboses OR venous thrombotic OR 
Phlebothrombosis OR Phlebothromboses OR Vein Thromboses OR Vein Thrombosis 
OR Deep-Venous Thrombosis OR Deep-Venous Thromboses OR Deep-Vein Thrombosis 
OR Deep-Vein Thromboses OR DVT OR Thrombophlebitis OR Thrombophlebitides OR 
venous thromboembolism OR  venous thromboembolic OR  venous thromboembolism 
OR Lung  Embolism OR Pulmonary Embolisms OR Pulmonary Thromboembolisms OR 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































b=twice daily; cer=certoparin; dal=dalteparin; dan=danaparoid; en=enoxaparin; fon=fondaparinux; 
UFH= unfractionated heparin; w=treated whole study period
i= treated initial period; nad= nadroparin; o=once daily; pa=parnaparin; rev=reviparin; tin= tinzaparin;
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Background: Multidose drug dispensing (MDD) is a dosing aid that provides 
patients with disposable bags containing all drugs intended for one dosing 
moment. MDD is believed to increase medication adherence, but studies are 
based on self-reported data and results may depend on socially desirable 
answers. 
objectives: We aimed to determine the effect of MDD on medication adherence 
in non-compliant patients taking vitamin K antagonists (VKAs), and to compare 
with instructing patients on medication use. 
methods: VKA patients are regularly monitored and the time in therapeutic 
range (TTR) reflects the stability of treatment and was selected as measure for 
adherence. Non-compliant patients (TTR <75% six months prior to MDD) were 
included and the TTRs before and after start of MDD were compared within 
patients to estimate the change in adherence. Non-compliant patients usually 
receive letters or calls from nurses from the anticoagulation clinic to improve 
adherence. To analyze whether standard care compares to MDD, non-compliant 
patients without MDD were also followed to estimate their TTR change over time. 
Results: 83 Non-compliant VKA patients started using MDD. The TTR increased 
by 13% (95%CI 6%-21%) within one month after starting MDD and remained 
stable during the next five months. The TTR of MDD-patients increased 10% 
(95%CI 2%-19%) more as compared with non-MDD patients within one month, 
but was similar after four months (TTR difference 3%, 95%CI -2%-9%). To 
conclude, MDD was associated with improved adherence. 
Conclusions: Compared with instructing patients, MDD led to better adherence 




 MDD as a tool to improve medication adherence: a study in patients using VKAs
IntRoduCtIon
Vitamin K antagonists are drugs used to treat and prevent thromboembolism.1 The 
treatment of patients on vitamin K antagonists in the Netherlands is monitored on a 
regular basis by anticoagulation clinics. There the international normalized ratio (INR) 
is measured and, if necessary, dose adjustments are made based on the measured INR, 
the INR target range and the previous dosage.2 
A measure that reflects how much time INRs of a patient are in therapeutic range 
is the time in therapeutic range (TTR). The TTR is calculated by interpolation between 
consecutive INRs3 and is on average 75% in patients on long term anticoagulant 
treatment in the Netherlands.4 A low TTR is associated with increased thromboembolic 
and bleeding risks5 and can be due to low adherence or other mistakes with medication 
intake (for example because patients are not able to regulate their medication 
themselves).
Multi-dose drug dispensing (MDD) is a dosing aid that provides patients with 
robot-dispensed unit doses. All drugs that should be taken at the same moment are 
gathered in a disposable bag and labeled with the date and time for intake.6 These 
are especially useful when patients are not able to regulate their medications or in 
case of low adherence. A cross-sectional study showed that MDD was associated with 
better medication adherence.7 However, the improved medication adherence was self-
reported and may also be due to socially desirable answers. 
The aim of this study was to determine whether MDD initiation improves subsequent 
medication adherence in patients with low adherence. Second, we examined whether 




The study base consisted of patients who were treated with vitamin K antagonists at 
the Leiden Anticoagulation Clinic. Patients were included for whom MDD was started 
between March 2012 and November 2013. MDD initiation and date of initiation is 
automatically registered in an electronic system of the anticoagulation clinic for all 
patients. MDD was started by the general practitioner or pharmacists for reasons 
that are not known by the anticoagulation clinic. As we were interested in improving 
medication adherence in non-compliant patients, we only included patients with a TTR 
< 75% (i.e. a surrogate for low adherence) six months prior to start MDD. Furthermore, 
patients were only included if they started with started MDD after having at least one 
year of treatment with vitamin K antagonists. At the anticoagulation clinic, INRs are 




After determining the INR, a new appointment is scheduled and the frequency of these 
appointments depends on the measured INR and the stability of the INR values during 
previous appointments. Together with the venepuncture, a standard short history is 
obtained regarding, amongst others, change in co-medications.2  
Patients who moved to a nursing home were excluded from the study because 
of uncertainty as to whether studied effects could be due to better caretaking at the 
nursing home or to MDD. 
data collection and outcomes
Patients’ characteristics and outcomes were collected from the computerized patient 
records at the Leiden Anticoagulation Clinic. Data variables needed for the present 
study include age at initiation of MDD, sex, main indication for therapy with vitamin 
K antagonists, type of vitamin K antagonist (acenocoumarol or phenprocoumon), INR 
target range (2.5 to 3.5 or 3.0 to 4.0), and concomitant drug use at baseline, and during 
follow-up.
Two treatment periods were examined: six months before starting MDD (referred 
to as the ’before MDD’ period) and six months after starting MDD (referred to as 
the MDD period). The TTR was used as a proxy for adherence to the treatment with 
vitamin K antagonists and was calculated using the method described by Rosendaal et 
al.8 The outcome was the TTR during the MDD period, but also the difference in TTR 
after initiating MDD as compared with before MDD. Neither informed consent nor 
approval by a medical ethics committee is, according to Dutch law, required for studies 
in which data are collected from the records by a member of the treatment team.
Comparing treatment strategies
Patients who do not adhere to VKA treatment and have a non-therapeutic INR level 
routinely receive calls and letters from the nurses and doctors of the anticoagulation 
clinic. The calls and letters are used to create awareness among patients of the 
importance of adhering to the treatment. To compare the two strategies (i.e. MDD 
versus this standard treatment strategy), MDD patients were matched to 1 to 6 
similar patients from the Leiden Anticoagulation Clinic who did not start MDD. 
Patients were matched on age (plus or minus 5 years), sex, main indication for 
vitamin K antagonists, duration of treatment with vitamin K antagonists and TTR 
(plus or minus 10%) of the patients during the six months prior to the MDD date 
of the match. As concurrent use of other medications could indicate that a patient 
is less able to adhere to medication or is less stable on vitamin K antagonists, 
we performed a sensitivity analysis where we additionally matched on use of 
other medication related to medication adherence (i.e. thiamine, antipsychotics, 
anxiolytics, antidepressants, antineoplastic agents, blood glucose lowering drugs, 
opioids and medicines to treat Alzheimer’s disease). 
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statistical analysis
The median (interquartile range [IQR]) time under, in and above therapeutic range 
was calculated for the standard treatment- as well as the MDD period. Also, the mean 
TTR difference and 95% confidence intervals (CIs) between the MDD- and standard 
treatment period were calculated. The MDD period was divided into several time 
frames, from MDD until 1, 2, 3, 4, 5, and 6 months after start of MDD. Additionally, the 
percentage of patients that was under, in or above therapeutic range was computed 
for every day and depicted per day with the MDD start date as a reference day (day 
0). A mixed model with an unstructured covariance matrix was used to compare the 
instruction strategy with the MDD strategy.
ResuLts
From 302 patients who started MDD between March 2012 and October 2013, 83 
moved to a nursing home, 1 had an uncertain MDD starting date and 135 had a TTR 
> 75%, leaving 83 patients for the analyses (Supplementary Figure 1). The mean age 
was 83 years (standard deviation [SD] 7) and 34 (41%) were male (Table 1). There were 
77 patients (93%) who used phenprocoumon and the indication for treatment with 
vitamin K antagonists was atrial fibrillation in 63 (76%) patients. The median treatment 
duration with vitamin K antagonists before starting MDD was 5 years (IQR 3 to 10).
The median TTR before starting MDD was 63% (IQR 54 to 91) during the 6 months 
before MDD and was 73% (IQR 59 to 91) during the 6 months after starting MDD 
(Table 2). After initiating MDD, the percentage of patients in therapeutic range increased 
(Figure 1). On an individual basis, TTRs increased in 66 (80%) patients (Supplementary 
Figure 2). Additionally, the TTR increase within a person was on average between 
13-16% after starting MDD (Table 3). 




table 1. General characteristics* 
mdd patients matched mdd patients matched non-mdd patients
General characteristics
Patients 83 (100) 63 (100) 333 (100)
Men 34 (41) 24 (38) 118 (30)
Age, mean (SD) 83 (7) 84 (7) 84 (7)
INR target range
2.5-3.5 68 (82) 55 (87) 307 (92)
3.0-4.0 15 (18) 8 (13) 26 (8)
Treatment indication
Atrial fibrillation 63 (76) 53 (84) 302 (91)
Venous thrombosis 3 (4) 1 (2) 4 (1)
Mechanical heart valves 2 (2) 1 (2) 2 (1)
Ischemic hearts disease 5 (6) 3 (5) 7 (2)
Peripheral arterial disease 7 (8) 5 (8) 19 (6)
Other 7 (8) 1 (2) 1 (0)
Vitamin K antagonist
Phenprocoumon 77 (93) 61 (97) 326 (98)
Acenocoumarol 6 (7) 2 (3) 7 (2)
Medication
Thiamine 4 (5) 3 (5)  5 (2)
Anxiolytic 5 (6) 2 (3) 20 (6)
Antidepressants 6 (7) 6 (10) 45 (14)
Antipsychotics 3 (4) 2 (3) 12 (4)
Anti-dementia drugs 0 (0) 0 (0) 6 (2)
Antineoplastic drugs 3 (4) 3 (5) 10 (3)
Opioids 10 (12) 9 (14) 20 (6)
Blood glucose lowering drugs 26 (31) 20 (32) 72 (22)
* Values are n (%) unless otherwise indicated. INR International Normalized Ratio; MDD Multidose drug 
dispensing; SD Standard Deviation
Matches were found in 63 (78%) of 83 patients who started MDD (Table 1) and for 
43 (51%) patients in the sensitivity analyses of concurrent medication use. In total, 
63 patients who started MDD were compared to 333 patients who received standard 
care in order to examine whether MDD was equally effective as instructing patients 
by the anticoagulation clinic. The analyses showed that patients who used MDD had 
a 10% (95% CI 2% to 19%) higher TTR increase as compared to patients who received 
standard care after one month (Table 4). At four months after starting MDD the TTR 
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median (IQR) median (IQR) median (IQR)
Before MDD 24 (0 to 30) 63 (54 to 69) 19 (0 to 24)
1 month after MDD 18 (0 to 28) 68 (58 to 74) 14 (0 to 14)
2 months after MDD 18 (0 to 31) 71 (55 to 76) 11 (0 to 16)
3 months after MDD 17 (0 to 29) 71 (58 to 81) 12 (0 to 19)
4 months after MDD 17 (0 to 25) 71 (57 to 85) 12 (0 to 19)
5 months after MDD 17 (0 to 28) 72 (57 to 89) 11 (0 to 16)
6 months after MDD 17 (0 to 24) 73 (57 to 91) 10 (0 to 16)
MDD Multidose drug dispensing; TTR time in therapeutic range
table 3. Mean difference of TTR (%) within patients after MDD compared with before MDD 









mean difference (95%CI) mean difference (95%CI) mean difference (95%CI)
Before MDD reference reference reference
1 month after MDD -6 (-30 to 18) 13 (6 to 21) -8 (-14 to -2)
2 months after MDD -7 (-13 to -1) 16 (10 to 22) -9 (-14 to -4)
3 months after MDD -8 (-13 to -3) 15 (10 to 21) -7 (-12 to -2)
4 months after MDD -7 (-12 to -2) 14 (9 to 19) -7 (-12 to -2)
5 months after MDD -7 (-11 to -2) 13 (9 to 18) -7 (-11 to -2)
6 months after MDD -6 (-11 to -2) 14 (10 to 18) -8 (-12 to -3)
MDD Multidose drug dispensing; TTR time in therapeutic range
increase was 3% (95% CI -2% to 9%) higher in the MDD as compared to the standard care 
group. The sensitivity analysis, where patients were also matched on co-medication, 
gave similar results (Table 4). 
dIsCussIon
Results of this study showed that incompliant patients starting MDD had an average 
TTR increase of 14% (95% CI 10% to 18%). This indicates that MDD improved medication 
adherence. To our knowledge, the association between MDD and better medication 
adherence has only been studied by Kwint et al.7 Results of that study showed that 




reported being adherent to all medications as compared with 58% among non-MDD 
patients.7 However, the study by Kwint et al. was cross sectional and the results 
were self-reported, which could have resulted in socially desirable answers and 
an overestimation of medication adherence. Our study adds an objective outcome 
(i.e. TTR) to measure medication adherence.
The second aim of this study was to compare MDD with standard care (i.e. calling 
patients and writing letters). The results showed that the MDD group had a 10% (95% 
CI 2% to 19%) higher TTR increase in the first month after MDD as compared with the 
instruction group. The higher TTR increase indicated that MDD improved adherence 
to vitamin K antagonists faster than standard care. However, the TTR increase was 
not different between the MDD- and instruction group four months after starting 
MDD. A possible explanation could be regression to the mean. Regression to the 
mean occurs when patients are selected according to their low (or high) value 
of a measurement and when that measurement shows intraindividual variability 
(e.g. blood pressure or in our case TTR). The value of that measurement will be 
higher (or lower respectively) on re-measurement due to variation in the circadian 
patterns, measurement or other biological mechanisms.9 An alternate explanation 
for the similar TTRs after four months is that MDD and instructing patients were 
equally effective in improving adherence in the long-run. Nevertheless, MDD may 
also improve adherence to other medications than vitamin K antagonists as these 
medications are all provided in the MDD in unit disposed bags. Our study used 
standard care of the anticoagulation clinic as comparison group, while such care is 
probably absent for other medications. The effect we found is therefore likely to be 
stronger for other medications. A potential disadvantage of MDD may be that MDD 
(when not further controlled) can lead to an increased prevalence of overmedication 
due to uncritical renewal of prescription.6,10,11 but this limitation is beyond the scope 
table 4. TTR difference (%) of patients starting MDD versus patients receiving standard care
 ttR difference (95% CI)
sensitivity analysis 
ttR difference (95% CI) 
Before MDD reference reference
1 month after MDD 10 (2 to 19) 11 (-1 to 22)
2 months after MDD 8 (2 to 15) 7 (2 to 16)
3 months after MDD 5 (-1 to 11) 4 (-4 to 12)
4 months after MDD 3 (-2 to 9) 2 (-6 to 9)
5 months after MDD 3 (-2 to 7) 2 (-5 to 9)
6 months after MDD 3 (-2 to 7) 2 (-5 to 9)
MDD Multidose drug dispensing; TTR time in therapeutic range
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of our study in which we wanted to quantify if MDD led to better adherence in 
vitamin K antagonist users. 
A strength of this study is that patients were compared with themselves thereby 
eliminating possible fixed confounding factors such as sex or chronic diseases. A 
potential limitation is that the association of MDD with adherence of patients in 
nursing homes could not be studied, making the results not generalizable to patients 
in nursing homes.  
In summary, MDD was associated with improved adherence in this study. Compared 
with instructing patients, MDD led to better adherence within one month but was 
associated with similar improvement after four months. 
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Patients with MDD (302) 
MDD-date not certain n=1 
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In nursing home n=83 
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Patients with TTR <75% 
n=83 
figure 1. flow chart of patients
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figure 2. ttR change 6 months after mdd as compared with before mdd, where every line 







Background: Vitamin K1 (VK1) reverses the effects of vitamin K antagonists 
(VKAs). The literature shows that the bioavailability from solutions might be 
higher than that from tablets, possibly resulting in different effects. 
objectives: To compare the bioavailability and effect on the International 
Normalized Ratio (INR) of 5-mg VK1 tablets and solution in three randomized 
clinical trials. 
methods and results: The bioavailability was determined in a crossover trial 
with 25 healthy volunteers. VK1 plasma concentrations were assessed at 0, 2, 4, 
5, 6, 8, 10 and 24 h, and the area under the curve was higher in the solution group 
than in the tablet group (mean difference 365 µg L-1 h, 95% confidence interval 
[CI] 230–501, P < 0.0001). In the other two trials, the effects of both formulations 
on the INR were measured at 0, 24 and 48 h. In the second trial, on 72 patients 
on phenprocoumon with planned invasive procedures, both formulations were 
similarly effective, because all patients reached an INR of < 2.0, which was the 
primary endpoint. In the last trial, on 72 patients on phenprocoumon with an 
INR of 7.0–11.0, the INR decreased slightly more in the solution group (4.7, 95% 
CI 4.3–5.1) than in the tablet group (4.2, 95% CI 3.8–4.6). The solution group 
had a 3.3-fold increased likelihood (95% CI 0.7–15.1) of reaching an INR of < 2.0 
at 48 h. Additionally, the increases in VK1 concentrations were similar (tablets, 
3.2 µg L-1; solution, 3.4 µg L-1; P = 0.99) after 24 h. 




Vitamin K1 in oral solution or tablets: a crossover trial and two RCTs to compare effects
IntRoduCtIon
The vitamin K family comprises fat-soluble proteins, consisting of menaquinones (vitamin 
K2) and phylloquinone (vitamin K1 [VK1]).1,2 In order for the vitamin K-dependent 
coagulation proteins to become biologically active, the glutamic acid residues are 
carboxylated to c-carboxyglutamic acid (Gla). In this carboxylation reaction, the stable 
hydroquinone form of VK1 is catalysed to the epoxide form.2,3 The epoxide form of 
vitamin K is then converted to the quinone form, and this is followed by reduction to 
the hydroquinone by vitamin K epoxide reductase (VKOR). These transformations of 
vitamin K are also known as the vitamin K epoxide cycle.4
Vitamin K antagonists (VKAs) are anticoagulant drugs that inhibit the activity of VKOR 
and thereby block the recycling of vitamin K.5 This results in fewer Gla residues and 
therefore reduced coagulation.5 The three vitamin K antagonists that are mainly used 
are warfarin, phenprocoumon, and acenocoumarol, which differ mainly in half-life: 120 h 
for phenprocoumon, 40 h for warfarin, and 7 h for acenocoumarol.6 VKAs have a narrow 
therapeutic window, and the dosage depends on interindividual and intraindividual factors. 
Therefore, the International Normalized Ratio (INR) is measured on a regular basis to allow 
adjustment of the dose of VKAs, thereby maximizing their effectiveness in preventing 
thrombosis and minimizing the risk of bleeding complications.7,8 An increased INR indicates 
an increased bleeding risk, which can be decreased with VK1. Other indications for 
decreasing the INR with VK1 in VKA-treated patients are invasive procedures.7
In The Netherlands, the main VKAs used are phenprocoumon and acenocoumarol. 
VK1 is available as an oral solution in oil9, but tablets have recently become available. 
An obvious advantage of tablets is that administration is easier, but it is not known 
whether tablets are as effective as the solution. As the absorption of VK1 is stimulated 
by fat10,11, it is possible that the oily solution has higher bioavailability and is therefore 
more effective in decreasing the INR than tablets.
To investigate the bioavailability of VK1 in an oral solution and tablets, we performed 
a crossover trial in healthy volunteers. Additionally, to compare the clinical effects 
of tablet and oral solution formulations of VK1 on the INR in patients treated with 
phenprocoumon, we compared the two treatments in a trial in patients who had to 
undergo an invasive procedure and in a third trial in patients who had a high INR 
(between 7.0 and 11.0).
methods
design and participants
Three studies were performed to determine the bioavailability and to compare the 
effects of tablets and the oral solution, all carried out with 5 mg of VK1. The VK1 solution 




The shelf-life of the tablets was adjusted from 36 to 12 months after the completion 
of the study. We subsequently verified the vitamin K1 content, which showed a mean 
reduction of 9% after 36 months (0.80 mg per tablet, standard deviation [SD] 0.01 mg) 
as compared with 12 months (0.88 mg per tablet, SD 0.005 mg), and a 20% decrease 
as compared with the intended 1 mg. The solution and tablets were provided by the 
hospital pharmacy of the Leiden University Medical Center. The solution consisted of 
VK1 at a concentration of 1 mg mL-1 in arachis oil. The tablets contained 1 mg of VK1, 
and mainly consisted of cellulose and lactose. 
The first study was a crossover trial with healthy volunteers aged ≥ 18 years, in 
which the bioavailability of both VK1 formulations was studied. The healthy volunteers 
were randomized by the hospital pharmacy to start with either the solution or tablets, 
and allocation concealment was ensured through a sealed envelope procedure. Also, 
VK1 was ingested in the presence of the researcher to ensure compliance.
The second and third studies were single-center, openlabel, randomized controlled 
trials. Randomization was performed by the hospital pharmacy, and allocation 
concealment was ensured through a sealed envelope procedure. Additionally, VK1 
was ingested in the presence of the researcher in both studies to ensure compliance. 
We recruited patients aged ≥ 18 years who were treated with phenprocoumon at the 
Leiden Anticoagulation Clinic. Patients suffering from liver failure and/or on dialysis 
were excluded. For the second study, patients were included who were scheduled to 
undergo an invasive procedure for which an INR of < 2.0 was required. For the third 
study, patients with a high INR (between 7.0 and 11.0) to whom 5 mg of VK1 was 
prescribed were included.
The study was performed in accordance with the Declaration of Helsinki and the 
International Conference on Harmonization Guidelines for Good Clinical Practice, and 
all participants gave written informed consent prior to participation in the study. 
The study was approved by the Medical Ethics Committee of the Leiden University 
Medical Center, Leiden, The Netherlands, and was registered at www.trialregister.nl 
(NTR3485).
Interventions and outcomes
Healthy volunteer study The bioavailability from both formulations was determined 
in 25 healthy volunteers. They took 5 mg of VK1 in tablets or the oral solution, and 
crossed over to the other formulation after a washout period of 2 weeks. Blood (5 mL) 
was taken just before ingestion of either tablets or the oral solution, and 2, 4, 5, 6, 8, 10 
and 24 h after ingestion. Breakfast was postponed until half an hour after ingestion of 
VK1, and all volunteers adhered to a low-VK1 diet (no green vegetables, vitamin tablets 
with VK1, or juice with VK1) during the days when blood draws were performed. VK1 
concentrations were determined by HPLC with fluorescence detection.12
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figure 1. mean concentrations with standard errors of means of vitamin K1 for the tablet 
and solution groups.
The primary outcomes were VK1 concentration after 4 h and area under the curve 
(AUC) during 24 h. The mean difference and 95% confidence intervals (CIs) were 
calculated between tablets and the oral solution.
Invasive procedures study Seventy-two patients from the Leiden Anticoagulation 
Clinic were included, who used phenprocoumon and to whom, in accordance with 
the standard protocol, 5 mg of VK1 was prescribed for an invasive procedure. They 
were randomized to receive 5 mg of VK1 in tablets or in the oral solution. INRs were 
measured with CoaguChek XS (Roche Diagnostics, Basel, Switzerland) before ingestion, 
and 24 and 48 h after ingestion, either at home, at the anticoagulation clinic, or at the 
hospital.
The primary endpoint was an INR of < 2.0 after 48 h, and effectiveness was 
considered to be similar if the proportion achieving this differed by < 10% between 
groups. Additionally, the INR decreases after 48 h and 95% CIs were calculated. Also, a 
repeated measures model was used with the INR as outcome and with an unstructured 
covariance matrix. This method deals with missing variables, and also estimates whether 
the decrease in INRs over time was different among users of the oral solution and 
users of tablets. Although the study was not powered to evaluate bleeding episodes 
and venous thrombotic events, both were studied from VK1 ingestion until 7 days 
afterwards. Scoring was performed by specialized physicians from the anticoagulation 




High-INR study Seventy-two patients from the Leiden Anticoagulation Clinic on 
phenprocoumon were recruited, with an INR between 7.0 and 11.0, to whom 5 mg 
of VK1 was prescribed to decrease the INR. They were enrolled on the day of the 
INR measurement, after which anticoagulant treatment was interrupted for at least 
2 days. They were randomized to receive tablets or the oral solution. Blood was 
drawn by venepuncture (5 mL) to determine the concentration of VK1 in serum before 
ingestion of the drug. After 24 h, blood was drawn (10 mL) to determine the INR and the 
concentration of VK1 in serum. After 48 h, the INR was measured with CoaguChek XS 
(Roche Diagnostics), and phenprocoumon treatment was restarted. VK1 concentrations 
were determined by HPLC with fluorescence detection.12
The primary endpoint was the difference in INR (95% CIs) between 24 h and the first 
day. To ensure that INRs did not become too low, a secondary endpoint was defined as 
the percentage of INRs of < 2.0 after 24 h and the percentage of INRs of < 2.0 after 48 h 
for both groups. Another secondary outcome was the difference in VK1 concentration 
between 24 h after injection and just before ingestion tested with a Wilcoxon signed 
rank test. Also, a repeated measures model was used with, depending on the analysis, 
INR or VK1 concentrations as outcome and an unstructured covariance matrix. Bleeding 
episodes and venous thrombotic events were scored from the day of VK1 ingestion until 
7 days after ingestion, although the study was not powered for these outcomes. Scoring 
was performed by specialized physicians from the anticoagulation clinic who were not 
aware of treatment allocation. To obtain insights into further decreases in INRs after 
the follow-up of the study (after 48 h), the first INR after the study was obtained from 
the patient records. Patients with a first INR of < 2.0 were classified as patients with 
a ‘late low INR’. All statistical analyses were performed in R version 2.15.0 and SPSS 
version 20 (Chicago, IL, USA).
ResuLts
healthy volunteer study
Between May 2013 and October 2013, 25 healthy volunteers were included in the study. 
Figure 1 shows the mean concentrations for tablets and the oral solution as a function 
of time. For both formulations, the peak values were seen 2–8 h after ingestion. The 
median VK1 concentrations after 4 h were 29 µg L-1 (interquartile range [IQR] 19–46) 
for tablets and 34 µg L-1 (IQR 20–95) for the oral solution, and the mean difference 
between tablets and the solution was 31 µg L-1 (95% CI 2–61). The median AUCs after 
24 h were 241 µg L-1 h (IQR 180-390) for tablets and 584 µg L-1 h for the oral solution 
(IQR 491–771). The mean difference between tablets and the solution was 365 µg L-1 h 
(95% CI 230–501, P < 0.0001).
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Between December 2011 and January 2013, 259 patients were screened for enrolment 
in the study. Sixty-three patients could not be reached on time, and 11 patients were 
ineligible because they were mentally confused. One hundred and eighty-five patients 
were asked to participate in the study, of whom 72 were enrolled (39%). Reasons for 
declining to participate are shown in Fig. 2A. Thirty-six patients were randomized to 
the tablet group and 36 to the oral solution group. Three patients on tablets did not 
complete the follow-up: one patient at 48 h, because of admission to hospital, one 
patient at 48 h, because he did not respond to VK1 and received an additional dose 
of 10 mg of VK1, and one patient because of a high INR at 24 h (INR 2.3), for which he 
received an additional 5 mg of VK1.
Patients were equally distributed in terms of age and sex (Table 1). The most 
frequently performed procedures were minor skin excisions (22 patients, 31%) and 
tooth extractions (16 patients, 22%). The mean INRs at baseline were 2.6 (SD 0.5) in 
the tablet group and 2.5 (SD 0.6) in the solution group. INRs of all patients for all time 
points are shown in Appendix 1 Fig. 1A. Median INRs for both study arms over time are 
shown in Fig. 3A. Table 2 shows the baseline INR and mean decrease in INR over time in 
table 1. Characteristics cohort at baseline
healthy volunteers* Invasive procedures high InRs
solution tablets solution tablets solution tablets
25 25 36 36 35 35
Male sex 12 (48) 12 (48) 23 (64) 24 (67) 20 (57) 17 (49)
Age, years 34 (12) 34 (12) 72 (8) 74 (8) 77 (10) 78 (10)
INR at baseline - - 2.5 (0.6) 2.6 (0.5) 8.1 (0.8) 8.4 (1.0)
Indication VKA treatment
Atrial fibrillation - - 23 (64) 28 (78) 25 (71) 27 (77)
Venous thrombosis - - 7 (19) 1 (3) 1 (3) 6 (17)
Other - - 6 (17) 7 (19) 9 (26) 2 (6)
Invasive procedure
Minor skin excisions - - 10 (28) 12 (33) - -
Tooth extraction - - 9 (25) 7 (19) - -
Pain blockade - - 2 (6) 4 (11) - -
Biopsy (prostate, liver) - - 3 (8) 1 (3) - -
Gastro-and colonoscopy - - 3 (8) 3 (8) - -
Other - - 9 (25) 9 (25) - -
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figure 3. median International normalized Ratios (InRs) with the 25th and 75th percentiles 
(boxes) and the 10th to 90th percentiles (whiskers) over time for the tablet and solution 
groups. (A) Invasive procedure study (B) High-INR study.








Oral solution 2.5 (0.6) 0.9 (0.8-1.1) 0.2 (0.2-0.2)
Tablets 2.6 (0.5) 0.9 (0.7-1.0) 0.2 (0.2-0.3)
High INRs
Oral Solution 8.1 (0.8) 4.7 (4.3-5.1) 0.6 (0.4-0.8)
Tablets 8.4 (1.0) 4.1 (3.6-4.6) 0.4 (0.1-0.8)
CI, confidence interval; SD, standard deviation.
both study arms. All participants (in both the tablet group and the oral solution group) 
had an INR of < 2.0 after 48 h, and all procedures were performed as scheduled. The 
INR decreases after 48 h were 43% (95% CI 40–46) in the tablet group and 43% (95% 
CI 40–46) in the solution group. The results did not change when a linear mixed model 
was used and missing values were taken into account (results not shown). Patients 






Between December 2011 and April 2013, 151 patients were screened for enrolment 
in this study. Of these, 26 (17%) could not be reached on time, 23 (15%) were ineligible 
because they were mentally confused, and one (1%) was on dialysis. The remaining 
patients (n = 101) were asked to participate in the study, and of these, 72 (71%) agreed 
to take part. The reasons for declining to participate are shown in Fig. 2B. Seventy-two 
patients were randomized to the tablet group (n = 36) and the oral solution group 
(n = 36). Three patients from the solution group did not complete the study; one patient 
dropped out at 24 h because he was admitted to hospital; and two other patients 
dropped out at 48 h because of terminal illness and admittance to hospital. The VK1 
concentrations of three patients at baseline (two on tablets and one on the solution) 
could not be determined, owing to technical errors. Two patients (one on tablets 
and one on the solution) were excluded from analysis because of protocol violations 
(that is, one acenocoumarol user was included and one patient did not stop using 
phenprocoumon during follow-up).
The mean age (78 years for the tablet group and 77 years for the solution group) 
and the proportion of males (49% for the tablet group and 57% for the solution group) 
were similar in both groups (Table 1). There were no signs or symptoms of active 
bleeding in any patient at the time of inclusion. The mean INRs at baseline were 8.4 
(SD 1.0) in the tablet group and 8.1 (SD 0.8) the solution group. INRs of all patients at 
all time points are shown in
Appendix 1 Fig. 1B. Median INRs for both study arms and all time points are shown 
in Fig. 3B. The mean decreases in INRs after 24 h were 4.1 (95% CI 3.6–4.6) for the tablet 
group and 4.7 (95% CI 4.3–5.1) for the oral solution group, as shown in Table 2. There 
was one patient in the tablet group with an INR of < 2.0 (3%, 95% CI 0–8) and none 
in the solution group at 24 h. After 48 h, these numbers were two (6%, 95% CI 0–13) 
in the tablet group and six (19%, 95% CI 6–32) in the oral solution group (relative risk 
for an INR of < 2.0 at 48 h for solution vs. tablets: 3.3, 95% CI 0.7–15.1). The median 
increases in VK1 concentration after 24 h were 3.2 µg L-1 (IQR 1.7–5.2 µg L-1) in the tablet 
group and 3.4 µg L-1 (IQR 2.0–4.8 µg L-1) in the oral solution group (P = 0.99). The results 
did not change when a linear mixed model was used and missing values were taken 
into account (data not shown). During the 7-day follow-up, no patients experienced a 
thrombotic or major bleeding episode, and two patients experienced a minor bleeding 
episode (one in the tablet group and one in the solution group). The INRs after the study 
were measured, on average, 4 days after the study, and two patients from the solution 
group and three patients from the tablet group had a ‘late low INR’. 
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dIsCussIon
These studies show that the bioavailability from the VK1 oral solution was, on average, 
365 µg L-1 h higher than that from tablets in healthy volunteers. Despite this difference 
in bioavailability, the decreases in INR for patients on phenprocoumon who had to 
undergo an invasive procedure were similar for both formulations. In the high-INR 
study, the INR decrease was slightly less in the tablet group than in the solution group 
(mean INR decrease 4.1 vs. 4.7, respectively), but satisfactory in both groups.
Despite the different compositions of the solution and tablets, peak concentrations 
of VK1 were found at similar time points for both formulations. Peak times were 2–8 h 
as compared with 4–6 h in a previous study.10 This difference could be attributable to 
different VK1 sources (in our study, we used VK1 tablets and solution, whereas Gijsbers 
et al.10 used spinach). However, in accordance with the study of Gijsbers et al.10, this 
study shows that the use of a fatty substance such as the oily VK1 solution results in 
higher bioavailability of VK1.
The bioavailability from the solution was higher than that from tablets, but did not 
result in different clinical effects in the invasive procedure study. Here, no difference 
was found in INR decrease between the solution and tablet groups. Also, all INRs were 
< 2.0 at 48 h, and therefore the effects of both formulations can be considered to 
be similar, based on the prespecified primary endpoint. In the high-INR study, INRs 
decreased slightly more in the solution group than in the tablet group, and more 
patients had an INR of < 2.0 in the solution group after 48 h (relative risk for solution 
vs. tablets: 3.3, 95% CI 0.7–15.1). This difference in the numbers of patients with an 
INR of < 2.0 at 48 h could have been caused by patients with a ‘relatively low’ high 
INR at 0 h who received a too high dosage of VK1. However, this was not the case, as 
shown in Appendix 1 Fig. 1B: INRs at baseline of the patients with an INR of < 2.0 at 
48 h were between 7.1 and 9.4, which are similar to the INRs of patients with an INR 
at 48 h of ≥ 2.0 (mean INR of 8.0 for the group with an INR of < 2.0 at 0 h as compared 
with a mean INR of 8.2 for the group with an INR of ≥ 2.0 at 0 h). This result suggests 
that the solution may have a stronger effect on INR reduction than tablets, which is in 
agreement with the higher bioavailability from the solution.
This is the first study to report the effect of 5 mg of VK1 on the INR in patients 
using phenprocoumon. We showed that the INR decreases most during the first 24 h 
after VK1 intake. Additionally, we showed that 5 mg of VK1 is effective and safe in 
patients who have either a too high INR or are scheduled for an invasive procedure. 
Considering the high number of patients with an INR of < 2.0 in the solution group of the 
high-INR study, a lower dose of VK1 solution may give a similar INR reduction and fewer 
patients with an INR of < 2.0. To our knowledge, no literature is available on the effects 
of different VK1 doses on patients using phenprocoumon, but a number of studies 




study, fewer ‘late low INRs’ were found than in the literature on warfarin.13,14,16,17 The 
difference from our findings may be explained by the longer half-life of phenprocoumon 
than of warfarin. When phenprocoumon is restarted on day 3, blood concentrations 
of phenprocoumon may be higher than those of warfarin, which may result in faster-
rising INRs. However, measuring the INR after follow-up was not the primary goal of 
this study, and no other literature is available on patients using phenprocoumon with 
which to compare our results. Hence, obtaining more insights into the course of the 
INR after different VK1 dosages in patients on phenprocoumon may be a subject for 
future research.
A potential limitation of this study is that the bioavailability of both formulations 
was determined in healthy volunteers and is assumed to be similar in patients on 
VKAs. To our knowledge, there is no literature on why the pharmacokinetics of VK1 in 
patients on VKAs would be different from those in healthy volunteers. Furthermore, the 
results of the trial on high-INR patients showed that the INRs decreased slightly more 
in the solution group than in the tablet group, making the assumption that the oral 
solution also has a higher bioavailability in patients on VKAs more plausible. Second, 
all trials were not blinded, which could lead to biased estimates of the outcomes. 
However, the allocation was concealed and the outcomes were laboratory tests that 
were assessed by technicians unaware of the treatment allocation. Therefore, there is 
no reason to suspect that there is bias. Third, our study was performed in patients on 
phenprocoumon. Therefore, absolute values of the INR decrease cannot be applied 
to patients on warfarin and acenocoumarol. However, the trends observed in this 
study (the at least as good effectiveness of tablets and the greatest increase in INRs 
in the first 24 h after intake) are unlikely to be different in patients on warfarin or 
acenocoumarol and phenprocoumon. Also, the VK1 oral solutions in oil and tablets that 
we investigated are only available in The Netherlands; different preparations are used 
in other countries. The differences between various preparations limit our findings and 
conclusions to these specific preparations. Fourth, after completion of our study, the 
shelf-life of the tablets was adjusted by the manufacturer from 36 to 12 months. We 
verified the vitamin K1 contents of the tablets that we used in our study and compared 
them with those of recently produced tablets. Because only a 9% difference was found, 
we believe that the limitation of the shelf-life has not influenced our results.
In this study, two patients randomized to tablets had no INR decrease after VK1 
ingestion. Both patients ingested the tablets in the presence of the researcher and also 
stopped using phenprocoumon. The patient in the invasive procedure study reported 
that he experienced no effect of VK1 on the previous occasion when he ingested VK1. 
The patient had an INR of 3.9 at 0 h, and ingested 5 mg of VK1. At 24 h, he had an INR of 
3.9, after which he received an additional 10 mg of VK1 solution; after this, his INR was 
3.2 at 48 h. Six months later, he was diagnosed with cholangiocarcinoma, which might 
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have contributed to the absence of response to VK1. The second patient participated in 
the high-INR study. She had an INR of 8.0 at 0 h, after which she ingested VK1. The INRs 
were 7.8 and 8.0 at 24 and 48 h, respectively. VK1 concentrations were not increased 
after 24 h, suggesting that VK1 was not absorbed. No explanation was found for why 
she did not respond to VK1.
In summary, the oral VK1 solution has a higher bioavailability than VK1 tablets. In 
patients on phenprocoumon, the INR decreases most in the first 24 h after ingestion 
of VK1, independently of the formulation. In patients with invasive procedures, the 
effects of both formulations on an INR level of < 2.0 were similar (reached in all patients 
after 48 h). However, in patients with a high INR, the INR decreased slightly more when 
they took the solution. This also resulted in a higher percentage of patients with a too 
low INR after 48 h. We conclude from this study that VK1 tablets are as effective and 
safe as the VK1 solution with regard to the ability to decrease the INR in patients on 
phenprocoumon.
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Background: Patients who have a minor bleed during treatment with vitamin K 
antagonists (VKAs) have a 3-fold increased risk of subsequent major bleeding. 
The nature of the underlying risk factors is largely unknown. 
objectives: To indicate why patients with minor bleeds are at increased risk of 
subsequent major bleeds (e.g. are risk factors of a transient or a fixed nature).
methods: Patients who started VKA treatment between 2003 and 2013 were 
included. Exposure was from the minor bleed until 3 months later. We used 
two analyses: a Cox model which we adjusted for several known risk factors, 
and a case-crossover (CCO) design, which corrects for all fixed risk factors (such 
as chronic diseases and genes) as patients are compared with themselves. The 
combination of both analyses gives insight into whether the association of minor 
with major bleeds is a result of fixed or transient risk factors. 
Results: Out of 26 130 patients who were included and followed for ‘61 672 
patient years’, 7194 experienced a minor bleed and 913 a major bleed. The Cox 
model indicated that patients with minor bleeds had a 2.5-fold increased risk 
of experiencing subsequent major bleeding after adjustment for known risk 
factors, whereas the CCO gave risk estimates around unity (odds ratio, 0.9; 95% 
confidence interval, 0.5–1.5).
Conclusions: The combination of both analyses indicates that minor bleeds are 
markers for fixed and currently unknown risk factors for major bleeding events.
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IntRoduCtIon
Vitamin K antagonists (VKAs) are used to treat and prevent thromboembolism. 
Treatment with VKAs requires regular monitoring of the international normalized 
ratio (INR), which in the Netherlands is performed by anticoagulation clinics.1 The 
most common side-effects are bleeding events, which, depending on the severity of 
the symptoms, are classified as major or minor.2 Minor bleeds occur 15–20 times per 
100 patients per year, whereas major bleeding events occur one to two times per 100 
patients per year.3 
A previous study showed that patients on VKAs with minor bleeding events have a 
3.2-fold (95% confidence interval [CI] 1.3–8.0) increased risk of a major bleeding event 
in the following month; the underlying causal mechanism for this was not elucidated.4 
A minor bleed is most likely a marker for other risk factors present in an individual 
that will cause a major bleed. Nevertheless, after adjustment for known risk factors in 
the aforementioned study (i.e. age, over-anticoagulation, diabetes mellitus, diuretic 
use and malignancy), a 2.9-fold (95% confidence interval [CI], 1.1–7.2) increase was 
still found.4 This remaining increased risk indicates that not all risk factors for major 
bleeds were adjusted for, possibly because not all are known. More knowledge on the 
nature of these yet unknown risk factors may provide new leads on risk factors for 
major bleeds and hence improve prediction of who is at high risk of major bleeding 
during VKA treatment.
The aim of this study was therefore to provide such leads on why patients with 
minor bleeds are at increased risk of subsequent major bleeds, such as whether risk 
factors are of a transient or a fixed nature. For this purpose, two analyses were carried 
out: a conventional follow-up analysis and a case-crossover analysis. The study was 
performed in a community-based cohort (n = 26 130) of patients on VKAs who were 
followed for, on average, 2 years, with a large number of minor (n = 7194) and major 
(n = 913) bleeding events.
methods
study population and data collection
All patients who started treatment with VKAs at the Leiden Anticoagulation Clinic 
between January 2003 and December 2013 were included. Patients’ characteristics and 
outcomes were extracted from the computerized records at the anticoagulation clinic. 
Baseline data consisted of sex, date of birth, indication for therapy with VKAs, starting 
date of VKA therapy, INR target range (2.5–3.5 or 3.0–4.0), type of VKA (acenocoumarol 
or phenprocoumon) and co-medication (non-steroidal anti-inflammatory drugs 
[NSAIDs], and antihypertensive, antidiabetic and antiplatelet medications). Blood was 




standard short history was taken regarding bleeds and changes in co-medication.1 
Additionally, the drug-dispensing pharmacy provided starting dates for usage of drugs 
that interact with VKAs.
exposure and outcome
Non-traumatic bleeds were classified as minor or major. Bleeding events were 
categorized as major if they required hospitalization or blood transfusion, were 
symptomatic in a critical area or organ, or led to death. All other bleeds were classified 
as minor.5 
Three exposure categories were defined: current exposure to minor bleeds, not 
exposed to minor bleeds and past exposure to minor bleeds (Fig. 1). The first category 
(‘current exposure to minor bleeds’) started at the time of the minor bleed. This 
exposure continued, dependent on the analysis, until 1, 2 or 3 months after the minor 
bleeding event occurred (see Fig. 1B–D). The use of three different time frames was 
chosen to study a potential transient component: risk estimates would dilute in the 
3-month analysis compared with the 1-month analysis if underlying risk factor(s) were 
of a transient nature. The second exposure category ‘not exposed to minor bleeds’, 
was defined as the period until the first minor bleed occurred (and if no minor bleeding 
event occurred, until the end of follow-up; see Fig. 1A–D). The last exposure category 
(‘past exposure to a minor bleed’) was defined as the period where patients had 
experienced a previous minor bleed, but were not currently exposed to a minor bleed. 
If minor bleeding events are a marker for fixed risk factors for major bleeding events, 
it is to be expected that ‘past exposure to minor bleeds’ would also be associated with 
an increased risk of major bleeds. 
statistical analysis
Follow-up was from the start of treatment with VKAs until occurrence of a major 
bleeding event, death, a move to a municipality that was not covered by the Leiden 
Anticoagulation Clinic, end of treatment with VKAs or the end date of the study 
(31 December 2013). Incidence rates were calculated by dividing the number of major 
bleeds by the observation time. The 95% confidence intervals were based on a Poisson 
distribution.
A Cox proportional hazards model with time-dependent variables was used 
to estimate hazard ratios (HRs) and 95% CIs with ‘not exposed to minor bleeds’ as 
the reference category. Analyses were time-dependently adjusted for age, sex, INR 
target range, antidiabetic medication, antihypertensive medication, NSAIDs and 
antiplatelet drugs.
Second, a case-crossover analysis was performed where only patients with a major 
bleed were included. For all these patients, the presence or absence of a minor bleed 
was compared for the time period directly preceding the major bleed and 1 year before 
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the major bleed (the reference date). An advantage of this analysis is that it corrects 
for all fixed risk factors, such as sex, chronic medication and socioeconomic status, as 
individuals are compared with themselves.6 This analysis would therefore inform us 
about the extent to which such fixed risk factors are involved. Relative risk estimates 
(ORs) and 95% CIs were estimated by means of conditional logistic regression, which 
only takes discordant pairs into account (i.e. only pairs in which one patient is exposed 
during the index date and not during the reference date or vice versa).
A sensitivity analysis was performed, in which skin hemorrhages were excluded 
because these are often trauma inflicted and may not be a good marker for nontraumatic 
causes of bleeding.
All analyses were performed in R 2.15.2 (Foundation for Statistical Computing, 
Vienna, Austria. URL http://www.R-project.org/).
ResuLts
The study cohort contained 26 130 patients. As patients could interrupt their treatment 
with VKA and start again later, these patients had 28 950 VKA treatment periods 
altogether (Table 1). The most common reasons for ending treatment were that the 
indicated period of treatment had passed (n = 6176, 21%) or that patients were cured 
of the disease for which they had received VKA treatment (n = 4755, 16%). The mean 
age at baseline was 70 years (standard deviation, 15) and 15 158 (52%) patients were 
male. Atrial fibrillation was the most common indication for treatment with VKAs 
(16 436 treatment periods, 57%) and the INR target range was 2.5–3.5 in 26 595 (92%) 
treatment periods.





table 1. Baseline characteristics
no minor bleeds minor bleeds
No. of patients 21 599 4531
No. of treatments 24 330 (100) 4620 (100)
Age 67 (16) 72 (12)
Male sex 12 764 (53) 2394 (52)
Vitamin K antagonist
   Phenprocoumon treatment 21 079 (87) 4263 (92)
   Acenocoumarol treatment 3251 (13) 357 (8)
Indication
   Atrial fibrillation 13 206 (54) 3230 (70)
   Venous thrombosis 6303 (26) 795 (17)
   Acute coronary syndrome 11 185 (5) 398 (9)
   Other 4509 (19) 496 (11)
Concomitant drugs, n (%) 
   Anti-platelet drugs 1740 (7) 424 (9)
   NSAIDs 1214 (5) 209 (5)
   Diabetes mellitus, n (%) 2733 (11) 516 (11)
   High blood pressure, n (%) 11 175 (46) 2664 (58)
INR target range, n (%)
   2.5-3.5 22 482 (92) 4113 (89)
   3.0-4.0 1848 (8) 507 (11)
Continuous variables denoted as mean (standard deviation), categorical variables as number (percent)
The mean follow-up per treatment period was 2.1 years, resulting in a total follow-up 
of 61 672 person-years; 913 major bleeds and 7194 minor bleeds, of which 1537 were 
minor skin bleeds, occurred during the follow-up period (Appendix 1 Table 1). The 
incidence rates of minor and major bleeding (per 100 patient years) were 11.7 (95% CI, 
11.4–11.9) and 1.5 (95% CI, 1.4–1.6), respectively. 
In the Cox proportional hazards analysis, ‘current exposure to minor bleeds’ 
was associated with a 2.4- to 2.7-fold increased risk of major bleeding events in the 
subsequent 1–3 months (Table 2). Risk estimates attenuated slightly after adjustment 
for known risk factors for bleeding. An approximately 2-fold increased risk of major 
bleeding was found in patients with ‘past minor bleeds’ (Table 2). Exclusion of skin 
bleeds did not affect these relative risk estimates.
Results of the case-crossover study (that adjusts for all fixed risk factors) showed 
that minor bleeds were not associated with major bleeds. Relative risk estimates 
remained close to unity when considering exposure periods of 1–3 months (Table 3). 
After exclusion of skin bleeds, risk estimates became slightly lower in all analyses.
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All minor bleeding complications
No minor bleeds 50378 668 1.3 Reference Reference
1 Month analysis
Minor bleed 538 18 3.3 2.4 (1.5-3.9) 2.2 (1.4-3.5)
Past minor bleed 10 755 227 2.1 2.1 (1.8-2.4) 1.9 (1.6-2.2)
2 Month analysis
Minor bleed 1017 35 3.4 2.6 (1.8-3.6) 2.3 (1.6-3.2)
Past minor bleed 10 272 210 2.0 2.0 (1.7-2.4) 1.8 (1.6-2.2)
3 Month analysis
Minor bleed 1455 52 3.6 2.7 (2.1-2.9) 2.5 (1.9-3.3)
Past minor bleed 9838 193 2.0 1.9 (1.6-2.3) 1.8 (1.5-2.1)
Minor bleeding complications except skin bleeds 
No minor bleeds 52578 728 1.4 Reference Reference
1 Month analysis
Minor bleed 419 13 3.1 2.1 (1.2-3.7) 1.9 (1.1-3.4)
Past minor bleed 8675 172 2.0 1.8 (1.5-2.1) 1.6 (1.4-2.0)
2 Month analysis
Minor bleed 788 26 3.3 2.3 (1.6-3.5) 2.1 (1.4-3.2)
Past minor bleed 5299 159 1.9 1.7 (1.4-2.1) 1.6 (1.3-1.9)
3 Month analysis
Minor bleed 1123 38 3.4 2.5 (1.8-3.4) 2.3 (1.6-3.1)
Past minor bleed 7965 147 1.9 1.7 (1.4-2.0) 1.5 (1.3-1.9)
* Time dependent analysis. † Time dependent analysis adjusted for age, sex, INR target range, 
antidiabetic -, antihypertensive -, antiplatelet drugs and NSAIDs
dIsCussIon
This study showed that patients with minor bleeding had a 2.5-fold increased risk of a 
subsequent major bleed. The increased risk did not change substantially after adjusting 
for several known risk factors, similar to what has been shown in a previous study on 
this issue.4 This suggests that the risk factors we and others adjusted for (age, sex, 
INR target range, antidiabetic medication, antihypertensive medication, NSAIDs and 





The results were similar in the conventional analysis when considering different 
time frames (i.e. 1, 2 and 3 months). This suggests that risk factors for major bleeds 
have a fixed nature, as otherwise it would be expected that the association would 
attenuate over time. Moreover, the association between minor and major bleeds 
disappeared in the case-crossover analysis. As such an analysis adjusts for all fixed 
risk factors, this result also implies that minor bleeding events are markers of fixed 
risk factors for major bleeding. Identification of these fixed risk factors, of which 
already several can be excluded as mentioned above, may provide new leads on who 
is at high risk of major bleeding during anticoagulant treatment. Such new predictors 
are necessary, considering that current prediction models for major bleeds do not 
perform well and cannot distinguish between patients who are at high risk for bleeds 
and thromboembolism.7
Based on the literature, there are some candidates for these risk factors for major 
bleeding. One characteristic that indicates who is at risk of bleeding complications, 
which was not taken into account in this study, is renal insufficiency8,9, as this variable 
was not available in our dataset. Other characteristics include coagulation-related 
indicators. One of them is ABO blood group, as it was previously shown that blood 
group O is associated with an increased risk of major bleeding events during VKA 
treatment.10 This is biologically plausible because individuals with blood group O 
have lower plasma concentrations of both von Willebrand factor and factor VIII.11 
Another candidate could be vessel wall damage, as suggested by the increased risk of 
bleeding associated with a high concentration of soluble trombomodulin12,13, which is 
table 3. Association of minor bleeding complications with major bleeding complications in all 







All minor bleeding complications
1 Month analysis 7 8 0.9 (0.3-2.4)
2 Month analysis 15 19 0.8 (0.4-1.6)
3 Month analysis 24 27 0.9 (0.5-1.5)
Minor bleeding complications without skin bleeds
1 Month analysis 4 6 0.7 (0.2-2.4)
2 Month analysis 9 15 0.6 (0.3-1.4)
3 Month analysis 16 22 0.7 (0.4-1.4)
* ‘Bleed+’: exposed to a minor bleed during the major bleed; ‘Bleed-’: not exposed to a minor bleed 
during the major bleed; ‘Reference+’: exposed to a minor bleed one year before the major bleed; 
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a marker for vessel damage. Other candidates are genetic variants (e.g. cytochrome 
P450 2C9 and vitamin K epoxide reductase complex 1), as these affect the required 
VKA dosage14 and risk of bleeding.15 Unfortunately, we have no information on these 
factors in our study.
A strength of this community-based cohort is that it contained over 900 major and 
7000 minor bleeding events, which made the results robust. The incidence rates of 
major bleeding events in this study were similar to those found in other community-
based studies of patients treated with VKAs1,4,16, indicating generalizability. A limitation 
is that minor bleeds were mainly self-reported and could be trauma related, although 
this was not reported by the patient. We tried to overcome this limitation with the 
sensitivity analysis where skin hemorrhages were excluded, which did not change our 
major outcomes. Still, this analysis was based on the assumption that skin bleeds are 
more likely to be caused by trauma, which may not be true for all skin hemorrhages.
To conclude, this study showed that in VKA patients, minor bleeding events are 
markers for fixed and currently unknown risk factors for major bleeding events.
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table 1. Type of bleeds
Bleeds, n (%) minor, n= 7194 major, n= 913
   Intracranial - 224 (25)
   Aneurysm - 16 (2)
   Joint, muscle - 57 (6)
   Gastro intestinal 713 (8) 410 (45)
   Haematoma 1534 (17) 38 (2)
   Epistaxis 1255 (14) 23 (3)
   Intraocular - 22 (2)
   Conjuctiva bleed 1867 (20) -
   Haematuria 1348 (15) 55 (6)
   Respiratory tract 167 (2) 34 (4)
   Urogenital 163 (2) 12 (1)







Background: Risk scores for patients who are at high risk for major bleeding 
complications during treatment with vitamin K antagonists (VKAs) do not 
perform that well. BLEEDS was initiated to search for new biomarkers that 
predict bleeding in these patients.
objectives: To describe the outline and objectives of BLEEDS and to examine 
whether the study population is generalizable to other VKA treated populations. 
Methods: A cohort was created consisting of all patients starting VKA treatment 
at three Dutch anticoagulation clinics between January-2012 and July-2014. We 
stored leftover plasma and DNA following analysis of the INR.
Results: Of 16 706 eligible patients, 16 570 (99%) were included in BLEEDS and 
plasma was stored from 13 779 patients (83%). Patients had a mean age of 
70 years (SD 14), 8 713 were male (53%). The most common VKA indications were 
atrial fibrillation (10 876 patients, 66%) and venous thrombosis (3 920 patients, 
24%). 326 Major bleeds occurred during 17 613 years of follow-up (incidence 
rate 1.85/100 person years, 95%CI 1.66–2.06). The risk for major bleeding was 
highest in the initial three months or VKA treatment and increased when the 
international normalized ratio increased. These results and characteristics are 
in concordance with results from other VKA treated populations.
Conclusion: BLEEDS is generalizable to other VKA treated populations and will 
permit innovative and unbiased research of biomarkers that may predict major 
bleeding during VKA treatment. 
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IntRoduCtIon
Vitamin K antagonists (VKAs) are used to treat and prevent thromboembolic events.1 
Monitoring of VKA treatment is required because VKAs have a narrow therapeutic 
window and the dosage depends on inter-individual, but also intra-individual factors.1 In 
the Netherlands, patients on VKA treatment are monitored by specialized anticoagulation 
clinics.2 The clinics are regionally organized and all patients who live in a certain area 
are monitored by the same clinic.2 At these clinics, the international normalized ratios 
(INRs) are measured on a regular basis, after which a specialized physician determines 
the VKA dosage and the time interval between INR measurements.2
Despite this monitoring system, the most common side effects of VKAs remain 
bleeding complications.1 Bleeding complications are, depending on the severity, 
categorized as minor or major bleeding complications. Minor bleedings, such as skin 
bruises or nosebleeds, occur annually in 6-10% of patients on VKAs and major bleedings, 
including (fatal) intra-organ bleeds, occur in 1-3% of VKA treated patients per year.2-4 
Risk factors for major bleeding events have been identified and subsequent bleeding 
risk scores have been developed.5-10 However, these risk scores do not accurately 
predict major bleeding (range of C statistics: 0.59-0.69).11 Additional biomarkers and 
genetic variants potentially yield a better accuracy of predicting major bleeding, but 
information on such predictors is scarce. The goal of the Biomarkers in the Leiden 
Etiology and Epidemiology of bleeding in vitamin K antagonists Drug users Study 
(BLEEDS) is to identify novel biomarkers and genetic variants that predict patients at 
risk for major bleeding events during treatment with VKAs. Here, we delineate the 
outline of the study. In addition, we provide an overview on classical risk factors for 




BLEEDS is a population based cohort study with longitudinal follow-up in 16 570 
patients who started VKA treatment and were recruited from three anticoagulation 
clinics in the Netherlands. 
study population
Consecutive patients aged 18 years or older who started VKA treatment at one of 
the three participating anticoagulation clinics in the Netherlands (Leiden, The Hague 
and Hoofddorp) between January 2012 and July 2014 were eligible (Figure 1). These 
regional anticoagulation clinics monitor the VKA therapy of those patients living in 




Patients were included if the planned treatment duration was at least six weeks, and 
patients who did not speak Dutch (n= 50) or experienced psychiatric problems (n= 74) 
were excluded. 
Considering an alpha value of 5%, statistical power of 80%, exposure prevalence 
of 10%, a relative risk of 1.8, an incidence rate of bleeding of 1.8 per year 100 patient 
years and a mean follow-up of one year, we estimated the necessary sample size at 
approximately 16 500 patients. Inclusion of patients took place by an opt-out procedure: 
all eligible patients received information regarding the study and were included if they 
did not decline to take part. The study was approved by the medical ethical committee of 
the Leiden University Medical Center. The included study population consisted of 16 706 
eligible patients, of whom 136 opted out (< 1%), resulting in 16 570 included patients.
Baseline examination and surveillance
When enlisted by the anticoagulation clinic, several patient characteristics were 
registered, including date of birth, sex, co-medication, indication for VKA treatment, 
planned duration of VKA treatment and INR target range. To monitor the INR, 
appointments are made with a frequency of at least every six weeks. The time interval 
between these measurements depends on the stability of the INR. In case of an 
unstable INR, the INR will be reassessed more frequently. In case of a stable INR, INR 



















2 791 patients no material collected 
   1 092 Ceased VKA treatment 
   858 Random exclusion 
   542 Used Coaguchek XS 
   190 External INR measurements 
   109 Logistic reasons 
   
    






16 706 Eligible 
16 830 Patients who started VKA treatment 
124 Ineligible 
   74 Psychiatric problems 
   50 Non Dutch speaking 
 
 136 Rejected to take part 
 
16 570 Included 
figure 1. flow chart of number of individuals included 
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To measure the INR, venous blood is drawn into vacuum tubes containing 0.1-volume 
0.109 mol/L trisodium citrate as anticoagulant. Blood was centrifuged (10 minutes at 
2800 G) within 4 hours of collection, upon which the INR was measured. Another 
second, less frequently performed method to measure the INR is by using a point-of-
care device (CoaguChek XS). At each appointment, a standardized short questionnaire 
is taken (and electronically stored) by a nurse in order to document changes in co-
medication, onset of co-morbidities, the occurrence of bleeding events, or scheduled 
invasive procedures (e.g. planned surgery or dental extractions).  
data collection 
Patient characteristics were extracted from the computerized patient records of the 
anticoagulation clinics. Baseline characteristics included sex, age, indication for VKA 
treatment, type of VKA, INR target range, and co-medications. The study population 
included 16 185 patients, and because some patients stopped VKA treatment and 
started again, these patients represented a total of 16 570 treatment periods. There 
were 8 713 male patients (53%) and the mean age was 70 years (standard deviation [SD] 
14; Table 1). The most common indications for VKA treatment were atrial fibrillation 
(10 876 treatment periods, 66%) and venous thrombosis (3 920 treatment periods, 
24%). Phenprocoumon was used during 12 083 (73%) periods, and approximately half 
of the patients used antihypertensive medication (8 354 patients, 50%) or glucose 
lowering drugs (8 013 patients, 48%). 
material collection
For his study, we used patient’s blood and plasma samples that were leftover 
following INR analyses. The sample collection started three weeks after initiations 
of VKA therapy and, if applicable, two weeks after termination of low-molecular-
weight-heparin (LMWH) treatment. To guarantee the privacy of the patients, 
technicians who were not involved in the study recoded patient numbers to study 
numbers. After recoding, patient specific characteristics were concealed and 
samples were labelled according to study number. The ‘key’ linking patient to study 
numbers is maintained by a data manager who is not involved in the study. Per 
patient, a minimum volume of 2.0 ml plasma was collected, which resulted from 
blood samples of two to three subsequent visits to the anticoagulation clinic. Plasma 
samples were initially stored at -20˚C up to one week. The remaining white blood 
cells, also encoded with the corresponding study number, were stored for up to one 
week at 2-8˚C, after which DNA was isolated.12 Plasma and DNA were both long-term 
stored at -80˚C.
Plasma and DNA was collected from 13 779 patients (83%). Material collection failed 
for 2 791 patients because they ceased VKA treatment early (1 092 patients), were 




table 1. Baseline characteristics
general characteristics
Patients 16 185
Treatment periods 16 570
Men 8 713 (53)
Age 70 (14)
INR target range
2.5-3.5 15 509 (93)
3.0-4.0 1 061 (7)
Treatment indication
Atrial fibrillation 10 876 (66)
Venous thrombosis 3 920 (24)
Mechanical heart valves 435 (3)
Ischemic heart disease 519 (3)




Phenprocoumon 12 068 (73)




Anti-platelet drugs 2 705 (16)
NSAIDs 1 004 (6)
Glucose lowering drugs 8 013 (48)
Anti-hypertensive drugs 8 354 (50)
Cholesterol lowering drugs 6 288 (38)
Digoxin 1 767 (11)
Anti-cancer drugs 339 (2)
Opioids 1 306 (8)
Methotrexate 155 (1)
the INR was established by the point-of-care device CoaguChek XS (542 patients), 
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follow-up and outcome
The follow-up lasted from starting VKA therapy to either the termination of VKA 
treatment, migration to an area not covered by the three anticoagulation clinics, 
death, the occurrence of a major bleeding event, or end of the study (31st December 
2014), whichever occurred first, resulting in a total follow-up of 17 613 years and a 
mean follow-up time of 13 months. Patients were followed according to the routine 
procedures of the anticoagulation clinic. During the appointments, major bleeding 
events were identified through short interviews that were part of the standard 
procedures of the anticoagulation clinic. If patients mentioned any bleeding event or 
hospitalization related to a bleeding event, information was obtained from the hospital, 
general practitioner or patient to classify the bleeding event as minor or major. Major 
bleeding events were defined according to the guidelines of the Federation of Dutch 
Anticoagulation clinics (FNT) by trained anticoagulation clinic physicians, who were not 
involved in the current study. Bleeding events were classified as major if these were 
fatal, lead to a blood transfusion or hospital admission, were an intracranial bleeding, 
objectively diagnosed joint bleed, or a bleeding event in a critical organ.13 In total, 326 
major bleeding events were identified during 17 613 years of follow-up.
ResuLts and dIsCussIon
BLEEDS provides a large set of patient information and material that will be used 
to discover new information on risk factors for major bleeding events during VKA 
treatment. The large number of major bleeding events (n=326) provides a unique 
opportunity to perform subgroup analyses and study relatively rare risk factors. 
Previously, three studies have been performed in which plasma and DNA were 
collected to discover new risk factors for major bleeding during VKA treatment.14-16 
However, in all of these studies, only a subgroup of the total VKA-treated patients was 
included. The first study excluded patients who died or became mentally disabled by 
the bleeding event and included only 22% of all patients who experienced a major 
bleeding complication in the final analyses.16 This makes the results susceptible to 
survivor bias.17 The second study’s inclusion criterion was a time in therapeutic range 
(TTR) of 100%15, while the third study included only 75% of the warfarin-treated 
patients. Furthermore, the patients were followed up to 5.5 years14, which may have 
diluted the results. By including only subsets of patients on VKA therapy, results can be 
biased and cannot be extrapolated to all VKA-treated patients.16,17 In BLEEDS, follow-up 
was short which creates the possibility to study risk factors that predict the short term 
risk for major bleeding. In addition, we have included 99% of the eligible patients 
treated with VKAs, thereby providing a strong case that our population represents 




incidence rate of the major bleeding events (1.85 per 100 patient-years, 95% CI 1.66-
2.06; see Table 2) compares well with major bleeding rates of other population-based 
studies.2,18,19 The major bleeding complications observed in our study also concur with 
previous findings, given that intracranial bleedings were the most common fatal major 
bleeding complications (37, 54% of all major bleeding events), while the non-fatal 
bleedings mostly resulted from digestive (106, 41%) and intracranial (40, 15%; see 
Table 3) bleedings.2,18,19
To further analyze if BLEEDS agrees with other VKA treated populations in terms 
of predictors for bleeding, we decided to calculate the TTR by linear interpolation 
as described by Rosendaal et al.20 Previous studies have shown that high TTRs are 
associated with lower bleeding rates as compared with low TTRs. The lowest TTR was 
observed shortly after the initiation of VKA treatment, which increased to approximately 
80% and stabilized until the end of follow-up (Figure 2), which in agreement with 
previous findings. This pattern is as expected based on other population based studies, 
although it should be mentioned that a TTR of 80% is within the upper range of normal 
for Western European anticoagulation clinics that on average achieve a TTR of 70%.21
table 2. Incidence rates of bleeding events stratified by clinical characteristics
no. of events Patient time (years)
events/100
patient-years (95% CI)
Total 326 17 613 1.85 (1.66-2.06)
Sex
Male 184 9 224 1.99 (1.72-2.30)
Female 142 8 387 1.69 (1.43-1.99)
INR target range
2.5-3.5 306 16 454 1.86 (1.66-2.08)
3.0-4.0 20 1 157 1.73 (1.09-2.62)
Vitamin K antagonist
Phenprocoumon 262 13 278 1.97 (1.75-2.22)
Acenocoumarol 64 4 333 1.48 (1.15-1.87)
Indication
Atrial fibrillation 241 13 162 1.83 (1.61-2.07)
Venous thrombosis 53 2 702 1.96 (1.48-2.55)
Mechanical heart valves 4 351 1.14 (0.36-2.75)
Ischemic hearts disease 7 555 1.26 (0.55-2.50)
Vascular 9 433 2.08 (1.01-3.81)
Postoperative 3 105 2.86 (0.72-7.78)
Other 9 384 2.34 (1.14-4.30)
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figure 2. time in therapeutic range per day after starting vKa treatment
Further TTR assessment revealed that a low TTR was dose-dependently associated 
with increased bleeding rates (see Table 4).20,22,23 Additional analyses confirmed that, 
similar to other population based cohorts, in BLEEDS the bleeding rates i) increased 
with age (see Figure 3)2,10,18,24-26, ii) were highest shortly after initiation of VKA treatment 
and became stable after four months of VKA treatment (Figure 4)18,25,27,28, iii) and 
increased after a high INR (Figure 5).18,26 Results of the subgroup analyses (atrial 
fibrillation patients, venous thrombosis patients, and patients with an INR target range 





table 4. Association of TTR with bleeding events
no. of events Patient years events/100 patient-years (95% CI)
Time in range
< 35% 63 448 13.02 (10.09-16.54)
> 35% and < 50% 33 1 145 2.88 (2.02-4.00)
> 50% and < 60% 35 1 538 2.28 (1.61-3.13)
> 60% and < 70% 48 2 212 2.17 (1.62-2.85)
> 70% and < 80% 40 2 821 1.42 (1.03-1.91)
> 80% and < 90% 37 3 059 1.21 (0.86-1.65)
> 90% 62 5 361 1.16 (0.89-1.47)
figure 3. Incidence rates of bleeding events stratified by age
Two characteristics of the study deserve a further comment. Material (plasma and 
DNA) of all patients was collected from the third week after initiating VKA therapy and, 
if applicable, two weeks after termination of LMWH therapy. As such, we did not collect 
material of 32 patients who experienced a major bleeding complication before this third 
week. As a possible consequence, risk estimates may dilute because the patients with 
the strongest risk factors ‘drop out’ of the study. Second, the low INR target range is 
2.5-3.5 in the Netherlands, which is 2.0-3.0 in other countries. This may result in slightly 
higher major bleeding rates in these patients.
In this study, 99% of the eligible patients were included which results in a unique, 
unselected study population. The number of major bleeding events is relatively high, which 
creates the possibility to perform subgroup analyses and study whether protein levels are 
dose dependently associated with major bleeding events. In addition, the availability of 
stored biological specimens (citrated plasma and DNA) will allow us to uncover new risk 
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factors for major bleeding complications during VKA treatment, with the goal of discovering 
new predictors for VKA-treated patients at high risk for major bleeding events. We would like 
to emphasize that results of BLEEDS with respect to classical risk factors for major bleeding 
are similar to other cohorts of patients who received VKAs for all long term indications, which 
indicates that this population is generalizable to other populations. In summary, the BLEEDS 
will permit innovative and unbiased research of multiple exposures for major bleeding events 
and will assist in the prevention of major bleeding events in patients treated with VKAs.
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figure 5. Incidence rates of bleeding events stratified by InR
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FIGURE 1: time in therapeutic range per day after starting VKA treatment presented per sub group (atrial fibrillation patients, venous 
thrombosis patients, patients with a low target range) 





















figure 1. time in therapeutic range per day after starting vKa treatment presented per sub 
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FIGURE 2: incidence rates of bleeding events stratified by age presented per sub group (atrial fibrillation patients, venous thrombosis patients, 
patients with a low target range) 
All       AF patients 
 


































figure 2. Incidence rates of bleeding events stratified by age presented per sub group (atrial 




FIGURE 3: incidence rates of bleeding events stratified by time since start of VKA treatment presented per sub group (atrial fibrillation patients, 
venous thrombosis patients, patients with a low target range) 

















































figure 3. Incidence rates of bleeding events stratified by time since start of vKa treatment 
presented per sub group (atrial fibrillation patients, venous thrombosis patients, patients 
with a low target range)
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figure 4. Incidence rates of bleeding events stratified by InR, presented per sub group (atrial 
fibrillation patients, venous thrombosis patients, patients with a low target range)
FIGURE 4: incidence rates of bleeding events stratified by INR, presented per sub group (atrial fibrillation patients, venous thrombosis patients, 
patients with a low target range) 
All        AF patients 
 
























































































































































Background: Major bleeding is a serious side effect of anticoagulant treatment. 
Existing prediction scores for major bleeds in anticoagulated patients perform 
moderately well, necessitating the need for better predictors for major bleeding. 
Here we assess whether markers of chronic endothelial damage, i.e. soluble 
thrombomodulin (sTM), or acute endothelial damage, i.e. von Willebrand 
propeptide (VWFpp), are associated with an increased risk for major bleeding 
in VKA patients.
methods: Plasma was collected from a cohort of 16570 patients starting VKA 
treatment between January 2012 and December 2014. Patients were followed 
until a major bleed, the end of VKA treatment, death, or December 31st 2014, 
whichever came first. From the cohort, we assembled a case-cohort study that 
included all 326 cases with a major bleeding and a random sample of 652 patients 
at baseline (subcohort). Plasma sTM and VWFpp levels were measured by ELISA 
and stratified by the 25th, 50th, 70th, and 85th percentiles. Hazard ratios (HRs) 
and 95% confidence intervals (CIs) were estimated by means of weighted Cox 
regression and adjusted for age, sex, diabetes mellitus and hypertension. 
Results: Plasma was available from 263 cases and 578 subcohort patients. 
Adjusted HRs increased dose dependently with increasing sTM levels, from 
1.30 (95%CI 0.82-2.06) in the 25th to 50th percentile to 1.77 (95%CI 1.09-2.87) 
above the 85th percentile. Adjusted VWFpp levels were not associated with an 
increased risk for major bleeding.
Conclusion: Increased sTM levels are associated with major bleeding during VKA 




Endothelial damage and major bleeding in VKA patients
IntRoduCtIon
Vitamin K antagonists (VKAs) are used to treat and prevent thromboembolism. 
Treatment with VKAs requires regular monitoring of the international normalized 
ratio (INR), which in the Netherlands is performed by anticoagulation clinics.1 Despite 
frequent monitoring, the risk of major bleeding associated with VKA therapy remains 
substantial: approximately 1–3% of VKA-treated patients suffer from major bleeding 
complications each year.1-3
These major bleeding complications could be prevented by ceasing or adjusting the 
treatment for patients at high risk for major bleeding. Studies have been performed to 
identify patients at risk for major bleeding, with patient characteristics, co-medication, 
and co-morbidity emerging as potential risk factors. These risk factors have been 
combined in five different prediction models, which each performs modestly well.4 
For instance, The HAS-BLED score is considered to perform best in predicting bleeding 
risk, but has a c-statistic of only 0.65 (95% CI, 0.61-0.69).4 Other prediction scores, like 
CHADS2 or CHA2DS2-VASc, poorly predict major bleeding risk as indicated by c-statistics 
of 0.55 (95% CI, 0.49-0.61) and 0.56 (95% CI, 0.53-0.59), respectively.4 The present rather 
low capability to predict major bleeding events in anticoagulated patients therefore 
asks for an enhanced understanding of risk factors for major bleeding, which may lead 
to new and better predictors for major bleeding. 
To reach this goal, we designed a case–cohort study in 16 570 patients who recently 
started with VKA treatment, of whom 326 experienced a major bleeding event.5 Here we 
describe whether a marker of chronic endothelial damage, i.e. soluble thrombomodulin 
(sTM)6-9, or of acute endothelial damage, i.e. propeptide of von Willebrand factor 
(VWFpp)10,11, are associated with major bleeding during VKA treatment. 
methods
study Population
This population-based study enrolled VKA-treated patients in the “Biomarkers in the 
Leiden Etiology and Epidemiology of bleeding in vitamin K antagonists Drug users Study” 
(BLEEDS). The design is described in detail elsewhere.5 In brief, between January 2012 
and December 2014, 16 570 consecutive patients aged 18 years or older who started 
treatment with VKAs were included from three anticoagulation clinics in the Netherlands. 
Patients were followed according to the routine procedures of the anticoagulation 
clinics, and the INR was monitored with a frequency of at least once every six weeks. 
Patient characteristics were extracted from the computerized patient records of the 
anticoagulation clinics. Baseline characteristics included sex, age, indication for VKA 
treatment, type of VKA, INR target range, and co-medications. The BLEEDS was approved 





Major bleeding events were defined according to the guidelines of the Federation 
of Dutch Anticoagulation clinics (FNT) by trained anticoagulation clinic physicians 
who were not involved in the current study.5 Bleeding events were classified as 
major if these were fatal, an intracranial bleeding, an objectively diagnosed joint 
bleed, a bleeding event in a critical organ, or lead to a blood transfusion or hospital 
admission.12
Blood sampling and laboratory procedures
We stored patient’s blood and plasma samples that were leftover following INR 
analyses. The sample collection started three weeks after initiation of VKA therapy and, 
if applicable, two weeks after termination of low-molecular-weight-heparin (LMWH) 
treatment. To guarantee the privacy of the patients, technicians who were not involved 
in the study recoded patient numbers to study numbers. After recoding, patient specific 
characteristics were concealed and samples were labeled according to study number. 
The key linking patient to study numbers was maintained by a data manager who is 
not involved in the study. 
Material was collected from 13 779 patients (83%). Material collection failed for 
2791 patients because of logistic complications (1699 patients) or because they ceased 
VKA treatment prior to blood sampling (1092 patients).5
Plasma levels of sTM (R&D Systems, Minneapolis, US) and VWFpp13 were assessed 
employing enzyme-linked immunosorbent assays. The assays were performed by a 
laboratory technician who was unaware of the case status of the samples.
Case-cohort study
A case-cohort study was performed in which we included all patients with a major 
bleeding (cases) and included a random subcohort from the BLEEDS cohort that was 
sampled at baseline as described by Prentice.14 All 326 cases were sampled with plasma 
available from 263 cases. For the subcohort, a random sample of 4% within the whole 
cohort (652 patients) was selected, with plasma available from 538 subcohort patients. 
Due to the case-cohort design in which every person in the cohort, including the 
cases, had the same probability of being selected to the subcohort, six cases were 
also included in the subcohort. 
statistical analysis
For each VKA treatment, person time was calculated from the start of VKA therapy until 
the bleeding event, death, moving to a city that was not covered by the participating 
anticoagulation clinics, end of treatment, or end of the study period (31st of December 
2014), whichever occurred first. 
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To account for the oversampling of cases, we estimated hazard ratios (HRs) and 95% 
confidence intervals (CIs) by means of weighted Cox proportional hazards models as 
described by Prentice 14. The proportional hazards assumption was tested based on 
Schoenfeld residuals. Levels of sTM and VWFpp were stratified by the 25th, 50th, 70th, 
and 85th percentiles, with the 25th percentile acting as the reference category. HRs were 
adjusted for the confounding factors age, sex, diabetes, and hypertension.
An additional analysis was performed in which events were restricted to the first 
six and twelve months of treatment as we expected that effects would dilute when 
time between the measurement and event elapsed. 
All analyses were performed with R version 2.15.2 (R Core Team (2014). R: A language 
and environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria. URL http://www.R-project.org/).
table 1. Baseline characteristics
whole Cohort subcohort cases
General characteristics
Patients 16 185 538 263
Treatment periods 16 570 538 263
Men 8 713 (53) 293 (54) 147 (56)
Age 70 (14) 70 (12) 75 (11)
INR target range
2.5-3.5 15 509 (93) 508 (94) 247 (94)
3.0-4.0 1 061 (7) 30 (6) 16 (6)
Treatment indication
Atrial fibrillation 10 876 (66) 374 (70) 200 (76)
Venous thrombosis 3 920 (24) 112 (21) 40 (15)
Mechanical heart valves 435 (3) 17 (3) 3 (1)
Ischemic heart disease 519 (3) 17 (3) 7 (3)
Vascular disease 412 (3) 6 (1) 5 (2)
Postoperative 125 (1) 3 (1) 1 (0)
Other 348 (2) 11 (2) 7 (3)
Vitamin K antagonist
Phenprocoumon 12 068 (73) 390 (72) 208 (79)
Acenocoumarol 4 481 (27) 148 (28) 54 (21)
Warfarin 18 (0) 0 1 (0)




table 2. Plasma levels of sTM and VWFpp in association with major bleeding during VKA treatment
Cases n (%) hR (95% CI) HRa (95% CI)
Total 263 (100)
sTM
< 25 (<5.3 ng/ml) 57 (22) reference reference 
25-50 (≥5.3  and <6.3 ng/ml) 63 (24) 1.15 (0.74-1.79) 1.30 (0.82-2.06)
50-70 (≥6.3  and <7.5 ng/ml) 46 (17) 1.18 (0.73-1.91) 1.27 (0.77-2.09)
70-85 (≥7.5 and <8.9 ng/ml) 44 (17) 1.51 (0.92-2.49) 1.63 (0.96-2.75)
> 85 (≥8.9 ng/ml) 53 (20) 1.77 (1.09-2.87) 1.79 (1.08- 2.97)
VWFpp
< 25 (<0.7 U/ml) 53 (20) reference reference 
25-50 (≥0.7 and <1.0 U/ml) 55 (21) 1.08 (0.65- 1.71) 1.04 (0.65-1.68)
50-70 (≥1.0 and <1.3 U/ml) 61 (23) 1.26 (0.79-1.99) 1.05 (0.64-1.71)
70-85 (≥1.3 and <1.6 U/ml) 47 (18) 1.39 (0.85-2.27) 1.15 (0.68-1.95)
> 85 (≥1.6 U/ml) 46 (18) 1.45 (0.88-2.39) 1.17 (0.69-1.99)
aAdjusted for age, sex, diabetes, and hypertension
ResuLts
We included 263 cases and 538 subcohort patients in the study (Table 1). Cases were 
on average 75 years old (SD 11 years), 147 (56%) were male, and the indication atrial 
fibrillation occurred most frequently (200 patients, 76%). Venous thrombosis patients 
were less prevalent among cases (40, 15%) than subcohort patients (112, 21%). The 
average age of the subcohort was 70 years (SD 12 years), 293 (54%) were male, and the 
indication atrial fibrillation was most frequent (374 patients, 70%). Phenprocoumon 
was used by 208 cases (79%) versus 390 subcohort patients (70%). Acenocoumarol was 
used by 148 cases (28%) and 54 subcohort patients (21%) 1 case used warfarin (0%).
The plasma levels of sTM and VWFpp were assessed for all subcohort patients and 
for 263 and 262 cases, respectively; one sample failed for technical reasons. The lower 
limit of detection was 5 ng/ml for the plasma sTM levels and 4 ml/dL for the VWFpp 
plasma levels. The highest plasma level measured was 53.5 ng/ml for sTM and 4.2 U/ml 
for VWFpp (Figure 1). 
Plasma levels of sTM > 8.9 ng/ml (85th percentile) were associated with a 1.77-fold 
increased risk for major bleeding (95%CI 1.09 to 2.87), which remained similar after 
adjustment for confounding (Table 2). There was no significant difference between 
the results of sTM of the whole follow-up as compared with the first six and twelve 
months of follow-up. 
Increased plasma levels of VWFpp were also associated with an increased risk for 
major bleeding (VWFpp > 1.6 U/ml, 85th percentile, HR 1.45, 95%CI 0.88 to 2.39) in a crude 
analysis, but were around unity after adjustment for confounding (Table 2). When the 
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figure 1. distribution of concentrations of stm (a) and vwfpp (B)
a
b
analyses were restricted to the first six and twelve months of VKA treatment, increased 
VWFpp levels were associated with a non-significant 1.44- and 1.30-fold increased risk 





Using a unique case-cohort comprising 263 cases that experienced major bleeding 
complications during VKA therapy, we showed that levels of VWFpp were associated 
with major bleeding, but that the association disappeared after adjustment for 
confounding factors (i.e. age, sex, diabetes, and hypertension). Levels of sTM were 
dose-dependently associated with major bleeding during VKA treatment before and 
after adjusting for confounding. The results on sTM are consistent with previous 
findings,7-9 which supports the premise that sTM is a marker of endothelial damage15,16 
and that endothelial damage leads to major bleeding. On the contrary, while VWFpp 
is also a marker of endothelial damage10 and VWFpp plasma levels were not - strongly 
- associated with major bleeding after adjustment for confounding factors. A possible 
explanation for this discrepancy is that VWFpp is a marker of acute endothelial damage10 
while sTM is a marker for chronic endothelial damage.15 In addition, the analyses on sTM 
restricted to cases with a major bleeding during the first six and twelve months gave 
similar results as the analyses with all cases. This also indicates that the association of 
sTM with major bleeding is as strong for the near- as the distant future, which could 
make it a good predictor for patients at risk for major bleeding. 
This population based cohort study contained data from over 16 000 individuals 
with over 300 major bleeding events, which makes the results robust and allowed us 
to perform multiple subgroup analyses. A notable result was that venous thrombosis 
patients were less prevalent among cases than subcohort patients. This difference 
is due to the shorter duration of VKA treatment of venous thrombosis patients and 
therefore a shorter period to develop a major bleeding than patients with a chronic 
indication (e.g. atrial fibrillation). 
A limitation of the study is that plasma was not collected from all patients who 
participated in the study as some patients experienced a major bleeding before plasma 
was collected. As a possible consequence, risk estimates may dilute because the 
patients with the strongest risk factors ‘dropped out’ of the study. Another limitation is 
that while the sTM concentrations measured were in the same range as those observed 
in other studies,7,9 the median upper quartile sTM levels varied from 4-8 ng/ml (this 
study and 7) to 61 ng/ml.9 This is likely due to the different assays used in the studies 
and impede a direct comparison of sTM levels between studies.  
Overall, this study showed that VWFpp levels were not associated with major 
bleeding during VKA treatment. On the contrary, sTM levels were associated with 
major bleeding, which indicates that chronic endothelial damage plays a role in major 
bleeding during VKA treatment. 
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table 3. Risk of major bleeding during VKA treatment at 6- and 12-month follow-up, stratified 
according to sTM and VWFpp plasma levels
Cases n (%) hR (95% CI) HRc (95% CI)
6 month follow-upa 145 (100)
sTM
< 25 (<5.3 ng/ml) 33 (23) reference reference 
25-50 (≥5.3  and <6.3 ng/ml) 29 (20) 0.88 (0.50-1.53) 0.94 (0.53-1.66)
50-70 (≥6.3  and <7.5 ng/ml) 25 (17) 0.97 (0.54-1.73) 1.01 (0.56-1.82)
70-85 (≥7.5 and <8.9 ng/ml) 25 (17) 1.25 (0.69-2.25) 1.29 (0.70-2.37)
> 85 (≥8.9 ng/ml) 33 (23) 1.61 (0.92-2.80) 1.59 (0.90-2.81)
VWFpp
< 25 (<0.7 U/ml) 27 (19) reference reference 
25-50 (≥0.7 and <1.0 U/ml) 30 (21) 1.12 (0.63-1.98) 1.09 (0.60-1.96)
50-70 (≥1.0 and <1.3 U/ml) 35 (24 1.57 (0.90-2.76) 1.32 (0.73-2.37)
70-85 (≥1.3 and <1.6 U/ml) 26 (18) 1.61 (0.88-2.94) 1.30 (0.69-2.46)
> 85 (≥1.6 U/ml) 27 (19) 1.74 (0.95-3.18) 1.44 (0.76-2.71)
12 month follow-upb 206 (100)
sTM
< 25 (<5.3 ng/ml) 40 (19) reference reference 
25-50 (≥5.3  and <6.3 ng/ml) 47 (23) 1.18 (0.73-1.93) 1.32 (0.79-2.18)
50-70 (≥6.3  and <7.5 ng/ml) 38 (18) 1.29 (0.77-2.16) 1.35 (0.79-2.30)
70-85 (≥7.5 and <8.9 ng/ml) 37 (18) 1.61 (0.95-2.74) 1.69 (0.97-2.94)
>85 (≥ 8.9 ng/ml) 44 (21) 1.90 (1.40-3.18) 1.90 (1.11-3.23)
VWFpp
< 25 (<0.7 U/ml) 39 (19) reference reference 
25-50 (≥0.7 and <1.0 U/ml) 47 (23) 1.21 (0.74-1.98) 1.17 (0.70-1.94)
50-70 (≥1.0 and <1.3 U/ml) 46 (22) 1.33 (0.81-2.20) 1.13 (0.67-1.90)
70-85 (≥1.3 and <1.6 U/ml) 39 (19) 1.59 (0.94-2.70) 1.33 (0.76-2.32)
> 85 (≥1.6 U/ml) 35 (17) 1.58 (0.92-2.70) 1.30 (0.74-2.30)
Analysis of the risk for major bleedings that had occurred during the first asix or btwelve months of VKA 
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General discussion and future perspectives
Pharmacoepidemiology is the study of utilization and effects of drugs in large numbers 
of people. It provides estimates of the probability of beneficial effects and the 
probability of adverse events. The first part of this thesis focusses on methodological 
aspects of pharmacoepidemiology research. The second part of this thesis describes 
interventions to reduce rates of major bleeding during treatment with antithrombotic 
drugs. New insights arise from this thesis, which will be discussed here. In addition, 
recommendations will be given for future research. 
PhaRmaCoePIdemIoLogy
Causality inferred from pharmacoepidemiologic statin studies 
The many beneficial effects that are attributed to statins may not be causal but due 
to biases. In Chapters 2 and Chapter 3, we set out to examine whether one beneficial 
effect (on bleeding risk in this case) of statin usage is due to three sorts of bias: survivor 
bias, prevalent user bias and healthy user bias. In the case-control study described in 
Chapter 2, we first determined if statin use was associated with a lower probability 
of major bleeding, and indeed we initially documented a protective association (odds 
ratio [OR]: 0.56; 95% confidence interval [CI]: 0.29 to 1.08). This protective association 
could, however, be fully attributed to survivor bias. This type of bias can occur when 
exposed cases are less likely to get included in a study as compared with other 
participants. Survivor bias became evident by stratifying on time between the onset 
of the major bleeding and the lapsed time before inclusion in the study, and repeated 
for a negative control: an exposure which is not related with death but is related with 
bleeding (i.e. blood group non-O). In Chapter 3 we showed that a ‘new user design’ 
(i.e. a comparison of patients who started using statins during follow-up with non-
users) produces more reliable risk estimates than a ‘current user design’ (i.e. statin 
users at baseline compared with non-users) for statin studies. Furthermore, it became 
apparent that in the elderly, beneficial associations can be attributed to a healthy user 
bias. Both Chapters showed that results from the straightforward analysis indicated 
that statins reduce the risk of bleeding complications, whereas sensitivity analyses 
indicated that these associations were likely due to bias. 
Survivor bias in case-control studies
One question that arose from Chapter 2 was whether survivor bias should always be 
suspected in case-control studies that showed positive effects of statin usage. In this 
context it is interesting to note results from a meta-analysis on the effect of statins on 
venous thrombosis.1 In this meta-analysis the authors report the lowest relative risk of 
venous thrombosis in studies that had enrolled individuals on statins who had survived 




studies reported relative risk estimates that were close to unity (between 0.74 and 
1.02).1 These results suggest that the studies with the lowest relative risks may also 
have suffered from survivor bias, supporting the conclusions in Chapter 2, that this 
type of bias may be common in case-control studies on effects of statins. This is a major 
concern, as causality is often inferred from such pharamacoepidemiological studies. 
For this reason, this thesis advocates checking for survivor bias in case-control studies 
by performing a sensitivity analysis where results are stratified by time between event 
and inclusion. Of note, such a sensitivity analysis only gives useful insight when patients 
were included gradually over a time period after the event. Often, cases are included 
immediately after the event, and as a result, the proposed sensitivity analysis will not 
add information on differential inclusion of (un)exposed cases. 
Ideally one would be able to know in advance whether a combination of an exposure 
and outcome is susceptible to survivor bias. To get more insight in survivor bias Hu et 
al. used a cohort and studied whether survivor bias would occur when time between 
the outcome (pancreatic cancer) and ‘simulated inclusion’ elapsed. Patients were 
considered able to participate in the study when they were alive.2 They showed that 
the association between the exposures body mass index and waist circumference and 
the outcome pancreatic cancer underestimates the risk when time between the event 
and inclusion elapsed. However, a downside of such a method is that it assumes that 
all patients will actually participate in a study, which is usually not the case. Another 
method to study issues regarding participation in a case-control study is by comparing 
included patients in case-control studies with groups of patients in registries, as patient 
populations from registries are usually unselected. 
A second recommendation from this thesis is to use negative- or positive controls 
in (pharmaco)epidemiological studies. Positive and negative controls (i.e. performing 
an analysis under conditions in which a null result [negative control] or a positive result 
[positive control]) is expected have been standard practise in experimental research for 
a long time. In (pharmaco)epidemiology, additional sensitivity analyses with a positive 
and/or negative control will provide additional information that may strengthen the 
conclusions. For statins, a negative control could be fibrate usage, as these drugs are 
prescribed for similar indications as statins, but have different pharmacodynamics.3 If 
protective results for fibrates are similar to results regarding statins, or even stronger, 
this may indicate that protective associations are due to bias, and not due to the statins. 
Prevalent- and healthy user bias in cohort studies
The analysis of the cohort study described in Chapter 3 suffered from prevalent user 
bias. In addition, results from our examination indicated that a ‘new user’ design may 
not overcome all biases, as elderly patients who initiate a statin may be healthier than 
elderly patients who did not initiate a statin. 
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Whether these biases affect results from other cohort studies on effects of statins 
is not known. A meta-analysis showed that studies where prevalent statins users were 
compared with non-users gave overoptimistic results.4 The bias that occurs from using 
current users instead of new users was also described in relation to the protective 
effects on cardiovascular disease attributed to hormone replacement therapy.5 Results 
of these studies suggest that a ‘new user’ design is always required when studying 
causal effects of drugs. 
The past few years it was advocated that all pharmacoepidemiological studies 
should be following a ‘new user’ design. However, a disadvantage of such a design is 
that the power of the study is lower as compared with a current user design and that 
a ‘new user’ design may not be preferable for all research questions. For example, 
one may expect that treatments that are initiated and mainly continued by health-
conscious people (e.g. statins, hormone replacement therapy, vitamins) combined with 
an outcome that relates to life style (e.g. cardiovascular disease) are more susceptible 
to bias due to a current user design. On the other hand, treatments that are not likely 
to be ceased (e.g. painkillers for chronic pain) and outcomes scarcely related to life style 
(breast cancer) may be less susceptible.6 In addition, exposures with a lasting effect may 
not suffer from current user bias (oral contraceptives on breast cancer). In contrast, 
the same exposure with a temporary and current effect can (oral contraceptives on 
venous thrombosis). These examples illustrate that a ‘new user’ design may not be 
necessary for al research questions.6  
Causality in studies on vitamins
Vitamins are known for their wide range of beneficial effects from observational 
studies, such as cardiovascular disease, cancer, and venous thrombosis.7 However, 
previous reports did not take confounding fully into account. The aim in Chapter 4 
was to determine whether vitamin supplementation decreases the risk of venous 
thrombosis using a case-control study. The MEGA case-control study provided an 
excellent opportunity to study this because the study has two controls groups (random-
digit dialing (RDD) controls or patients’ partners), which enabled us to correct for both 
measured and unmeasured confounding factors. The comparison with RDD controls 
was corrected for measured confounding. The comparison with partners enabled 
to also correct for unmeasured confounding as partners tend to have the same life-
style. We found that vitamin use led to a 37% lower risk of venous thrombosis than 
no vitamin use (OR: 0.63, 95% CI 0.57 to 0.70) when comparing patients with RDD 
controls. Adjustment for confounding factors did not change the estimate (OR 0.68, 
95% CI 0.61 to 0.77). However, when patients were compared with partner controls, 
ORs attenuated to unity. Therefore, the initial protective risk estimates that were 




for lifestyle-dependent confounding might not be sufficient when studying health-
conscious exposures. In addition, the control group must be selected with care, which 
may also be true for other studies on health-conscious exposures such as sports, food 
patterns and alcohol intake.
Control selection in case-control studies
Chapter 5 focused on differences in risk estimates when using RDD controls or partner 
controls in case-control studies. The motivation to perform this study was that patients 
were less willing to participate in the trial described in Chapter 10 if they had a relative 
(e.g. partner, child) who was also ill. We therefore hypothesized that partner controls 
are less willing to participate in a study if they, next to their partner (i.e. the case), are 
seriously ill. If true, differences in participation rates can lead to discrepancies between 
effect estimates (ORs) when exposures that impair quality of life are studied and 
partner- and RDD controls are used. The results of this study showed that decreased 
quality of life due to exposure to a chronic condition was associated with higher 
ORs when using partner controls as compared with RDD controls. The results were 
confirmed by an analysis with a negative control that showed that two exposures not 
associated with changes in quality of life (genetic variants), gave similar risk estimates 
for both control groups. 
Unfortunately, we were not able to study the reason for the differences between the 
risk estimates. This was because data on reasons not to participate were not available. 
In addition, literature that describes differences between participation rates of partner- 
and RDD controls is not available. However, RDD control groups have been compared 
with other population based controls. One study found that RDD controls, as compared 
with controls who were recruited by mail and visited at home, were subject to more 
screening tests and had a slightly higher prevalence of health outcomes such as a high 
cholesterol.8 These differences may indicate that ill subjects recruited by RDD may 
participate more frequently as compared with other control groups. This difference 
in participation rate may explain the differences in risk estimates found between the 
partner- and RDD controls. An alternate explanation for the different risk estimates may 
be that the burden of care for the patient by a very ill partner (control) is high and may 
result in declining to participate in a study, as was also experienced during participant 
selection of Chapter 10. These lower participation rates would result in higher risk 
estimates when using partner controls instead of RDD controls.
A limitation of this study is that it is not possible to study the cause of the 
difference in risk estimates. Therefore, a recommendation cannot be given on the 
most appropriate control group when studying research questions with exposures that 
impair the quality of life considerably. Future research is needed to determine what 
the source of these discrepancies is and show what control group is most appropriate 
under these circumstances. 
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BLeedIng duRIng antICoaguLant tReatment
Pharmacological interventions
The second part of this thesis looks into major bleeding during treatment with oral 
anticoagulants. Patients have been treated with vitamin K antagonists for over half 
a century9, but we still cannot predict very well who is at high risk of major bleeding 
and should receive no or alternative anticoagulant treatment. This urgently calls for 
optimization of treatment, interventions to ease medication intake, and a better ability 
to identify patients at risk of major bleeding complications. 
optimization of treatment
Triple therapy
Atrial fibrillation patients often have coexisting cardiovascular diseases that may 
require concurrent treatment with platelet inhibitors. Some patients receive triple 
therapy (VKA, aspirin, clopidogrel), which increases the risk of major bleeding four-fold 
as compared with patients who receive VKA monotherapy.10 In previous studies it was 
not clear what the major bleeding rates were for different groups of patients and thus 
what the clinical impact of this four-fold increased risk was. Results from Chapter 6 
showed that patients who receive triple therapy have very high rates of major bleeding 
(5.8 to 50.0 per 100 patient-years). These high rates of major bleeding raise the 
question whether concomitant use of three anticoagulants is recommended. Such 
recommendations could not be given based on this study for two reasons. First, risk 
factors for ischemic events and major bleeding overlap11, making it hard to distinguish 
which patients are at high risk for major bleeding, but not at risk for ischemic events, 
and vice versa. Second, due to confounding by indication, this non-randomized study 
does not permit evaluation of the effectiveness of combinations of antithrombotic 
drugs (i.e., medication could have been indicated due to high risk of thromboembolic 
outcomes). Still, two groups that stood out were patients over 90 years of age (incidence 
rate of major bleeding 50.0 per 100 patient-years) and those with a CHA2DS2-VASc of 
7 to 9 (incidence rate 20.0 per 100 patient-years). These high rates of major bleeding 
suggest that triple therapy is contra-indicated in these patients. 
Low-Molecular-Weight-Heparins
The Low-Molecular-Weight-Heparins (LMWHs) currently on the market are considered 
members of a class of drugs with similar anticoagulant properties. However, 
pharmacodynamics and pharmacokinetics between LMWHs differ.12 These differences 
could result in different bleeding risks for single LMWH agents. Chapter 7 and Chapter 8 
suggest that, in venous thrombosis patients, nadroparin was associated with the 
lowest bleeding risk of all LMWHs. In addition, results suggest that twice daily dosing 




dosing. Results from the network meta-analysis (Chapter 8) also show that once daily 
nadroparin is not associated with an increased risk of venous thrombosis as compared 
with other LMWHs. Based on these results, the most optimal LMWH strategy in patients 
with acute venous thrombosis appears to be treatment with nadroparin once daily. Still, 
small numbers of events and considerable risks of bias prevented us from concluding 
whether one LMWH should be preferred over the other. 
One way to further explore whether a single LMWH agent and dosing schedule 
has benefits over other LMWHs and dosing schedules is by conducting a randomized 
controlled trial. However, such a trial would have to be very large (for example for 
a trial with two LMWHs, with a risk of 5% of recurrent venous thrombosis during 
LMWH treatment, one would need 1600 patients to find a relative risk of 0.6 with 
sufficient power) and will therefore be expensive and time consuming. An alternative 
for such trials could be a pragmatic trial, which is a trial conducted in routine clinical 
practice.13 In such a trial, hospitals or general physicians are asked to participate and 
patients will be randomized to one of the available LMWHs by the prescription system 
when the physician prescribes the LMWH. As there is currently no preference for a 
particular LMWH, it may not even be necessary to obtain written informed consent 
for such a study. Outcomes can be collected through registries. Such pragmatic trials 
may not only provide an adequate way to study differences between LMWH agents, 
but also for other classes of drugs. It is often assumed that drugs from the same class 
do have similar effects on the studies outcomes. However, pharmacodynamics can 
differ and pharmacokinetics do usually differ between agents from a drug class, which 
may result in differences in effectiveness and rates of side effects. Pragmatic trials 
may provide a feasible way to study these differences in the population that actually 
receives the drugs. 
Practical interventions
Multidose drug dispensing
Adherence can be challenging for polypharmacy patients. Research shows that 
adherence decreases with the number of prescribed medications and increasing 
regimen complexity.14,15 An intervention that may improve medications adherence 
is multidose drug dispensing (MDD). MDD is a dosing aid that provides patients with 
disposable bags containing all drugs intended for one dosing moment. The effect of 
MDD was only examined in one cross sectional study by Kwint et al. where MDD was 
associated with a better self-reported medication adherence.16 Chapter 9 shows that 
in non-compliant patients, MDD improves medication adherence within one month, 
whereas instructing patients is associated with equal improvement of drug adherence 
over a four month period. This result suggests that medication adherence improves 
faster by MDD than by instructing patients. In addition, MDD contains all medications, 
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whereas the instructions in this study were limited to VKAs. Currently, this and the 
study from Kwint et al.16 are the only studies on adherence improvement of MDD, 
and more research is necessary to confirm these results. A relating question is which 
patients would benefit from MDD. Currently, patients are using MDD on request of 
the patient or when a relative or health care professional of the patient initiates MDD. 
By identifying patients in need of MDD proactively, it may be possible to prevent 
medication intake errors and subsequent failure of therapy or side effects.
Vitamin K tablets 
In Chapter 10 we compared a soluble vitamin K1 formulation with tablets with respect 
to the bioavailability and effects on the international normalized ratio (INR) in three 
randomized controlled trials. Results show that the bioavailability from the vitamin K1 
solution is higher than that from the tablets. Still, the tablets were as effective and safe 
as the vitamin K1 solution with regard to the ability to decrease the INR in patients on 
phenprocoumon. This indicates that pharmacies can safely provide tablets instead of 
the solution. 
This was the first study to report the effect of 5 mg vitamin K1 in patients using 
phenprocoumon. Patients who participated in the study with a scheduled invasive 
procedure all had an INR low enough for the procedure, indicating that 5 mg of 
vitamin K1 is an appropriate dosage for lowering the INR for invasive procedures in 
phenprocoumon users. In the study involving patients with an INR between 7.0 and 
11.0, 11% of all patients had an INR < 2.0 after 48 h. Future research may be required 
to determine the best vitamin K1 dosage to decrease the INR in phenprocoumon users 
with a high INR. Such data is also necessary for acenocoumarol and warfarin users.
In our study, fewer ‘late low INRs’ were found than in the literature on warfarin.17-20 
The difference between our and the earlier findings may be explained by the longer 
half-life of phenprocoumon than of warfarin. When phenprocoumon is restarted on 
the third day, blood concentrations of phenprocoumon may be higher than those of 
warfarin, which may result in faster-rising INRs. 
One other notable result was that two patients had no INR decrease after ingesting 
vitamin K1. Some physicians or dentists do not measure the INR before performing an 
invasive procedure. These results indicate that it may be necessary to measure the INR 
before starting procedures where it is clinically relevant that the INR is low. 
Prediction of major bleeding complications
Chapter 11 describes why patients on vitamin K antagonists with minor bleeds are at 
increased risk of subsequent major bleeding (e.g. are risk factors of a transient or fixed 
nature). Two analyses were performed: a Cox proportional hazards model which was 
adjusted for known risk factors and a case-crossover design which corrects for fixed risk 




the risk of major bleeds was 2.5-fold increased in patients with a preceding minor bleed. 
The case-crossover analysis gave risk estimates around unity (OR 0.9, 95% CI 0.5 to 1.5). 
The combination of both analyses indicated that minor bleeds are markers for fixed 
and currently unknown risk factors for major bleeds. Identification of these risk factors 
may provide new predictors for whom is at risk of major bleeding complications during 
treatment with vitamin K antagonists, especially considering that current prediction 
models for major bleeding complications do not distinguish well between patients who 
are at moderate and high risk of major bleeding complications.21  
Biomarkers and genetics may be a source for new risk factors for major bleeding 
during VKA treatment. These may be discovered in the Biomarkers in the Leiden Etiology 
and Epidemiology of bleeding in vitamin K antagonists Drug users Study (BLEEDS) which 
is described in Chapter 12. Patients starting VKA treatment were included in the BLEEDS, 
with an inclusion rate of 99%, resulting in 16 570 patients, who experienced 326 major 
bleeding complications during 17 613 patient years of follow-up. The characteristics 
of the study showed that the population is in concordance with previously published 
cohorts with regard to bleeding complications during treatment with VKAs. This is the 
first population based study with a high number of bleeding complications that will 
provide the possibility to perform subgroup analyses and provide information on the 
currently treated population with vitamin K antagonists. 
Chapter 13 shows the first results from the BLEEDS, where elevated levels of soluble 
thrombomodulin - a biomarker for chronic endothelial damage - were associated 
with major bleeding during VKA treatment. These results do cohere with those 
from two other studies.22,23 Results also showed that another potential biomarker, 
von Willebrand factor propeptide, which reflects acute endothelial damage, was not 
associated with major bleeding during VKA treatment. These results were corroborated 
by the results from Chapter 11, which indicated that fixed risk factors are associated 
with major bleeding. Future research needs to clarify what these risk factors are and 
subsequently improve prediction models to ensure that patients receive their optimal 
personalized treatment.
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Dit proefschrift bestaat uit twee delen. Het eerste deel van het proefschrift gaat over 
de methodologie van geneesmiddelonderzoek (farmacoepidemiologie). Het tweede 
deel bevat informatie over bloedingen tijdens de behandeling met bloedverdunners. 
deel I: farmacoepidemiologie
Epidemiologie is het vakgebied dat patronen, oorzaken en effecten van interventies, 
bijvoorbeeld het starten van een geneesmiddel, bestudeert in groepen mensen. 
Farmacoepidemiologie is een deelgebied dat zich specifiek richt op geneesmiddelen 
(hoofdstuk 1). In hoofdstuk 2 tot en met 5 worden verscheidene facetten beschreven 
waaraan moet worden gedacht wanneer epidemiologische studies worden uitgevoerd. 
Zo wordt in hoofdstuk 2 een case-control studie beschreven waarbij patiënten met een 
ernstige bloeding in de voorgeschiedenis de cases zijn en patiënten die geen ernstige 
bloeding hebben gehad als controles fungeren. Cases gebruikten minder vaak statines 
(cholesterolverlagers) dan controles, waardoor kon worden geconcludeerd dat statines 
beschermen tegen ernstige bloedingen. Het beschermende effect uit de gebruikelijke 
analyse werd echter veroorzaakt door een systematische fout (bias): de aan statine 
blootgestelde cases namen minder vaak deel aan de studie dan de statine gebruikende 
controles. Deze bias kan in andere case-control studies worden opgemerkt door te 
stratificeren voor de tijd tussen de bestudeerde uitkomst, in dit geval een bloeding, 
en deelname aan de studie. 
In hoofdstuk 3 wordt een cohortstudie beschreven waarin wederom het effect 
van statines op bloedingen werd bestudeerd. De resultaten van de standaardanalyse 
suggereren ook dat statines beschermen tegen bloedingen. Vervolgens zijn de 
statinegebruikers ingedeeld naar startdatum van statinegebruik, waarbij onderscheid 
werd gemaakt tussen patiënten die al statines gebruikten toen de studie begon en 
patiënten die met statines zijn begonnen tijdens de studie. Uit deze analyse bleek dat 
de gevonden beschermende effecten werden veroorzaakt door de groep patiënten die 
aan het begin van de studie al statines gebruikten. Literatuur beschrijft echter alleen 
dat patiënten die tijdens de studie starten met statines moeten worden meegenomen 
in de analyse. Toen de al gestarte groep uit de analyse werd gehaald, werden geen 
beschermende effecten meer waargenomen. De in hoofdstuk 2 en hoofdstuk 3 
gevonden systematische fouten geven een mogelijke verklaring voor de beschermende 
effecten van statines die in andere studies worden gevonden tegen een groot scala 
aan ziektes zoals depressie, ziekte van Parkinson en botbreuken. Toekomstige studies 
over effecten van statines kunnen daarom de bovenstaande analyses meenemen als 
sensitiviteitsanalyse om te voorkomen dat gevonden beschermende effecten van 




In het verlengde van de voorgaande hoofdstukken is in hoofdstuk 4 en hoofdstuk 5 
gekeken naar bias die wordt veroorzaakt door verkeerde selectie van controle personen 
in case-control studies. In hoofdstuk 4 wordt beschreven dat je voor het bestuderen 
van effecten van vitamines, dat wil zeggen leefstijlgerelateerde interventies, beter 
controles kunnen worden geselecteerd die een vergelijkbare levensstijl hebben als de 
cases (i.c. partners). Partnercontroles zijn niet altijd de beste optie. Zo laat hoofdstuk 5 
zien dat bias werd veroorzaakt doordat partnercontroles juist minder vaak meedoen 
dan controles die random werden gebeld indien de partners van de cases lijden aan 
een ernstige ziekte (bijvoorbeeld hartfalen of verlamming). 
deel II: bloedingen tijdens de behandeling met bloedverdunners
In hoofdstuk 1 wordt ook de geschiedenis en farmacoepidemiologie van vitamine 
K-antagonisten beschreven. Vitamine K-antagonisten zijn bloedverdunners die voor 
het eerst in 1948 werden gebruikt als rattengif. Gedurende de jaren 50 werden deze 
bloedverdunners geregistreerd als geneesmiddel om trombose te voorkomen. Vanwege 
de grote variabiliteit van het antistollend effect tussen en binnen patiënten wordt de 
behandeling in Nederland gemonitord door trombosediensten. Bij de trombosedienst 
wordt minstens één keer per zes weken bloed afgenomen van alle patiënten die 
vitamine K-antagonisten gebruiken. In het bloed wordt gemeten of de mate van stolling 
(international normalized ratio, of INR) in het bloed goed is. Bij gezonde personen is 
de INR 1,0 en indien vitamine K-antagonisten worden geslikt moet de INR vaak tussen 
de 2,5 en 3,5 zijn. Nadat de INR door de trombosedienst is bepaald krijgen patiënten 
de volgende dag een kalender met daarop aangegeven hoeveel pillen dagelijks tot de 
volgende afspraak moeten worden ingenomen. 
Ondanks het constant monitoren van de behandeling blijven de meest voorkomende 
bijwerkingen bloedingen. De kunst bij deze geneesmiddelen is dan ook om een goede 
balans tussen de effectiviteit (voorkomen trombose) en bijwerkingen (bloedingen) 
te vinden. De bloedingen waarnaar, net als in dit proefschrift, voornamelijk 
onderzoek wordt gedaan zijn ernstige bloedingen. Dit zijn bloedingen die leiden tot 
bloedtransfusies, opnames in het ziekenhuis of het overlijden van patiënten. Deze 
komen bij 1-2% van de patiënten per jaar voor. Verscheidene risicofactoren voor 
bloedingen zijn bekend, maar we zijn nog niet goed in staat om patiënten met een hoog 
bloedingsrisico te onderscheiden van de patiënten die dit niet hebben. Het tweede deel 
van het proefschrift gaat in op risicofactoren voor het krijgen van deze bloedingen en 
op interventies die kunnen zorgen dat het aantal bloedingen wordt verminderd.
Een eerste groep patiënten die is bestudeerd zijn patiënten die naast de vitamine 
K-antagonisten nog twee andere bloedverdunners (clopidogrel en aspirine) krijgen 
(hoofdstuk 6). De literatuur laat zien dat deze patiënten een bijna viervoudig verhoogd 




Er zijn echter groepen die een laag (basis)risico voor bloedingen hebben, waardoor een 
viermaal verhoogd risico geen hoog bloedingsrisico hoeft te zijn (bijvoorbeeld voor 
jonge patiënten, dit zijn patiënten van 50 tot 60 jaar). Anderzijds zijn er ook groepen die 
een hoog basisrisico voor bloedingen hebben, bijvoorbeeld oude patiënten (boven de 
90 jaar), waardoor het bloedingsrisico bij drie bloedverdunners erg hoog zou moeten 
zijn. hoofdstuk 6 laat zien dat eigenlijk alle groepen, inclusief de groepen patiënten met 
laag basisrisico, die drie bloedverdunners tegelijkertijd gebruiken een hoog risico op 
ernstige bloedingen hebben. Groepen die een bijzonder hoog bloedingsrisico hebben 
zijn patiënten met een CHA2DS2-VASc score boven de 6 en patiënten boven de 90 jaar 
(20% en 50% per jaar respectievelijk). 
In hoofdstuk 7 en hoofdstuk 8 wordt onderzocht of bloedverdunners uit de groep 
LMWHs (low molecular weight heparines) verschillende bloedingsrisico’s geven. Er 
wordt meestal van uitgegaan dat geneesmiddelen in dezelfde groep eenzelfde patroon 
van werkzaamheid en bijwerkingen hebben, hoewel de geneesmiddelen verschillen in 
bepaalde opzichten. hoofdstuk 7 laat zien dat eenmaal daags doseren van de LMWH 
nadroparine minder bloedingen geeft dan tweemaal daags doseren. Dit resultaat komt 
overeen met de huidige literatuur. Bij een verlaagd bloedingsrisico bij eenmaal daags 
doseren lijkt het logisch dat het tromboserisico toeneemt. Dit bleek echter niet uit 
hoofdstuk 8. Een kanttekening bij beide studies is dat de aantallen te klein waren om 
definitieve uitspraken te doen over de vraag welke LMWH en welk doseringsregime 
het beste is voor de patiënten.
Een andere manier om bloedingen te voorkomen is door het innemen van 
medicatie makkelijker en overzichtelijker te maken. Een hulpmiddel om dit te doen 
zijn ‘baxterrollen’. Dit zijn rollen bestaande uit zakjes met alle medicatie die op één 
moment moet worden ingenomen in één zakje (dus een zakje voor maandagochtend 
8 uur, een zakje voor maandagochtend 10 uur, enzovoorts). Hoewel dit hulpmiddel 
veel wordt ingezet om inname van medicatie te verbeteren, is er weinig onderzoek 
gedaan naar de vraag of het gebruik van baxterrollen de therapietrouw van patiënten 
verbetert. In hoofdstuk 9 wordt de therapietrouw van patiënten met een baxterrol 
vergeleken met de therapietrouw van patiënten die door de medewerkers van de 
trombosedienst worden gebeld indien bloedverdunners niet goed werden ingenomen. 
Uit het onderzoek bleek dat op korte termijn (binnen een maand) de therapietrouw van 
patiënten met baxterrol verbetert ten opzichte van de groep die alleen werd gebeld. 
Op lange termijn (vier maanden) lijkt de therapietrouw in de groep die werd gebeld 
over inname van de bloedverdunners door een trombosedienstmedewerker echter 
overeenkomstig te zijn met die van de groep die bloedverdunners via de baxterrol kreeg.
In hoofdstuk 10 is onderzocht of er verschil is in de werkzaamheid van fytomenadion 
(vitamine K) drank en fytomenadion tabletten. Fytomenadion is het antidotum tegen 




bloeding hebben, of voor het tegengaan van de bloedverdunnende werking (couperen) 
van vitamine K-antagonisten voorafgaand aan een operatie. Fytomenadion was altijd 
in de vorm van een drank op de markt, waarbij orale spuitjes met de goede dosering 
fytomenadion werden klaargemaakt door de apotheek. Dit leidde bij patiënten soms 
tot verwarring: ‘Moet ik dit spuitje oraal innemen of moet ik het inspuiten?’. Sinds 
enkele jaren zijn ook tabletten op de markt, maar hiervan was niet onderzocht of deze 
even effectief zijn als de drank. 
hoofdstuk 10 omvat drie studies waarin wordt onderzocht of de drank en tabletten 
in gelijke mate aankomen in het bloed en of ze even goed werken als antidotum. De 
resultaten van de eerste studie laten zien dat twee keer zo veel fytomenadion in het 
bloed aankomt na inname van de drank als na inname van de tabletten. In de twee 
andere studies is onderzocht of dit ook leidt tot verschillen in het couperend effect van 
het antidotum in patiënten die fenprocoumon gebruiken (een langwerkende vitamine 
K-antagonist). In de tweede studie is onderzocht of er verschillen tussen de tablet en 
drank zijn bij patiënten die een geplande operatie hebben. Bij deze groep patiënten 
bleken de drank en tabletten even effectief te zijn in het couperen van fenprocoumon. 
In de derde studie werd gekeken naar de effecten bij patiënten met een te hoge INR. 
In deze studie bleek dat de drank iets sneller werkte, maar dat na inname van de drank 
ook meer mensen doorschoten naar een te lage INR, waardoor de tabletten en drank 
even effectief bleken. Uit deze studie is geconcludeerd dat de drank en tabletten even 
effectief zijn. 
In de slothoofdstukken van het proefschrift wordt getracht om nieuwe 
risicofactoren voor het krijgen van ernstige bloedingen tijdens de behandeling met 
vitamine K-antagonisten te identificeren. In hoofdstuk 11 wordt gekeken naar welk 
type risicofactoren (kortdurende of chronische) moet worden gezocht. De resultaten 
van dit hoofdstuk laten zien dat risicofactoren voor ernstige bloedingen voornamelijk 
chronisch zijn. 
hoofdstuk 12 beschrijft de Biomarkers in the Leiden Etiology and Epidemiology of 
bleeding in vitamin K-antagonists Drug users Study (BLEEDS). Deze studie is opgezet 
om risicofactoren voor het krijgen van ernstige bloedingen tijdens de behandeling 
met vitamine K-antagonisten te identificeren. Het eerste wat is gecontroleerd, is of de 
populatie van BLEEDS overeenkomt met eerder beschreven populaties die vitamine 
K-antagonisten kregen en waarin ernstige bloedingen zijn onderzocht. Uit de resultaten 
blijkt dat de populatie van de BLEEDS qua karakteristieken overeenkomt met eerder 
onderzochte populaties, wat indiceert dat resultaten kunnen worden doorgetrokken 
naar andere populaties. Bij BLEEDS is van een grote groep patiënten (13.779) materiaal 
verzameld. Dit schept de mogelijkheid veel verschillende groepen met elkaar te 
vergelijken, waarbij bijvoorbeeld het al dan niet hebben van een bepaalde genetische 




bloedingen voorspelt. hoofdstuk 13 is de eerste studie die is uitgevoerd in de BLEEDS 
waarbij wordt onderzocht of markers van vaatwandschade indiceren wie een hoog 
bloedingsrisico hebben. Het achterliggende idee is dat patiënten met een beschadigde 
vaatwand eerder een bloeding krijgen dan patiënten die minder schade aan de vaatwand 
hebben. Uit de studie bleek dat patiënten met hoge concentraties van markers van 
chronische vaatwandschade een verhoogd bloedingsrisico op ernstige bloedingen te 
hebben. Markers die samenhangen met kortdurende vaatwandschade bleken niet 
samen te hangen met een verhoogd bloedingsrisico. De resultaten uit dit hoofdstuk 
werden dan ook weer bevestigd door hoofdstuk 11, waarin werd gevonden dat 
chronische risicofactoren vooral voorspellen wie een verhoogd bloedingsrisico hebben. 
Conclusies en toekomstperspectief
Dit proefschrift heeft inzicht gegeven in bias die ervoor kan zorgen dat effecten 
van geneesmiddelen (statines en vitamines) positiever lijken dan ze zijn. Omdat 
observationeel onderzoek een groot deel van de uitgevoerde onderzoeken behelst, 
is het relevant om genoeg epidemiologisch-methodologisch onderzoek uit te voeren 
om in de toekomst (nog) beter in te kunnen schatten waar de valkuilen zitten in 
observationele studies. 
Verder zijn in dit proefschrift een aantal interventies beschreven om het aantal 
bloedingen tijdens de behandeling met bloedverdunners te verminderen. Resultaten 
laten zien dat couperen van fenprocoumon met fytomenadion tabletten veilig kan 
worden gedaan, het gebruik van baxterrollen therapietrouw op korte termijn verbetert 
en het kiezen van een specifieke LMWH die eenmaal daags wordt gedoseerd wellicht 
kan leiden tot minder bloedingen. Daarnaast is onderzoek gedaan naar groepen die 
een hoog risico hebben op ernstige bloedingen. Enkele risicogroepen die naar voren 
kwamen zijn patiënten boven de 90 jaar met drie bloedverdunners en patiënten met 
chronische vaatwandschade. 
Toekomstig onderzoek dient zich te richten op andere chronische risicofactoren voor 
het krijgen van bloedingen tijdens de behandeling met bloedverdunners, omdat huidige 
risicoscores niet goed identificeren welke patiënt een hoog of laag bloedingsrisico 
heeft. Om een optimale klinische beslissing te maken is het wenselijk om naast het 
hoge bloedingsrisico ook te weten wie een laag of hoog tromboserisico heeft. Hiervoor 
hebben we op dit moment nog geen goede risicoscores. Bij het verbeteren van deze 
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